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Cells constitute every organ in every organism. As such, cells are principal players in any disease. 
Hence, rational attempts to ameliorate disease will benefit from a thorough understanding of the 
cells involved and their specific functions. This thesis focuses on multiple sclerosis (MS), a disease of 
the central nervous system (CNS) with a central involvement of glial cells. Glial cells, a term referring 
to all CNS cells that are not neurons, comprise half the volume of the CNS and outnumber neurons 
by a factor of five to ten (Stevens 2003). Major glial cell types are oligodendrocytes, astrocytes and 
microglia, all of which play a role in MS pathology. In MS, myelin produced by oligodendrocytes 
is damaged and its biosynthesis is impaired, and a variety of functions from astrocytes and 
microglia change. In accordance with the concept that the development of rational therapeutic 
strategies requires basic molecular insights, first a brief overview of our current understanding 
of what comprises the myelin sheath will be given, followed by a short introduction to the glial 
cells mentioned. Then, contemporary insights into MS pathology are summarized, as well as 
the therapeutic options at hand. Finally, the current status of therapies that interfere with glial 
cell pathology in MS are discussed, in particular strategies aimed at the regeneration of myelin 
(remyelination).
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THE MYELIN SHEATH COMPOSITION: A BRIEF OVERVIEW
Node, internode, paranode and juxtaparanode
Myelin is the extended plasma membrane from the oligodendrocyte, albeit with a unique 
composition of myelin-specific proteins and lipids. In multiple layers, myelin compactly wraps 
around an axon, the nerve fiber projected from a neuron (Fig. 1). One oligodendrocyte can provide 
myelin for up to sixty axons (de Monasterio-Schrader et al. 2012), which marks an important 
difference with Schwann cells from the peripheral nervous system (PNS), that wrap myelin only 
around one axon each. In addition, one CNS axon is usually ensheathed by myelin from more than 
one oligodendrocyte. However, not all oligodendrocytes make myelin and not all CNS axons are 
wrapped in myelin, although in complex, mammalian brains, the vast majority is (Wang et al. 2008). 
Along the axon, myelin sheaths and short, bare axon segments alternate. The myelin sheath is 
called the internode in this context, and the short stretches of bare axon are known as the nodes of 
Ranvier, which contain a high density of sodium channels. The internodal myelin sheath is tightly 
wrapped and compact, except for the innermost (periaxonal or adaxonal) and outer (abaxonal) 
loops, where myelin is non-compact. These differences in myelin tightness within the internode 
allow for the discrimination of the paranode, which refers to the inner, non-compact myelin layer 
with its underlying axon, and the juxtaparanode, comprising the 10 to 15 nanometer of myelin 
internode between the paranode on one side and the internode on the other (Baumann, Pham-



































Figure. 1. Overview of the myelin sheath composition. A. Oligodendrocytes extend multiple processes to 
enwrap the axon from the neuron (blue) with a compact myelin sheath (pale grey; internode), leaving only small 
stretches of axon bare (node of Ranvier). This allows for saltatory conduction of nerve impulses (orange, dashed 
line), resulting in neurotransmitter release (orange circles). B. Cross section of the myelin sheath around the 
axon, showing compact myelin and the periaxonal and abaxonal loops. C. Unwrapped myelin sheath, revealing 
that myelin consists of compacted plasma membranes, with non-compacted cytoplasmic channels creating 
the abaxonal, paranodal and periaxonal loops. D. Closer look at compact myelin internode with the adjacent 
juxtaparanode, the non-compacted paranode, and the axonal node of Ranvier. Elements of the figure were 
adapted from (Aggarwal, Yurlova & Simons 2011, Soldan, Pirko 2012).
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A polarized membrane with an extensive communication network
The myelin sheath has several striking features. First, the myelin membrane is uniquely polarized. 
Correct folding of the myelin membrane into the complex myelin structure described above 
requires a distinction between the plasma and myelin membranes, and further between the 
compact and non-compact regions of myelin (subpolarization). Although exact mechanisms for 
how the oligodendrocyte discriminates these membrane domains are still under investigation, the 
extraordinary molecular composition of the myelin sheath is considered pivotal (Baron, Hoekstra 
2010, Simons, Snaidero & Aggarwal 2012). The lipid content of myelin is unusually high, with the 
main lipids being cholesterol, phospholipids, galactosylceramide (GalC) and its sulfated equivalent 
sulfogalactosylceramide or sulfatide (SGalC). The major proteins in the myelin sheath are myelin 
basic protein (MBP), particularly isoforms lacking exon II, and proteolipid protein (PLP) together with 
its isoform DM20. Other important proteins include myelin and lymphocyte protein (MAL), myelin 
oligodendrocyte glycoprotein (MOG), ‘myelin associated glycoprotein (MAG), 2’,3’-cyclic nucleotide 
3’-phosphodiesterase (CNP) and neurofascin-155 (NF-155). The myelin lipids and proteins tend to 
cluster at specific sites on the myelin sheath, enabling polarization and proper folding of the myelin 
sheath (which will be further discussed below). A second important feature of the myelin sheath is 
its surrounding communication network. The oligodendrocyte nucleus communicates with its own 
myelin internodes via channel-like tubes that originate from non-compact myelin sites and may 
run through the entire internode (Soldan, Pirko 2012). These tubes contain organelles, such as the 
endoplasmatic reticulum (ER), and vesicles, all of which may play a role in biosynthetic maintenance 
of the myelin sheath (de Monasterio-Schrader et al. 2012, Perkins et al. 2008). Furthermore, 
oligodendrocytes are often linked to other oligodendrocytes and to different CNS cells, such as 
astrocytes, among others via gap junctions (Aggarwal, Yurlova & Simons 2011, Kamasawa et al. 
2005, Maglione et al. 2010), and therefore, an extensive network of communicating glia appears 
around the axon. Finally, oligodendrocytes express receptors for neurotransmitters, such as the 
NMDA-receptor for glutamate (Karadottir et al. 2005). Signaling via this receptor plays a role in 
the transfer of exosomes between neurons and oligodendrocytes (Fruhbeis et al. 2013). Further, 
neurotransmitter release from neurons may also evoke electrical currents in oligodendrocytes, 
although this is still under investigation (Karadottir, Attwell 2007). 
WHY ARE OLIGODENDROCYTES AND MYELIN USEFUL?
Insulation of axons by myelin enables fast nerve impulse conduction, possibly saving energy
The first benefit of the myelin sheath is the insulation of the axon that it provides. Nerve impulses, 
or action potentials, result from changes in the axon membrane potential (depolarization) by an 
influx of sodium through sodium channels. Because 99.5% of the axon is insulated by myelin, 
depolarization needs to occur only at the remaining 0.5% of the surface area, i.e. at the nodes of 
Ranvier (Fig. 1). Hence, the action potential travels over the myelin sheath from node to node (of 
Ranvier), allowing for fast, saltatory nerve impulse conduction (Fig. 1). Without myelin, the axon 
15
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would have to tremendously increase its size in order to conduct nerve impulses as fast as with 
myelin. Also, depolarization exclusively at the node of Raniver means that myelinated axons need 
to restore ion gradients over a much smaller proportion of their membranes than unmyelinated 
axons. In this way, myelin cuts down on ATP requirements, because restoration of homeostatic ion 
gradients is largely driven by the ATP-dependent Na+,K+-ATPase pump (Nave 2010a). Indeed, in 
Long-Evans shaker rats, which bear an autosomal recessive mutation in MBP and therefore display 
gradual loss of myelin sheath integrity (Delaney et al. 1995), affected axons were found to contain 
more mitochondria (Smith, Cooksey & Duncan 2013). However, myelinated brain regions (white 
matter) use as much energy as areas that contain less myelin (grey matter), and therefore it has also 
been proposed that although myelin allows for rapid impulse conduction, it does not necessarily 
decrease overall energy demands of the CNS (Harris, Attwell 2012). Nonetheless, most scientists 
agree that myelin in one or both of these ways enabled evolution of large, yet fast and relatively 
energy-sparing nervous systems and, therefore, enabled better muscle control and more complex 
behavior. As such, myelin has likely been a critical factor in vertebrate evolution (Nave 2010a, Harris, 
Attwell 2012, Zalc, Goujet & Colman 2008). 
Myelin may preserve axons
As a third benefit, oligodendrocytes may be required for the preservation of axons (Nave 2010a, Nave 
2010b). For example, oligodendrocytes provide trophic support to axons via the delivery of pyruvate 
or lactate through monocarboxylic acid transporters (MCT)-1 and -2. This supplies the axons with 
a ready-to-use source of energy, and saves axons from performing glycolysis (Funfschilling et al. 
2012, Lee et al. 2012b). In addition, adult oligodendrocytes express neurotrophic factors, such as 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and insulin-like growth factor-1 
(IGF-1) (Smith, Cooksey & Duncan 2013). Furthermore, oligodendrocytes may stabilize the axonal 
cytoskeleton and facilitate transport of axonal organelles (reviewed in: (Franklin et al. 2012b)).  
Finally, the importance of myelin and oligodendrocytes is evident from diseases that primarily 
affect these cells, such as genetic leukodystrophies. A well-known example is Pelizaeus-Merzbacher 
disease, resulting from a recessive, X-linked mutation in the PLP gene. The type of mutation varies 
and so does the disease phenotype, but important clinical signs include nystagmus and hypotonia 
that usually progress to gait disturbance and spastic paraplegia. These symptoms generally develop 
in young children, signifying that oligodendrocyte progenitor cell (OPC) development, which occurs 
prenatally, is normal, but postnatal myelin folding to a compact wrap is severely disturbed (Garbern 
2007). What, then, is required for normal oligodendrocyte development and myelination? 
16
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THE MYELIN MAKERS AND MORE: OLIGODENDROCYTE PROGENITOR CELLS AND 
OLIGODENDROCYTES
Specific transcription factors mediate the generation of oligodendrocyte progenitor cells 
from neural stem cells
During embryonic development of the vertebrate CNS, when many neurons have already been 
developed, OPCs are derived from neural stem cells in the neural tube. Different cell types develop 
from the same neuroepithelium, because the neural tube is patterned into distinct domains by 
regional gradients of specific morphogens. These morphogens are bone morphogenetic protein 
(BMP), fibroblast growth factor (FGF) and Wnt for the roof plate or dorsal zone, and sonic hedgehog 

















































Figure 2. Oligodendrocyte progenitor cell development and lineage progression towards myelinating 
oligodendrocytes. The embryonic spinal cord is patterned into distinct domains by regional gradients of the 
morphogens bone morphogenic protein (BMP), Wnt and sonic hedgehog (Shh). Neural progenitor cells from 
the dP6 and pMN domains develop into oligodendrocyte progenitor cells. Oligodendrocyte progenitor cells 
are repressed in their undifferentiated state through a complex inhibitory transcription factor network, of 
which several key players are shown. Olig2 expression is prevented by Inhibitor of DNA-binding-2 (Id2), Id4 and 
transcription factor 4 (Tcf4), for which β-catenin is an important stimulant. Further, Sox10 is inhibited by Hes5 and 
Sox5/6, with additional important transcription factors being Olig1, Nkx2.2, Egr1 and Sox11. Oligodendrocyte 
progenitor cells proliferate under the influence of growth factors, including platelet-derived growth factor-AA 
(PDGF-AA), fibroblast growth factor-2 (FGF-2), brain-derived neurotrophic factor (BDNF), insulin-like growth 
factor-I (IGF-I) and neuregulin. These growth factors signal together with extracellular matrix molecules, such as 
tenascin-C, which binds to the integrin receptor αvβ3. On removal of signaling from the inhibitory transcription 
factor network, mediated among others by YingYang-1 (YY1) and the micro RNAs (miRNA) -138, -219, and 
-318, oligodendrocyte progenitor cells develop into pre-myelinating oligodendrocytes. Transcription of the 
important myelin proteins myelin basic protein (MBP) and proteolipid protein (PLP) is initiated. To prevent 
premature myelination, oligodendrocytes express Lingo-1 and axons (blue) synthesize several factors, including 
Jagged, polysialylated-neural cell adhesion molecule (PSA-NCAM), nerve growth factor (NGF) and galectin-4. 
Conversely, presumably at the correct time, axons also promote myelination from signaling via adenosine and 
glutamate, as well as the axonal adhesion molecules laminin-2 and L1. Correct folding of the oligodendrocyte 
plasma membrane into the compacted myelin sheath requires, among others, polarized transport of PLP 
and MBP. The compacted structure is only maintained if myelin gene regulatory factor (MRF) is continuously 
expressed from the post-mitotic stage, and all the elements of the sheath are properly localized, shown here for 
neurofascin-155 (NF-155; brown) in the paranode, PLP (red) and MBP (yellow) at distinct sites in the internode, 
and myelin-associated protein (MAG) in the periaxonal site. Elements of the figure were adapted from (Emery 
2010, Fancy et al. 2011).
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specific transcription factors relevant for the development towards their eventual cell fate (Rowitch, 
Kriegstein 2010). The majority of OPCs originate from neural progenitor cells in the motoneuron 
(pMN) domain of the ventricular zone. Specifically, on Shh signaling here, the transcription factors 
Nkx6 and Olig2 are transcribed, initiating the differentiation of ventral neural progenitor cells into 
motor neurons and OPCs (Briscoe et al. 2000, Zhou, Anderson 2002). In addition, a smaller proportion 
of OPCs originate from neural progenitors in the dorsal neuroeptihelium (dP6) (Cai et al. 2005, 
Vallstedt, Klos & Ericson 2005, Fogarty, Richardson & Kessaris 2005) (Fig. 2). OPCs can be recognized 
by the expression of transcription factors (as discussed below), platelet-derived growth factor 
receptor alpha (PDGFR-α) and the proteoglycan NG2 (Rivers et al. 2008, Zhu, Bergles & Nishiyama 
2008, Zhu, Hill & Nishiyama 2008), although PDGFR-α is expressed by many other cell types outside 
the CNS, and NG2 also marks immature Schwann cells, pericytes and muscle progenitor cells (Trotter, 
Karram & Nishiyama 2010). OPCs display some lineage plasticity, in that they can also differentiate 
into neurons (Rivers et al. 2008), astrocytes (Tatsumi et al. 2008) and Schwann cells (Zawadzka et al. 
2010), but the vast majority of OPCs commits to differentiate into oligodendrocytes (reviewed in: 
(Richardson et al. 2011)). 
Migration and proliferation of oligodendrocyte progenitor cells is promoted by a variety of 
signaling pathways
Before differentiating into myelin-producing oligodendrocytes, OPCs proliferate and migrate 
throughout the developing CNS. To this end, motility of OPCs is increased, most notably by PDGF-AA 
from astrocytes (Fruttiger et al. 1999, Baron, Shattil & ffrench-Constant 2002b) and FGF-2 (McKinnon 
et al. 1990) that activates several mitogen-activated protein kinase (MAPK) pathways downstream 
(Baron et al. 2000). Simultaneously, OPCs proliferate to increase their numbers, which is guided by 
a variety of extracellular signals. Among these signals are growth factors, such as BDNF signaling to 
tyrosine kinase receptor-B (trkB) (Van’t Veer et al. 2009, Wong et al. 2013), PDGF-AA (Fruttiger et al. 
1999), neuregulin (Canoll et al. 1996), IGF-1 (McMorris, Dubois-Dalcq 1988) and FGF-2 (McKinnon et 
al. 1991), while IGF-1 and FGF-2 can also synergize (Jiang, Frederick & Wood 2001) (Fig. 2). Cellular 
sources of these growth factors are OPCs themselves, but also, for example, astrocytes for PDGF-
AA and neurons for neuregulin (Fruttiger et al. 1999, Canoll et al. 1996). In addition to these long-
range signals, some extracellular matrix (ECM) proteins act as local promoters of OPC proliferation, 
for instance tenascin-C (Garcion, Faissner & ffrench-Constant 2001). OPCs recognize ECM proteins 
among others via a variety of integrin receptors, namely αvβ3, αvβ8, α6β1, αvβ5 and αvβ1 (Baron, 
Colognato & ffrench-Constant 2005, O’Meara, Michalski & Kothary 2011). Binding of ECM ligands to 
integrin receptors on OPCs provides a means of integrating long-range cues from growth factors 
with short-range cues from the ECM. For example, proliferation of OPCs on PDGF-AA benefits 
from binding of ligands to αvβ3, with binding partners being the local ECM proteins fibronectin 
and vitronectin in addition to PDGF-AA itself (Baron, Shattil & ffrench-Constant 2002a). Further, 
tenascin-C, a ligand for αvβ3, amplifies responsiveness of OPCs to PDGF-AA (Garwood et al. 2004) 
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(Fig. 2). Migration of OPCs throughout the CNS occurs in parallel to proliferation and is stimulated 
to some extent by the same factors. Accordingly, PDGF-AA also acts as a chemoattractant (Zhang 
et al. 2004), similar to semaphorins of class 3 and netrin-1 (Spassky et al. 2002). Additional signals 
to enhance proliferation of OPCs include neuregulin-1 (Ortega et al. 2012) and ECM proteins, such 
as anosmin-1 (Bribian et al. 2008) and laminin-2 (Frost et al. 1996). To promote OPC proliferation 
and migration, integrin activation results, among others, in cytoskeletal remodeling downstream, 
for which the phospoinositide-3-kinase (PI3K)/Akt and Ras/MAPK pathways are important. Integrin 
receptors also interact with other receptors, such as the epidermal growth factor (ErbB) receptor 
(O’Meara, Michalski & Kothary 2011) and PDGFR-α, which further enhances proliferation and 
migration (Baron, Colognato & ffrench-Constant 2005, Baron, Shattil & ffrench-Constant 2002a, 
Baron et al. 2003). Finally, electrical activity from axons is an important regulator for proliferation and 
migration, as well as throughout the myelination process. Early evidence for the necessity of action 
potentials for myelination was provided by studies on newborn mice that were reared in the dark. 
Without light, and hence without much electrical activity in their optic nerves, these mice displayed 
a substantial decrease in myelinated optic nerve fibers (Gyllensten, Malmfors 1963). Moreover, early 
opening of rabbit eyes facilitates early myelination (Tauber, Waehneldt & Neuhoff 1980) (reviewed 
in (Coman et al. 2005)). Proliferation of OPCs is stimulated by electrical activity via the release of 
PDGF-AA (Barres, Raff 1993, Gallo et al. 1996). Similarly, migration is promoted by reducing binding 
of αv integrin on OPCs to the ECM (Gudz, Komuro & Macklin 2006). Additional roles for electrical 
signals at later stages in the myelination process will be discussed below.
Differentiation of oligodendrocyte progenitor cells according to the derepression model
Maturation of OPCs involves their progression through different development stages from immature, 
premyelinating oligodendrocytes towards mature, myelinating oligodendrocytes (Fig. 2), with 
myelination taking place predominantly after birth. Differentiation of OPCs into oligodendrocytes 
requires appropriate timing, so that eventual myelination is initiated when both the OPC and the 
axon are ready. Among others, this careful coordination in time and space avoids myelin assembly 
from occurring inside the OPC or in processes that are not within close reach of axons (Simons, Trotter 
2007). In fact, myelination is such a neatly timed process that assessing the extent of myelination in 
a human fetus allows for a precise determination of its age (Friede 1973, Wang et al. 1998), and the 
time window of opportunity for developmental myelination to take place is considered extremely 
narrow (Czopka, ffrench-Constant & Lyons 2013). The intrinsic regulation of OPC differentiation 
is proposed to occur according to the ‘derepression model’ of myelination (Casaccia-Bonnefil, 
Liu 2003, Wegner 2008, Emery 2010). In this model, OPCs are repressed in their undifferentiated 
state by the continuous expression of transcription factors that inhibit myelin gene expression, 
and this repression is mediated by extracellular signals. When the environment is permissive for 
oligodendrocyte differentiation, downregulation of the inhibitory transcription factors occurs in 
OPCs, which enables transcription of myelin genes. Important transcription factors that stimulate 
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myelin gene expression, including the transcription of PLP and MBP, are Olig2 (Zhou, Anderson 
2002) and Sox10 (Wegner 2008, Stolt et al. 2003). Hence, to maintain OPCs in their undifferentiated 
state, repression of Olig2 and Sox10 is required. The inhibitory transcription factors that repress 
Olig2 comprise Inhibitor of DNA-binding-2 (Id2), Id4 and transcription factor 4 (Tcf4) (Wegner 2008, 
Kondo, Raff 2000, Samanta, Kessler 2004, Marin-Husstege et al. 2006, He et al. 2007). At this stage, 
OPCs express the G-protein coupled receptor-17 (GPR-17), which may enforce Id2/Id4 activity (Chen 
et al. 2009). Furthermore, an important regulator of Tcf4 expression in OPCs is stabilized β-catenin 
resulting from Wnt signaling (Fancy et al. 2009). Myelin gene transcription from Sox10 activity is 
repressed by the transcription factors Hes5 (Liu et al. 2006) and Sox5/6 (Stolt et al. 2006) (reviewed 
in (Wegner 2008)). On maturation of OPCs, the expression of Id4 and Tcf4 is eventually inhibited 
by Ying Yang-1 (YY1) via chromatin remodeling through histone deacetylase-1 (HDAC-1) (Wegner 
2008, He et al. 2007). Other transcription factors that are essential for myelination include Olig1 (Xin 
et al. 2005) and Nkx2.2 (Qi et al. 2001), and additional important inhibitory transcription factors are 
Egr1 and Sox11 (Swiss et al. 2011). 
At the controls of this inhibitory transcription factor network (or: ‘transcriptome’) sits the OPC 
together with its environment. Internal control of maturation from OPC to oligodendrocyte is evident 
from primary oligodendrocyte cultures without any other cells – most notably axons – in which OPCs 
still mature towards oligodendrocytes, albeit with flat myelin sheets rather than sheaths (Dubois-
Dalcq et al. 1986). However, in vivo, the environment interferes with rapid lineage progression, 
presumably to ensure that myelination is properly timed. In particular axons communicate with 
OPCs at different steps of the myelination process. First, axonal signals are important to inhibit 
premature OPC differentiation. Inhibitory signaling molecules from axons include Jagged1 to 
the Notch1 receptor on OPCs (Wang et al. 1998), polysialylated-neural cell adhesion molecule 
(PSA-NCAM) (Charles et al. 2000), nerve growth factor (NGF) to tyrosine kinase receptor-a (TrkA) 
on OPCs (Chan et al. 2004) and galectin-4 (Stancic et al. 2012). Also, the transmembrane protein 
Lingo-1 in differentiating OPCs inhibits premature myelination (Mi et al. 2005) (Fig. 2). Secondly, 
axonal signals participate in target-dependent survival. This process, also named ‘oligodendrocyte 
pruning’ (Piaton, Gould & Lubetzki 2010), describes how, during CNS development, a substantial 
proportion of OPCs undergoes apoptosis, because OPCs are physiologically generated in excess 
relative to final oligodendrocyte numbers in the mature CNS (Barres et al. 1992). The majority of 
surviving OPCs are those that establish contacts with axons, and one of the survival signals involved 
is laminin-2 from axons, which binds to the α6β1 integrin receptor on OPCs (Frost et al. 1999). 
Thirdly, axonal molecules promote differentiation of selected OPCs into oligodendrocytes before 
the actual myelination process commences. Axonal molecules that stimulate differentiation of OPCs 
include laminin-2 signaling to α-dystroglycan and α6β1 integrin, with the latter facilitating MAPK 
activation on neuregulin-1 (Colognato et al. 2002, Colognato et al. 2007). Laminin also acts via Fyn, 
focal adhesion kinases and Rho GTPases to change actin dynamics and initiate OPC differentiation 
(Hoshina et al. 2007). Although laminin is not the single essential factor in myelination, its relative 
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significance is clear from regional hypomyelination that is observed in dy/dy mice, which are largely 
deficient in laminin-α2 (Chun et al. 2003). In fact, based on the complex molecular mechanisms 
involved in CNS myelination, it is considered unlikely that this process is under control of a single 
essential molecular element at all. This marks a difference with PNS myelination, where Schwann cell-
mediated myelination is largely controlled by axonal growth factor neuregulin-1 type III signaling 
to ErbB receptors (Michailov et al. 2004, Taveggia et al. 2005). In addition to axonal molecules, 
electrical activity from axons also promotes differentiation of OPCs (Demerens et al. 1996). This 
may be mediated by neurotransmitters released from axon potentials, such as adenosine signals to 
purinergic receptors on OPCs (Stevens et al. 2002). Furthermore, some OPCs respond to glutamate 
with membrane depolarization, resulting from ion travel through voltage-gated sodium and 
potassium channels (Karadottir et al. 2008), although it is still unclear how this affects their lineage 
progression and myelination (reviewed in (Emery 2010)). Alongside stimulatory axonal factors, 
differentiation of OPCs also requires downregulation of transcription factors that inhibit myelin 
gene expression. Important mediators to downregulate these transcription factors are microRNAs, 
a type of small non-coding RNAs that inhibit gene expression after transcription by preventing 
translation or by degrading mRNA. During differentiation of OPCs, microRNAs are induced, in 
particular microRNA-138, -219 and -338, that downregulate Sox6, Hes5 and PDGFR-α among others, 
thereby exiting OPCs from the proliferative cell cycle (Dugas et al. 2010, Zhao et al. 2010). Further, 
post-mitotic oligodendrocytes express the transcription factor myelin-gene regulatory factor (MRF), 
which is essential for myelination and myelin maintenance (Emery et al. 2009, Koenning et al. 2012). 
Biosynthesis and compaction of the myelin sheath involves axonal signals as well as site-
specific clustering of myelin proteins and lipids
Once OPCs are differentiated into oligodendrocytes, they face the task of extending their plasma 
membrane to the axons and produce myelin. This is again a complex, multi-step program, 
requiring polarization (Baron, Hoekstra 2010, Simons, Trajkovic 2006). First, the oligodendrocyte 
plasma membrane needs to recognize and adhere to the correct axon, avoiding interactions with 
dendrites (Lubetzki et al. 1993). Then, myelin proteins and lipids are synthesized and transported 
in a polarized manner to the plasma membrane extensions or processes, followed by biogenesis 
of the sheath. Finally, the sheath is wrapped around the axon in multiple layers, before compaction 
to its mature form occurs. Axons play an important role in the coordination of myelination at this 
stage. Biochemically, the axonal adhesion molecule L1 and laminin-2 signal to the α6β1 receptor, 
expressed on the surface of oligodendrocytes, to activate Fyn kinase, which promotes MBP mRNA 
synthesis and transport to the correct site in the outgrowing oligodendrocyte processes (White et al. 
2008, Laursen, Chan & ffrench-Constant 2009). Also, laminin-2 signals via the dystroglycan receptor 
to promote myelin membrane formation (Colognato et al. 2007). In addition, action potentials 
may play a role. For example, the neurotransmitter glutamate signals to NMDA and metabotropic 
glutamate receptors on oligodendrocytes to activate Fyn kinase which, as indicated, promotes MBP 
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synthesis (Wake, Lee & Fields 2011) (Fig. 2). Finally, by an indirect mechanism, the release of ATP 
from action potentials stimulates astrocytes to synthesize leukemia inhibitory factor (LIF), which 
also promotes myelination by oligodendrocytes (Ishibashi et al. 2006). 
In the final steps of myelination, the myelin sheath is properly folded around the axon and 
compacted into its definite form. In order to achieve this, site-specific clustering of myelin proteins 
and lipids is required. This involves, among others, polarized transport and proper positioning of 
MBP and PLP to distinct sites in the internode, that of NF-155 to the paranode, and MAG to the 
periaxonal site (Simons, Trajkovic 2006) (Fig. 2). In addition, glycolipid-enriched microdomains, 
termed ‘lipid rafts’, are generated, which also contribute to correct positioning of myelin molecules 
at axon-myelin sheath interaction sites, and hence to myelin assembly (reviewed in: (Gielen et al. 
2006)). MBP, which exists in different isoforms that may have different functions (de Vries et al. 1997, 
Harauz, Boggs 2013), is transported from the oligodendrocyte nucleus to the myelin sheath in the 
form of mRNA, packed in granules, which are only translated into MBP in the sheath, presumably 
to prevent premature membrane clustering. Conversely, after protein translation at the ER, the 
transport of PLP occurs in vesicles, via the Golgi to the plasma membrane and subsequently to the 
myelin sheath in a process known as transcytosis (Baron, Hoekstra 2010, Trajkovic et al. 2006). The 
coordination of correct and polarized transport from these and other proteins and lipids is complex 
and incompletely understood, although they are likely mediated by axonal cues (Simons, Trajkovic 
2006, Trajkovic et al. 2006), with important roles for  axonal adhesion factors and secreted soluble 
factors (reviewed in: (Baron, Hoekstra 2010, Simons, Trotter 2007, Maier, Hoekstra & Baron 2008). 
However, the observation that oligodendrocytes myelinate synthetic nanofibers (Lee et al. 2012a) 
indicates that axonal signals may also be largely non-specific and perhaps more important for 
correct timing of myelination. Finally, important players in the myelin-related trafficking machinery 
are likely Rab proteins and soluble NSF attachment protein receptor (SNARE) proteins, including 
distinct vesicle-associated membrane proteins (VAMPs), acting as v-SNARES, and syntaxins, as part 
of the t-SNARES at the recipient target membrane (Simons, Trajkovic 2006, Feldmann et al. 2009).  
Oligodendrocyte progenitor cells in the adult central nervous system
During adulthood, OPCs remain present throughout the CNS (Pringle et al. 1992, Dawson et al. 
2003). An important source of OPCs in the adult are neural stem cells from specific niches, such as 
the subventricular zone (Menn et al. 2006a), and signals to induce OPC formation from these neural 
stem cells include Wnt (Ortega et al. 2013) and those repressing sirtuin 1 (SIRT1) (Rafalski et al. 2013). 
The purposes of OPCs in the healthy, adult CNS have not yet been fully elucidated. Yet, it is likely 
that OPCs differentiate and continue to generate myelin during adulthood (Young et al. 2013), and 
in this way may replace ‘old’ oligodendrocytes and add to existing myelin (reviewed in (Richardson 
et al. 2011)). Indeed, myelin appears to be a dynamic structure in the adult, because myelination 
continues until late in life (Fields 2008). Interestingly, myelination may even increase in specific 
regions on practicing of particular skills, for example juggling (Scholz et al. 2009) or piano playing 
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(Bengtsson et al. 2005). For this myelin plasticity, myelin is hypothesized to play an important role 
in cognitive processes, such as learning, and cognitive diseases, among others depression and 
schizophrenia (reviewed in (Fields 2008)). OPCs are also pivotal in myelin regeneration after injury, 
which will be discussed further below.
ASTROCYTES
Phenotypic properties of astrocytes
Astrocytes are the most abundant cells of the CNS. Development of astrocytes starts in the 
embryonic, patterned neural tube, where astrocytes derive from neural progenitor cells in the 
ventricular zone. Important transcription factors to promote development of neural progenitor 
cells into the astrocyte lineage are nuclear factor-IA (NFIA) (Deneen et al. 2006) and Sox9 (Kang et 
al. 2012). Subsequently, astrocytes migrate throughout the developing CNS in strict accordance to 
their original embryonic site (Tsai et al. 2012). In the adult, astrocytes do not normally proliferate, 
except for after injury to the CNS (Buffo et al. 2008). On invasive injuries, such as stab wounding, 
astrocytes can acquire neural stem cell properties again via Shh signals (Sirko et al. 2013). Astrocyte 
morphologies differ per brain region, and on injury, astrocytes from different regions cannot fully 
replace each other functionally (Tsai et al. 2012). In the grey matter, astrocytes are protoplasmic 
with ramified branches that connect to synapses and blood vessels. In the white matter, astrocytes 
are fibrous (or fibrillary) and have longer and thinner processes that contact nodes of Ranvier 
and blood vessels. Further, additional astrocyte phenotypes can be recognized in specific brain 
locations, such as Bergmann glia in the cerebellum and Müller glia in the retina (reviewed in: (Barres 
2008, Sofroniew, Vinters 2010)). Astrocytes express glial fibrillary acidic protein (GFAP) and aldehyde 
dehydrogenase 1 family member L1 (Aldh1L1) (Lovatt et al. 2007, Cahoy et al. 2008). Mutations in 
the GFAP gene are associated with Alexander’s disease that causes clinical symptoms ranging from 
convulsions and mental retardation to bulbar signs, muscle weakness and hyperreflexia. How GFAP 
and, by extension, astrocyte dysfunction mediates these symptoms is unknown (Yoshida, Nakagawa 
2012), and in fact, functions of astrocytes in the healthy brain are still far from being completely 
understood (Barres 2008)
Functions of astrocytes
Thus far, astrocytes have mainly been considered support cells for the blood-brain barrier (BBB) and 
neurons. The BBB consists of closely linked endothelial cells, sealed via tight junctions, and connected 
to a basal lamina of extracellular matrix proteins, including laminin and fibronectin, and to pericytes 
and astrocytes (Lampron, Elali & Rivest 2013). The BBB protects the parenchyma of the CNS against 
entry of potentially adverse molecules, whereas it facilitates the entry of nutrients via specific 
transporters. In addition, the BBB is closely associated with neurons to regulate a correct CNS ion 
balance. Ultimately, cerebral blood flow is largely controlled by neuronal activity (Koehler, Roman & 
Harder 2009). Astrocytes structurally support the BBB with their end-feet that are connected to the 
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capillaries, largely via integrin receptors (Koehler, Roman & Harder 2009). In addition, astrocytes play 
a role in regulating blood flow through the capillaries (Hawkins, Davis 2005), although molecular 
mechanisms behind this remain to be elucidated (Koehler, Roman & Harder 2009). Astrocytes 
also sustain neurons (Rowitch, Kriegstein 2010), and they may participate in neuronal signaling at 
the synapse in the concept of the ‘tripartite synapse’. To modify synaptic transmission, astrocytes 
may release neurotransmitters (Araque et al. 1999), although there is controversy over whether 
astrocytes release glutamate (Barres 2008) or any other neurotransmitter (Agulhon et al. 2008) in 
vivo. However, astrocyte signaling at the synapse may also occur independent of neurotransmitters 
(Nedergaard, Verkhratsky 2012). Finally, astrocytes are mediators of the innate immune response in 
the brain (Ransohoff, Brown 2012), which will be discussed next.
ARCHITECTURE OF THE BRAIN IMMUNE SYSTEM: MICROGLIA AND MACROPHAGES
The central nervous system is relatively immune privileged
The immune defense system of the brain is unlike that of any other organ. The healthy brain 
parenchyma is largely depleted of adaptive immune cells, with T-cells predominantly residing in 
the cerebrospinal fluid (CSF). Cells with innate immune functions are present, primarily astrocytes 
and microglia, but also a minority of mast cells and macrophages are settled in the meninges and in 
perivascular spaces of parenchyma capillaries and arteries (Ransohoff, Engelhardt 2012). The brain 
is relatively ‘immune privileged’, meaning that delivery of immunogenic material directly to the 
brain parenchyma does not elicit a classical, adaptive immune response. Such a classical immune 
response would require antigen presentation to naïve T-cells (the afferent arm), and the subsequent 
entry of activated T-cells into the brain parenchyma, thereby resulting in local immune activity 
(the efferent arm). The immune privilege of the brain is principally considered to be mediated by 
unusual functioning of the afferent arm, in that CNS antigen presenting cells (APCs) cannot easily 
travel to lymph nodes to present antigens to naïve T-cells (Galea, Bechmann & Perry 2007). APCs in 
the CNS comprise the meningeal and perivascular macrophages, whereas microglia, although they 
express some major histocompatibility class (MHC) II molecules, have a limited capacity to present 
antigens (Ransohoff, Cardona 2010). Despite the limitations in APC travel to lymphoid organs, 
soluble antigens drain through the perivascular spaces to lymphatic vessels in the nasal submucosa 
(reviewed in: (Galea, Bechmann & Perry 2007)). Also, memory T-cells likely enter the CNS from the 
CSF by various trafficking mechanisms, including α4β1 integrin-mediated transmigration across 
the BBB (Ransohoff, Engelhardt 2012, Ousman, Kubes 2012). This implies that the brain is relatively 
immune privileged, but does not completely lack adaptive immunity.
Microglia are likely versatile cells with a function in brain immunity
Astrocytes and microglia mediate innate immune responses in the CNS. Astrocytes express innate 
immune receptors, such as toll-like receptor (TLR)-2 and TLR-3 (Bsibsi et al. 2002) and nucleotide-
binding oligomerization domain receptor (NLR) proteins (Minkiewicz, de Rivero Vaccari & Keane 
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2013). On immunological activation, astrocytes express complement factors, interleukins and other 
cytokines and chemokines (reviewed in: (Ransohoff, Brown 2012)). Microglia originate from myeloid 
yolk sac progenitors, which colonize the CNS early in embryonic life, and they maintain their 
population by local proliferation (Ginhoux et al. 2010). Hence, microglia classify as haematopoietic 
cells, unlike macroglia (such as oligodendrocytes and astrocytes) and neurons (Ransohoff, Cardona 
2010). Indeed, microglia share many properties with macrophages, and cannot be discriminated 
from macrophages by known biochemical markers. Microglia express all TLRs (van Noort, Bsibsi 
2009, Lehnardt 2010), and on engagement of these receptors display innate immune activity 
similar to astrocytes, albeit generally more fulminantly (Ransohoff, Brown 2012). Furthermore, 
several microglia phenotypes can be distinguished in correspondence with the M1/M2 concept 
for macrophages (Durafourt et al. 2012). In this concept, macrophages and microglia can display 
a pro-inflammatory phenotype (M1), for instance if activated by interferon-γ (IFN-γ), to enhance 
antigen presentation properties and secrete pro-inflammatory cytokines, such as tumor necrosis 
factor-α (TNF-α), interleukin-1β (IL-1β) and IL-12, as well as reactive oxygen species. Conversely, an 
alternatively activated profile (M2) has been described as well, and was later subdivided into the 
M2a, M2b and M2c subtypes. In M2a and M2c, microglia and macrophages display anti-inflammatory 
and pro-regenerative features; for M2a including enhanced expression of arginase-1, the mannose 
receptor, IGF-1 and PDGF, and for M2c comprising IL-10 and TGF-β expression. The M2b phenotype 
is associated with the humoral response to bacteria, and thus involves macrophage and microglia 
secretion of TNF-α, Il-1β and IL-12 (Gordon 2003, Edwards et al. 2006, Martinez, Helming & Gordon 
2009). In addition, intermediate activation types likely exist.  
However, microglia maintain brain homeostasis also independent of immune activity. In the 
healthy brain, ramified microglia elongate and retract their processes unremittingly, likely to 
monitor the environment (Nimmerjahn, Kirchhoff & Helmchen 2005). Non-activated microglia 
promote survival and maturation of developing OPCs (Nicholas, Wing & Compston 2001). Similarly, 
ramified microglia contribute to the regulation of neuronal cell numbers in developmental and 
adult neurogenesis, partly independent of phagocytosis. Furthermore, microglia likely participate in 
neuronal circuit formation via direct interactions with neurons (reviewed in: (Wake et al. 2013)). Also, 
microglia may mediate myelin turnover via macropinocytosis of exosomes from oligodendrocytes 
(Fitzner et al. 2011). Finally, primary microglia dysfunction may partly explain the pathogenesis of 
Nasu-Hakola disease (also known as polycystic lipomembranous osteodysplasia with sclerosing 
leukoencephalopathy). This disease, which affects patients with recessively inheritable mutations in 
the DAP12 and TREM2 genes, is characterized by the insidious development of ossal pain from bone 
cysts and subsequent character changes and dementia from neurodegeneration. Because DAP12 
and TREM2 are exclusively expressed in osteoclasts and myeloid cells, microglia are implied in Nasu-
Hakola pathogenesis (Bianchin et al. 2004). In short, to regard microglia solely as brain resident 
macrophages, with a primary immune function, could well impose a limited view on these cells 
(Graeber 2010).
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Having discussed roles of glial cells in health, we will now focus on their involvement in the CNS 
disease multiple sclerosis (MS).
MULTIPLE SCLEROSIS
Clinical symptoms of multiple sclerosis
MS is a CNS disease of diverse symptoms and progression. Patients, usually between the ages of 15 
and 50 years at onset and predominantly females, typically suffer from sensory and motor symptoms, 
visual loss, gait disturbance, balance problems, vertigo and/or bladder problems. These symptoms 
develop from lesions at specific sites within the CNS. To make the diagnosis of MS therefore requires 
the demonstration of such lesions and of their dissemination in time and space according to the 
2010 revisions of the McDonald criteria (Polman et al. 2011). The disease course of MS is variable 
and fairly unpredictable. A relapsing-remitting pattern (relapsing-remitting MS), in which symptom 
attacks and recovery periods alternate, is most common. A minority of patients suffers few attacks 
and recovers completely (benign MS). However, rather than recovery, patients may also experience 
steady decline of neurological functions between relapses from disease onset onwards (progressive 
relapsing MS), or deteriorate after an initial period of relapsing-remitting MS (secondary progressive 
MS). In addition, approximately 10% of MS patients do not experience recovery periods at all and 
deteriorate straight from the onset of the disease (primary progressive MS) (Weinshenker 1994, 
Compston, Coles 2008, Koch-Henriksen, Sorensen 2010). Eventually, disabilities accumulate in 
the majority of MS patients, usually within the course of several decades of time (Tremlett, Paty & 
Devonshire 2006). Therefore, the burden of MS is often considered as one of disability rather than 
increased mortality. MS patients are, however, likely also at a three-fold increased risk for premature 
death, most commonly due to respiratory disease (Hirst et al. 2008, Lalmohamed et al. 2012).  
Pathological hallmarks of multiple sclerosis are versatile and involve neurons as well as glial 
cells
The ethiology of MS lesions is still incompletely understood, despite intense scientific research. 
Many factors have been suggested by inference. These include Eppstein-Barr virus infection (Tzartos 
et al. 2012, Serafini et al. 2013) and reduced vitamin D levels, but also cigarette smoking (reviewed 
in: (Ascherio, Munger & Lunemann 2012)), Further, susceptibility for MS is also associated with 
certain genetic architectures, especially with genes implied in (cell-mediated) immunity and human 
leukocyte antigen (HLA) composition for relapsing-remitting patients (International Multiple 
Sclerosis Genetics Consortium et al. 2011). MS is most prevalent in Europe, North America, Australia 
and New Zealand, where up to 0.1% of the population is affected (Koch-Henriksen, Sorensen 2010). 
However, whether there is a latitudinal gradient for MS incidence, which would suggest a trigger 
from shared environmental exposure, is currently debated (Koch-Henriksen, Sorensen 2010, Poser, 
Brinar 2007)
Several pathological hallmarks are apparent on examining an archetypal acute, active MS lesion 
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(or ‘plaque’) in relapsing-remitting MS patients. Loss of oligodendrocytes occurs with degeneration 
of myelin (demyelination) (Barnett, Prineas 2004). Possibly as a result of demyelination, axons are 
degraded, especially thin axons (Evangelou et al. 2001). Inflammation is evident from activated 
macrophages with ingested myelin sheath fragments, perivascular infiltrates containing T-cells, 
and a minority of B-cells (Lassmann, Bruck & Lucchinetti 2007, Lassmann 2011). Microglia also 
display an activated morphology (Lassmann, Bruck & Lucchinetti 2007) and microglia and infiltrated 
macrophages are of an intermediate activation status, possibly predominantly of the M1 phenotype 
(Vogel et al. 2013). Microglia and macrophages also express NADPH oxidase that may participate in 
oxidative tissue damage (Fischer et al. 2012). Autoantibodies from the complement system against 
axons or myelin are present in a subset of patients (Elliott et al. 2012), and some target the potassium 
channel Kir4.1, thereby likely damaging astrocytes and oligodendrocytes (Srivastava et al. 2012). 
To complete the inflammatory events, astrocytes become hypertrophic and possibly present 
antigens, because they may express MHC molecules (Zeinstra et al. 2000). Also, astrocytes likely 
become activated in other ways, for example by expressing an excess of the free radical precursor 
NADPH (Trapp et al. 1999) and nitric oxide (NO) (De Groot et al. 1997, Oleszak et al. 1998). A final 
pathological feature is the disruption of the BBB (Kirk et al. 2003), which is reflected in an enhanced 
accumulation of gadolinium in active MS lesions when visualized by magnetic resonance imaging 
(MRI). In progressive MS, lesions display largely similar pathological features, but the BBB is often 
intact and axonal injury becomes more pronounced (reviewed in: (Lassmann, van Horssen & Mahad 
2012)). Active and chronic MS lesions can be further sub classified by differences in the density and 
distribution of inflammatory cells (Lassmann 2011). MS lesions occur throughout the CNS white 
matter, but also grey matter (reviewed in: (Geurts, Barkhof 2008)) with cortical lesions accumulating 
especially during progressive MS (Peterson et al. 2001). In cortical lesions, pathological events 
are similar to those in white matter lesions, notably also with respect to inflammatory features 
(Kutzelnigg et al. 2005, Lucchinetti et al. 2011), although inflammation may not be as abundant in 
cortical lesions later in the disease (Peterson et al. 2001). 
Hypotheses to explain the pathogenesis of multiple sclerosis
Which pathological events cause MS lesion formation, and which are merely consequences of the 
disease process? The definite answer to this question is not yet clear, but several hypotheses are 
tested and refined. The autoimmune hypothesis broadly states that myelin-reactive T-cells invade 
the brain, possibly after switching to a migratory phenotype in the lung (Odoardi et al. 2012), 
where they elicit local immune responses and demyelination with secondary axonal degeneration 
(reviewed in: (Nylander, Hafler 2012)). Although the autoimmune hypothesis explains several 
aspects of MS, including the similarities to the experimental autoimmune encephalomyelitis 
(EAE) animal model as well as some of the therapeutic benefits of immunosuppressive agents, 
other features of MS are inconsistent with autoimmunity (reviewed in: (Stys et al. 2012)). Primary 
demyelination is apparent in at least a subset of MS patients (Lucchinetti et al. 2000), and hence, 
27
Glial cells in health and multiple sclerosis
1
in a second hypothesis, it is stated that oligodendrocyte pathology could initiate MS. However, 
whereas inducing oligodendrocyte death in experimental animal models provokes demyelination 
and activation of macrophages and microglia, this does not generate an immune response from 
T-cells, even under conditions favoring autoimmunity (Locatelli et al. 2012, Caprariello et al. 2012). 
Further, others explore whether MS could in effect be a neurodegenerative disorder (Trapp, 
Nave 2008). Still others investigate the possibility that multiple degenerative and immunological 
processes occur in parallel, with a central role for changes in copper-dependent regulation of 
NMDA receptors on myelin (Stys et al. 2012) and/or oxidative stress and mitochondrial dysfunction 
(Lassmann, van Horssen & Mahad 2012). These represent some major contemporary hypotheses on 
MS pathogenesis, but certainly more theories are investigated.  
Therapeutic agents for multiple sclerosis reduce relapses, but do not achieve structural 
recovery 
From a therapeutic perspective, MS relapse rates can be prevented to some extent, but no agent 
currently available definitely halts progression or promotes structural recovery of the inflicted 
injury. Relapse rates in relapsing-remitting MS are decreased on interferon β-1a, interferon β-1b or 
glatiramer acetate (PA et al. 2001, Loredana et al. 2012). Second-line treatments for patients who 
respond poorly or suffer from substantial side-effects include (addition of ) natalizumab (Polman 
et al. 2006, Rudick et al. 2006) and fingolimod (Kappos et al. 2010, Cohen et al. 2010). Natalizumab 
is a selective antibody against the α4 integrin receptor on leukocytes and effectively prevents 
their entry into the brain (Yednock et al. 1992), but it can also reactivate the John Cunningham 
(JC) polyomavirus to cause progressive multifocal leukoencephalopathy (Clifford et al. 2010), and 
hence is prescribed with caution. Fingolimod modifies the sphingosine-1-phosphate receptor 
on lymphocytes to prevent them from leaving lymph nodes (Mandala et al. 2002) and is the first 
oral drug for MS patients, but clinical experience with fingolimod is still limited and requires 
careful monitoring of eventual risks that possibly become evident in clinical practice, such as 
the development of tumefactive MS or rapid disease progression on switching to fingolimod 
(Kinney et al. 2013). Expected first-line additions to this therapeutic arsenal comprise the oral 
immunomodulators laquinimod (Comi et al. 2012) and dimethyl fumarate (BG-12) (Fox et al. 2012, 
Gold et al. 2012). Further, the possible usefulness of alemtuzumab, a monoclonal antibody against 
the CD52 protein on mature lymphocytes, is investigated (Cohen et al. 2012, Coles et al. 2012), as 
well as the additional value of the antibody rituximab against CD20 on B-cells (Dian et al. 2011). 
Although not all of these drugs have been tested or subjected to long-term monitoring in progressive 
MS, their contribution to structural recovery of CNS damage is likely modest (Franklin et al. 2012a), 
allowing for disability to accumulate in MS patients. Substantial therapeutic benefit could therefore 
be expected from strategies that overcome demyelination and axonal degeneration. Given the 
importance of myelin for proper axonal function and axon protection (Franklin et al. 2012a, Bruce, 
Zhao & Franklin 2010) (see above), one of these strategies would be to restore myelin sheaths to 
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demyelinated axons (remyelination), thereby promoting functional recovery after demyelination 
(Duncan et al. 2009). In addition, treatments that promote remyelination would likely also offer a 
therapy for other demyelinating conditions, such as Pelizaeus-Merzbacher disease (see above). 
EXPERIMENTAL MODELS TO STUDY REMYELINATION 
Culture systems and animal models
Insights into why remyelination fails will be facilitated by a thorough understanding of the 
biology of myelin biogenesis and remyelination. Remyelination is a physiological process in the 
CNS, occurring spontaneously for example after demyelination in traumatic injury (Smith, Jeffery 
2006). Remyelination is executed by local OPCs (Zawadzka et al. 2010) (see above), while SVZ OPCs 
contribute predominantly to remyelination of lesions in their proximity (Menn et al. 2006b). Our 
comprehension of the biology of complete remyelination grows from studying OPCs in several 
models. To start with, OPCs are examined in vitro, with the major culture systems making use of 
a) primary OPCs and oligodendrocytes, b) co-cultures of OPCs with dorsal root ganglion neurons, 
c) spinal cord cultures, to which an astrocyte feeding layer may be added and d) cerebellar slice 
cultures. In the latter system, demyelination can be induced by adding lysolecithin to the culture 
medium, which is subsequently followed by remyelination over two weeks. Despite their artificial 
nature, observations from these models are generally in agreement with in vivo findings, and, from 
a practical perspective, genetic manipulation and controlled modulation of other experimental 
conditions are relatively easy to accomplish (reviewed in: (Jarjour et al. 2012, van der Star et al. 
2012)). Whereas the culture systems thrive on cells from neonatal mice and rats, culturing human 
adult OPCs and oligodendrocytes is also attempted (Roy et al. 1999). Secondly, remyelination can 
also be examined in vivo, for example in rodent toxin-induced animal models. These models induce 
demyelination by administering toxins harmful to oligodendrocytes, which evokes an endogenous 
response to achieve remyelination over time, usually several weeks. Examples are a) the dietary 
cuprizone model, resulting in demyelination in distinct brain regions, most notably the corpus 
callosum but also other white and gray matter areas (Matsushima, Morell 2001, Kipp et al. 2009), 
and b) the direct injection of lysolecithin or ethidium bromide into white matter (Woodruff, Franklin 
1999, Blakemore, Franklin 2008). In other in vivo models, rodents with innate mutations in myelin 
genes (‘myelin mutants’) are studied, providing valuable insights into developmental myelination, 
which resembles remyelination in many ways (Franklin, Hinks 1999, Fancy et al. 2011b) (see below). 
A well-known example is the shiverer mouse that suffers from a mutation in the MBP gene and 
hence fails to generate compact myelin (reviewed in: (Duncan, Kondo & Zhang 2011)). Furthermore, 
additional models are tested for their eventual merits, with examples being zebrafish myelination 
(Buckley, Goldsmith & Franklin 2008, Czopka, Lyons 2011) and targeted cell ablation in Xenopus 
(Kaya et al. 2012). Our understanding of why remyelination fails in MS will improve by using these 
models in conjunction with studies on post-mortem human MS lesions and models of the MS 
disease, such as Theiler’s murine encephalomyelitis virus (TMEV) model (van der Star et al. 2012, 
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Tsunoda, Fujinami 2010) and the EAE animal model for relapsing-remitting MS. The EAE model is 
characterized by adaptive immune-mediated demyelination in a chronic or relapsing pattern as 
a result of immunizing animals with myelin-derived antigens, for instance MOG, MBP or PLP, or 
constitutive expression of a myelin receptor on T-cells. Relapses are followed by remissions, in which 
remyelination is evident (Batoulis et al. 2011). Remyelination also occurs to a variable extent in a 
proportion of MS lesions (Patrikios et al. 2006), as is evident from thinner myelin sheaths relative to 
the axon diameters and shorter internode lengths (reviewed in: (Franklin, ffrench-Constant 2008)). 
However, remyelination is unsuccessful in chronic demyelinated lesions despite a relative excess of 
OPCs in most lesions (Wolswijk 1998, Wolswijk 2002). Why, then, does remyelination eventually fail 
in MS?
REMYELINATION IN MULTIPLE SCLEROSIS BY ENDOGENOUS CELLS
Remyelination commences with the activation of oligodendrocyte progenitor cells
Spontaneous remyelination requires OPCs to a) become activated, b) proliferate and migrate 
towards the lesion (‘recruitment’) and c) differentiate into myelinating oligodendrocytes (reviewed 
in: (Franklin, ffrench-Constant 2008)). Activation of OPCs may be achieved by soluble signals 
from activated astrocytes and microglia (Rhodes, Raivich & Fawcett 2006) and is characterized by 
alterations in the morphology of OPCs (Reynolds et al. 2002). Further, activated OPCs re-express 
factors important for myelination, for example Shh (Ferent et al. 2013) and transcription factors such 
as Nkx2.2 and Olig2 (Watanabe, Hadzic & Nishiyama 2004, Talbott et al. 2005) as well as Olig1, which 
is essential for remyelination (Arnett et al. 2004). Indeed, coordination of subsequent proliferation 
and migration involves recapitulation of many intracellular and extracellular factors that guide 
developmental myelination (Franklin, Hinks 1999, Fancy et al. 2011a) (see above). For example, the 
familiar mitogens FGF-2 and PDGF-AA (Williams et al. 2007), and ECM molecules such as laminin (van 
Horssen et al. 2006, Satoh, Tabunoki & Yamamura 2009) are upregulated in demyelinated lesions. 
Several prerequisites for successful oligodendrocyte progenitor cell maturation
In order for activated OPCs to proceed through subsequent stages of remyelination successfully 
(Fig. 2), several prerequisites have to be met. These include the presence of astrocytes, possibly 
favourably activated (Talbott et al. 2005, Blakemore, Gilson & Crang 2003), microglia (Li et al. 2005) 
and macrophages (Kotter et al. 2005). Which elements in the presence of these cells are necessary 
for remyelination and which are redundant is not yet clear. Many beneficial elements may be similar 
to those required for regeneration of other tissues, such as salamander limbs or cutaneous wounds 
that also need innate immune activity (Deonarine et al. 2007, Godwin, Pinto & Rosenthal 2013). 
Some specific helpful effects of innate immune activity for remyelination have been identified. An 
example is tumor necrosis factor-α (TNF-α) (Arnett et al. 2001), which is synthesized, among others, 
by microglia/ macrophages on iron efflux of astrocytes (Schulz, Kroner & David 2012). To enhance 
remyelination, TNF-α signals to the TNF receptor 2 (TNFR-2) on astrocytes, which results in increased 
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expression of CXCL12, a chemokine that promotes remyelination (Patel et al. 2012) by stimulation 
of its receptor CXCR7 on OPCs (Gottle et al. 2010). In line with these beneficial effects, inhibition 
of TNF-α enhances the number of relapses in MS (The Lenercept Multiple Sclerosis Study Group, 
1999). However, TNF-α may also signal to the TNF receptor 1 (TNFR-1) on OPCs and other glial cells, 
which is associated with cell death (Tartaglia et al. 1991, Tchelingerian et al. 1995). In accordance, a 
blocking antibody against soluble TNF-α, which predominantly signals to TNFR-1, is associated with 
recovery and remyelination in EAE (Brambilla et al. 2011). Other (predominantly) favorable immune 
molecules include IL-1β (Mason et al. 2001), activin-A from M2 polarized microglia (Miron et al. 2013) 
and endothelin-2, which signals to the endothelin receptor B on OPCs (Yuen et al. 2013). Innate 
immune activity is further considered important for the removal of myelin debris. Whether myelin 
debris is a major obstacle for remyelination in MS remains to be established, but myelin debris has 
the capacity to inhibit remyelination (Kotter et al. 2006). Phagocytosis of myelin debris benefits 
from a) recruitment of microglia by astrocytes (Skripuletz et al. 2013) and b) competent monocytes, 
which in this study meant ‘juvenile’ rather than ‘aged’ monocytes (Ruckh et al. 2012). Indeed, 
remyelination likely becomes less efficient with age due to a change in the innate immune response 
to demyelination (Ruckh et al. 2012, Zhao, Li & Franklin 2006). Possibly reflecting the availability of 
some of the factors just discussed, the capacity to remyelinate also differs between brain regions. 
For example, white matter lesions remyelinate less extensively than grey matter lesions (Albert et al. 
2007). This may be related to the observation that white matter lesions display more pronounced 
astrogliosis, which refers to an excess of hypertrophic, scarring astrocytes thought to frustrate 
regeneration (Chang et al. 2012). 
Remyelination failure: insufficient mature oligodendrocytes
In MS lesions, OPCs may not meet with sufficient prerequisites for remyelination. In addition, MS 
lesions contain factors that specifically impair remyelination. Contemporary thoughts focus on two 
major obstacles that OPCs meet during their development towards remyelinating oligodendrocytes 
in MS. First, in a subset of MS lesions, insufficient migration and proliferation of OPCs likely accounts 
for remyelination failure. Defective recruitment could be an effect of repeated assaults on OPCs 
as such during the MS disease process (Niehaus et al. 2000, Mason et al. 2004). However, a more 
substantial barrier likely results from the inappropriate expression of factors repellent to OPCs, 
such as certain semaphorins (Williams et al. 2007, Boyd, Zhang & Williams 2013). An upregulation 
of chemorepellent semaphorins corresponds to remyelination failure in up to a third of MS 
lesions (Williams et al. 2007, Boyd, Zhang & Williams 2013), possibly predominantly larger ones 
(reviewed in: (Franklin, ffrench-Constant 2008)). In general, though, OPCs are considered capable 
of replenishing their numbers on repetitive demyelination (Penderis, Shields & Franklin 2003), 
and are abundantly present in the majority of both active and chronic MS lesions (Wolswijk 1998, 
Wolswijk 2002, Schonrock et al. 1998, Kuhlmann et al. 2008). Therefore, the second hypothesis 
attributes remyelination failure largely to defective differentiation of OPCs and further maturation 
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(Franklin, ffrench-Constant 2008, Kuhlmann et al. 2008, Franklin 2002). In support of this, several 
factors that inhibit OPC differentiation have been identified and, in some cases, detected in MS 
lesions. For example, several ECM proteins are not transiently, but permanently upregulated in MS. 
These include chondroitin sulfate proteoglycans (CSPGs) (Sobel, Ahmed 2001) and high molecular 
weight hyaluronan (Back et al. 2005), both inhibitory for remyelination (Back et al. 2005, Lau et al. 
2012). For high molecular weight hyaluronan, the mechanism involves triggering activity from the 
hyaluronidase PH20 in OPCs, resulting in expression of adverse hyaluronan digestion products 
(Preston et al. 2013). Several other ECM proteins are also prominently expressed in demyelinated 
lesions, including fibronectin (Satoh, Tabunoki & Yamamura 2009, Sobel, Mitchell 1989, Zhao et 
al. 2009, Hibbits et al. 2012, Stoffels et al. 2013) (this thesis). However, among these are also ECM 
proteins with a known stimulatory influence on myelination, such as laminin (Colognato et al. 
2002, van Horssen et al. 2006), whereas tenascin-C and tenascin-R are depleted from acute, but not 
chronic lesions (Gutowski, Newcombe & Cuzner 1999). Therefore, the overall effects of ECM and 
other environmental signals, as well as their mutual interactions remain to be established, although 
the net outcome is ultimately unfavourable, given the failure of remyelination. Additional inhibitory 
signals from the environment include PSA-NCAM from axons (Charles et al. 2000), and Jagged 
from astrocytes, which signals to Notch1 on OPCs and keeps them in an undifferentiated state by 
sustaining expression of the transcription factor Hes5 (John et al. 2002). Indeed, other transcription 
factors from the derepression model, which were discussed above, are also persistently upregulated 
in MS OPCs, such as Tcf4, resulting from aberrant canonical Wnt activity via Axin2 (Fancy et al. 2009, 
Fancy et al. 2011c). OPCs further remain undifferentiated due to sustained Lingo-1 expression (Mi et 
al. 2007, Mi et al. 2009)) (reviewed in: (Huang et al. 2011a)). Finally, adverse innate immune activity 
likely contributes to remyelination failure, with unfavourable macrophage/ microglia polarization 
(Miron et al. 2013) and, possibly, mainly detrimental macrophage/ microglia activity (reviewed in: 
(Rawji, Yong 2013)). 
The dysregulation hypothesis of remyelination failure
Interestingly, many of the factors that may impede remyelination in MS are involved in the timing of 
developmental myelination (discussed above) (Franklin, Hinks 1999, Fancy et al. 2011a). Therefore, 
their sustained activity in MS suggests a dysregulation mechanism of remyelination failure. This 
dysregulation mechanism describes that, in contrast to molecular events in developmental 
myelination, the timing and sequence of events guiding OPCs towards remyelination is 
inappropriate, thereby disturbing successful remyelination (Franklin, ffrench-Constant 2008, Fancy 
et al. 2011a, Franklin 2002). Of interest, impairment of glial cell maturation is also apparent in 
leukoencephalopathy with vanishing white matter. This genetic disease is clinically characterized 
by spasticity and progressive cerebellar ataxia, often with onset at childhood. Pathologically, myelin 
degeneration is evident, but with abundance of oligodendrocytes, and relatively few and immature, 
dysmorphic astrocytes (van der Knaap, Pronk & Scheper 2006). Interestingly, high molecular weight 
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hyaluronan accumulates here, as well as in MS lesions, and thus may frustrate maturation of 
oligodendrocytes and astrocytes, thereby hampering regeneration (Bugiani et al. 2013).
In addition to the continuous expression of obstructing factors, remyelination is also 
dysregulated in MS from a relative deficiency of various stimulants for remyelination. For example, 
stimulation of estrogen receptors promotes remyelination by activation of the PI3k/Akt/mTOR and 
ERK1/2 pathways in OPCs (Xiao et al. 2012, Hirahara et al. 2013, Kumar et al. 2013), and plasma levels 
of estrogen tend to be lower when MS activity is more severe (Dwosh et al. 2003). Also, progesterone 
and prolactin, both important hormones during pregnancy or lactation, promote remyelination 
(Ibanez et al. 2004, Gregg et al. 2007), and provide a possible mechanism for why pregnancy is 
associated with MS remission (Confavreux et al. 1998). Furthermore, testosterone promotes 
remyelination via interactions with both the brain immune system and the neural androgen 
receptor on neurons and glia (Hussain et al. 2013), whereas a relative testosterone deficiency 
is associated with progressive MS in males (Safarinejad 2008) as well as a higher MS lesion load 
in females (Tomassini et al. 2005). Certainly, these steroid hormones are versatile molecules that 
also exert distinct effects on the immune system, but given their ability to promote remyelination, 
further investigations are warranted. An additional hormone that may benefit remyelination 
is the thyroid hormone (Fernandez et al. 2004). Thyroid hormone signals via its nuclear receptor 
that functions by engaging in heterodimeric association with other nuclear receptors. Of interest, 
another nuclear receptor, retinoid X receptor gamma (RXRγ), appears to be a positive regulator of 
OPC differentiation that is expressed in MS lesions by OPCs, macrophages/microglia and astrocytes. 
This suggests that remyelination could also be supported by administration of appropriate ligands 
for RXRγ, such as rexinoids, or for the heterodimeric permissive partners of RXRγ, which are likely 
the liver X receptor (LXRs) and peroxisome proliferator activator proteins (PPAR) (Huang et al. 2011a, 
Huang et al. 2011b). Lastly, although local levels of several important growth factors are not precisely 
known for MS lesions, some may become deficient in chronic lesions. These may include neuregulin 
(Viehover et al. 2001) as well as PDGF, which enhances remyelination of chronic experimental white 
matter lesions (Vana et al. 2007) and, possibly, epidermal growth factor (EGF) (Aguirre et al. 2007). 
In summary, in order to enhance endogenous remyelination, the majority of MS lesions will 
likely benefit from promoting differentiation of OPCs, possibly even into Schwann cells (Zawadzka 
et al. 2010, Fancy et al. 2011a, Crawford, Chambers & Franklin 2013). A thorough understanding of 
which negative factors are overexpressed or dominant, and which positive factors are deficient or 
subdominant in MS lesions will contribute to identifying molecular targets to promote endogenous 
remyelination. One such a negative factor, Lingo-1, is currently targeted in an early-phase clinical trial 
with a humanized anti-Lingo-1 monoclonal antibody to possibly benefit endogenous remyelination 
(Mi, Pepinsky & Cadavid 2013). 
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The other approach: remyelination by transplantation of exogenous cells
Finally, this overview on the background and current status of strategies to promote remyelination 
would be rather incomplete without briefly addressing the possibility of stem cell transplantation. 
This approach aims at delivering exogenous stem cells to demyelinated areas so that they may 
promote or execute local remyelination. Considering the rationale behind this design, it seems more 
logical to use small-molecule therapies in MS for boosting endogenous OPCs, equally well-equipped 
to remyelinate (Franklin, ffrench-Constant 2008). However, mitotic exhaustion of OPCs could be an 
obstacle for remyelination of chronic lesions, although this is not well-established (Robins et al. 
2013), and then the supply of fresh, mitotic competent cells could add benefits, albeit a potential 
risk of tumorigenesis as well (Goldman, Nedergaard & Windrem 2012). Also, transplanted cells may 
well add further beneficial support via ‘bystander effects’ and immune modulation (reviewed in: 
(Martino et al. 2010, Rivera, Aigner 2012)). 
Major outstanding issues for exogenous strategies are to resolve a) where cells should be 
transplanted to, and b) which cells they should be. As for the location, because intra-lesion 
injection is anatomically and practically complex, more benefit is expected from intraventricular or 
intravenous delivery (Franklin, ffrench-Constant 2008). The major candidate cells to be transplanted 
include allogenic cells, such as human embryonic stem cells (Nistor et al. 2005), fetal neural stem 
cells or glial progenitor cells (Windrem et al. 2008). Alternatively, autologous cells may be used, 
including haematopoietic (Mancardi 2009) and mesenchymal stem cells (reviewed in: (Rivera, 
Aigner 2012)), olfactory ensheathing cells (Franklin 2003) as well as induced pluripotent stem 
cells (iPSCs) (Takahashi, Yamanaka 2006). For allogenic human neural stem cells, relative safety 
and enhanced myelination is suggested from two pioneering studies in infants with Pelizaeus-
Merzbacher disease and its shiverer mouse animal model (Gupta et al. 2012, Uchida et al. 2012). 
However, in general, the use of autologous cells would likely reduce the risk of graft rejection and 
need for immune suppression (Goldman, Nedergaard & Windrem 2012). Haematopoietic stem cells 
reduce inflammatory activity in MS (Mancardi, Saccardi 2008), but do not contribute to structural 
recovery (Metz et al. 2007). Mesenchymal stem cells are currently tested in clinical trials (Connick et 
al. 2012), whereas olfactory ensheathing cells benefit local pathology on transplantation after spinal 
cord injury in dogs (Granger et al. 2012). Finally, iPSCs from rodent fibroblasts can be differentiated 
into oligdenderocyte lineage cells to create functional oligodendrocytes both in vitro and in vivo 
(Czepiel et al. 2011, Najm et al. 2013, Yang et al. 2013), offering an encouraging prospective on this 
possibility for human fibroblasts. In summary, exogenous cell therapies may offer therapeutic benefit 
in distinct ways, but carry risks as well and have not proven superiority over endogenous strategies. 
This warrants intense investigation in both directions to hopefully accelerate the availability of 
(complementary) therapies, ensuring structural recovery and reducing progression in MS. 
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SCOPE OF THIS THESIS
In order to identify molecular targets for promoting endogenous remyelination, an understanding 
of how remyelinating OPCs are affected by extrinsic factors from the MS environment is pivotal 
(chapter 1). In this thesis, the ECM molecule fibronectin was studied with the aim of identifying 
how fibronectin affects CNS remyelination and its failure in MS. Hereto, fibronectin expression 
was characterized after demyelination in experimental animal models and in MS, revealing a 
correlation between fibronectin aggregation and failure of remyelination. Therefore, functional 
consequences of fibronectin aggregation for remyelination were evaluated (chapter 2). Because 
fibronectin is expressed on demyelination seemingly ‘by default’, an initially beneficial role in 
complete CNS remyelination was presumed. Hence, conditional knockout of plasma fibronectin and 
cellular fibronectin from astrocytes was induced to study how this affects complete, physiological 
remyelination (chapter 3). In addition to OPCs, other cells in MS lesions likely also receive signals 
from fibronectin aggregates. In chapter 4, therefore, the effects of fibronectin aggregates on 
microglia and macrophages were assessed. As indicated, fibronectin expression on myelin injury 
(demyelination) seemed a common response, and in fact, tissue injury in general evokes synthesis 
of a fibronectin matrix. A literature review on fibronectin expression in tissue injury was therefore 
undertaken in chapter 5. From this review, it became evident that improper degradation of 
fibronectin harms tissue regeneration also in chronic wounds and osteoarthritis, suggesting that 
degradation of fibronectin is a prerequisite for complete regeneration of tissue (chapter 5). Finally, 
main conclusions and future perspectives are summarized (chapter 6). 
35
Glial cells in health and multiple sclerosis
1
REFERENCES
“TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple 
Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group”, 1999, Neurology, vol. 
53, no. 3, pp. 457-465.
Aggarwal, S., Yurlova, L. & Simons, M. 2011, “Central nervous system myelin: structure, synthesis and assembly”, 
Trends in Cell Biology, vol. 21, no. 10, pp. 585-593.
Aguirre, A., Dupree, J.L., Mangin, J.M. & Gallo, V. 2007, “A functional role for EGFR signaling in myelination and 
remyelination”, Nature Neuroscience, vol. 10, no. 8, pp. 990-1002.
Agulhon, C., Petravicz, J., McMullen, A.B., Sweger, E.J., Minton, S.K., Taves, S.R., Casper, K.B., Fiacco, T.A. & McCarthy, 
K.D. 2008, “What is the role of astrocyte calcium in neurophysiology?”, Neuron, vol. 59, no. 6, pp. 932-946.
Albert, M., Antel, J., Bruck, W. & Stadelmann, C. 2007, “Extensive cortical remyelination in patients with chronic 
multiple sclerosis”, Brain Pathology, vol. 17, no. 2, pp. 129-138.
Araque, A., Parpura, V., Sanzgiri, R.P. & Haydon, P.G. 1999, “Tripartite synapses: glia, the unacknowledged partner”, 
Trends in Neurosciences, vol. 22, no. 5, pp. 208-215.
Arnett, H.A., Fancy, S.P., Alberta, J.A., Zhao, C., Plant, S.R., Kaing, S., Raine, C.S., Rowitch, D.H., Franklin, R.J. & Stiles, 
C.D. 2004, “bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS”, Science, 
vol. 306, no. 5704, pp. 2111-2115.
Arnett, H.A., Mason, J., Marino, M., Suzuki, K., Matsushima, G.K. & Ting, J.P. 2001, “TNF alpha promotes proliferation 
of oligodendrocyte progenitors and remyelination”, Nature Neuroscience, vol. 4, no. 11, pp. 1116-1122.
Ascherio, A., Munger, K.L. & Lunemann, J.D. 2012, “The initiation and prevention of multiple sclerosis”, Nature 
Reviews Neurology, vol. 8, no. 11, pp. 602-612.
Back, S.A., Tuohy, T.M., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N.L., Banine, F., Liu, Y., Chang, A., Trapp, 
B.D., Bebo, B.F.,Jr, Rao, M.S. & Sherman, L.S. 2005, “Hyaluronan accumulates in demyelinated lesions and 
inhibits oligodendrocyte progenitor maturation”, Nature Medicine, vol. 11, no. 9, pp. 966-972.
Barnett, M.H. & Prineas, J.W. 2004, “Relapsing and remitting multiple sclerosis: pathology of the newly forming 
lesion”, Annals of Neurology, vol. 55, no. 4, pp. 458-468.
Baron, W., Colognato, H. & ffrench-Constant, C. 2005, “Integrin-growth factor interactions as regulators of 
oligodendroglial development and function”, Glia, vol. 49, no. 4, pp. 467-479.
Baron, W., Decker, L., Colognato, H. & ffrench-Constant, C. 2003, “Regulation of integrin growth factor interactions 
in oligodendrocytes by lipid raft microdomains”, Current Biology, vol. 13, no. 2, pp. 151-155.
Baron, W. & Hoekstra, D. 2010, “On the biogenesis of myelin membranes: sorting, trafficking and cell polarity”, 
FEBS letters, vol. 584, no. 9, pp. 1760-1770.
Baron, W., Metz, B., Bansal, R., Hoekstra, D. & de Vries, H. 2000, “PDGF and FGF-2 signaling in oligodendrocyte 
progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling 
pathways”, Molecular and Cellular Neurosciences, vol. 15, no. 3, pp. 314-329.
Baron, W., Shattil, S.J. & ffrench-Constant, C. 2002a, “The oligodendrocyte precursor mitogen PDGF stimulates 
proliferation by activation of alpha(v)beta3 integrins”, The EMBO Journal, vol. 21, no. 8, pp. 1957-1966.
Barres, B.A. 2008, “The mystery and magic of glia: a perspective on their roles in health and disease”, Neuron, vol. 
60, no. 3, pp. 430-440.
Barres, B.A., Hart, I.K., Coles, H.S., Burne, J.F., Voyvodic, J.T., Richardson, W.D. & Raff, M.C. 1992, “Cell death and 
control of cell survival in the oligodendrocyte lineage”, Cell, vol. 70, no. 1, pp. 31-46.
Barres, B.A. & Raff, M.C. 1993, “Proliferation of oligodendrocyte precursor cells depends on electrical activity in 
axons”, Nature, vol. 361, no. 6409, pp. 258-260.
36
Chapter 1
Batoulis, H., Recks, M.S., Addicks, K. & Kuerten, S. 2011, “Experimental autoimmune encephalomyelitis--
achievements and prospective advances”, APMIS : Acta Pathologica, Microbiologica, et Immunologica 
Scandinavica, vol. 119, no. 12, pp. 819-830.
Baumann, N. & Pham-Dinh, D. 2001, “Biology of oligodendrocyte and myelin in the mammalian central nervous 
system”, Physiological Reviews, vol. 81, no. 2, pp. 871-927.
Bengtsson, S.L., Nagy, Z., Skare, S., Forsman, L., Forssberg, H. & Ullen, F. 2005, “Extensive piano practicing has 
regionally specific effects on white matter development”, Nature Neuroscience, vol. 8, no. 9, pp. 1148-1150.
Bianchin, M.M., Capella, H.M., Chaves, D.L., Steindel, M., Grisard, E.C., Ganev, G.G., da Silva Junior, J.P., Neto 
Evaldo, S., Poffo, M.A., Walz, R., Carlotti Junior, C.G. & Sakamoto, A.C. 2004, “Nasu-Hakola disease 
(polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia 
associated with bone cystic lesions. From clinical to genetic and molecular aspects”, Cellular and Molecular 
Neurobiology, vol. 24, no. 1, pp. 1-24.
Blakemore, W.F. & Franklin, R.J. 2008, “Remyelination in experimental models of toxin-induced demyelination”, 
Current Topics in Microbiology and Immunology, vol. 318, pp. 193-212.
Blakemore, W.F., Gilson, J.M. & Crang, A.J. 2003, “The presence of astrocytes in areas of demyelination influences 
remyelination following transplantation of oligodendrocyte progenitors”, Experimental Neurology, vol. 184, 
no. 2, pp. 955-963.
Boyd, A., Zhang, H. & Williams, A. 2013, “Insufficient OPC migration into demyelinated lesions is a cause of poor 
remyelination in MS and mouse models”, Acta Neuropathologica, vol. 125, no. 6, pp. 841-859.
Brambilla, R., Ashbaugh, J.J., Magliozzi, R., Dellarole, A., Karmally, S., Szymkowski, D.E. & Bethea, J.R. 2011, 
“Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis 
and promotes axon preservation and remyelination”, Brain, vol. 134, no. Pt 9, pp. 2736-2754.
Bribian, A., Esteban, P.F., Clemente, D., Soussi-Yanicostas, N., Thomas, J.L., Zalc, B. & de Castro, F. 2008, “A novel role 
for anosmin-1 in the adhesion and migration of oligodendrocyte precursors”, Developmental Neurobiology, 
vol. 68, no. 13, pp. 1503-1516.
Briscoe, J., Pierani, A., Jessell, T.M. & Ericson, J. 2000, “A homeodomain protein code specifies progenitor cell 
identity and neuronal fate in the ventral neural tube”, Cell, vol. 101, no. 4, pp. 435-445.
Bruce, C.C., Zhao, C. & Franklin, R.J. 2010, “Remyelination - An effective means of neuroprotection”, Hormones and 
Behavior, vol. 57, no. 1, pp. 56-62.
Bsibsi, M., Ravid, R., Gveric, D. & van Noort, J.M. 2002, “Broad expression of Toll-like receptors in the human central 
nervous system”, Journal of Neuropathology and Experimental Neurology, vol. 61, no. 11, pp. 1013-1021.
Buckley, C.E., Goldsmith, P. & Franklin, R.J. 2008, “Zebrafish myelination: a transparent model for remyelination?”, 
Disease Models & Mechanisms, vol. 1, no. 4-5, pp. 221-228.
Buffo, A., Rite, I., Tripathi, P., Lepier, A., Colak, D., Horn, A.P., Mori, T. & Gotz, M. 2008, “Origin and progeny of reactive 
gliosis: A source of multipotent cells in the injured brain”, Proceedings of the National Academy of Sciences of 
the United States of America, vol. 105, no. 9, pp. 3581-3586.
Bugiani, M., Postma, N., Polder, E., Dieleman, N., Scheffer, P.G., Sim, F.J., van der Knaap, M.S. & Boor, I. 2013, 
“Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white 
matter disease”, Brain, vol. 136, no. Pt 1, pp. 209-222.
Cahoy, J.D., Emery, B., Kaushal, A., Foo, L.C., Zamanian, J.L., Christopherson, K.S., Xing, Y., Lubischer, J.L., Krieg, 
P.A., Krupenko, S.A., Thompson, W.J. & Barres, B.A. 2008, “A transcriptome database for astrocytes, neurons, 
and oligodendrocytes: a new resource for understanding brain development and function”, The Journal of 
Neuroscience, vol. 28, no. 1, pp. 264-278.
37
Glial cells in health and multiple sclerosis
1
Cai, J., Qi, Y., Hu, X., Tan, M., Liu, Z., Zhang, J., Li, Q., Sander, M. & Qiu, M. 2005, “Generation of oligodendrocyte 
precursor cells from mouse dorsal spinal cord independent of Nkx6 regulation and Shh signaling”, Neuron, 
vol. 45, no. 1, pp. 41-53.
Canoll, P.D., Musacchio, J.M., Hardy, R., Reynolds, R., Marchionni, M.A. & Salzer, J.L. 1996, “GGF/neuregulin 
is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of 
oligodendrocyte progenitors”, Neuron, vol. 17, no. 2, pp. 229-243.
Caprariello, A.V., Mangla, S., Miller, R.H. & Selkirk, S.M. 2012, “Apoptosis of oligodendrocytes in the central nervous 
system results in rapid focal demyelination”, Annals of Neurology, vol. 72, no. 3, pp. 395-405.
Casaccia-Bonnefil, P. & Liu, A. 2003, “Relationship between cell cycle molecules and onset of oligodendrocyte 
differentiation”, Journal of Neuroscience Research, vol. 72, no. 1, pp. 1-11.
Chan, J.R., Watkins, T.A., Cosgaya, J.M., Zhang, C., Chen, L., Reichardt, L.F., Shooter, E.M. & Barres, B.A. 2004, “NGF 
controls axonal receptivity to myelination by Schwann cells or oligodendrocytes”, Neuron, vol. 43, no. 2, 
pp. 183-191.
Chang, A., Staugaitis, S.M., Dutta, R., Batt, C.E., Easley, K.E., Chomyk, A.M., Yong, V.W., Fox, R.J., Kidd, G.J. & Trapp, B.D. 
2012, “Cortical remyelination: a new target for repair therapies in multiple sclerosis”, Annals of Neurology, 
vol. 72, no. 6, pp. 918-926.
Charles, P., Hernandez, M.P., Stankoff, B., Aigrot, M.S., Colin, C., Rougon, G., Zalc, B. & Lubetzki, C. 2000, “Negative 
regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule”, 
Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7585-
7590.
Chen, Y., Wu, H., Wang, S., Koito, H., Li, J., Ye, F., Hoang, J., Escobar, S.S., Gow, A., Arnett, H.A., Trapp, B.D., Karandikar, 
N.J., Hsieh, J. & Lu, Q.R. 2009, “The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-
intrinsic timer of myelination”, Nature Neuroscience, vol. 12, no. 11, pp. 1398-1406.
Chun, S.J., Rasband, M.N., Sidman, R.L., Habib, A.A. & Vartanian, T. 2003, “Integrin-linked kinase is required for 
laminin-2-induced oligodendrocyte cell spreading and CNS myelination”, The Journal of Cell Biology, vol. 
163, no. 2, pp. 397-408.
Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G. & Nath, A. 2010, “Natalizumab-associated 
progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases”, 
Lancet Neurology, vol. 9, no. 4, pp. 438-446.
Cohen, J.A., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, 
G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L. & TRANSFORMS Study Group 
2010, “Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis”, The New England 
Journal of Medicine, vol. 362, no. 5, pp. 402-415.
Cohen, J.A., Coles, A.J., Arnold, D.L., Confavreux, C., Fox, E.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., Weiner, 
H.L., Fisher, E., Brinar, V.V., Giovannoni, G., Stojanovic, M., Ertik, B.I., Lake, S.L., Margolin, D.H., Panzara, M.A., 
Compston, D.A. & CARE-MS I investigators 2012, “Alemtuzumab versus interferon beta 1a as first-line 
treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial”, 
Lancet, vol. 380, no. 9856, pp. 1819-1828.
Coles, A.J., Twyman, C.L., Arnold, D.L., Cohen, J.A., Confavreux, C., Fox, E.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., 
Weiner, H.L., Miller, T., Fisher, E., Sandbrink, R., Lake, S.L., Margolin, D.H., Oyuela, P., Panzara, M.A., Compston, 
D.A. & CARE-MS II investigators 2012, “Alemtuzumab for patients with relapsing multiple sclerosis after 
disease-modifying therapy: a randomised controlled phase 3 trial”, Lancet, vol. 380, no. 9856, pp. 1829-
1839.
Colognato, H., Baron, W., Avellana-Adalid, V., Relvas, J.B., Baron-Van Evercooren, A., Georges-Labouesse, E. & 
38
Chapter 1
ffrench-Constant, C. 2002, “CNS integrins switch growth factor signalling to promote target-dependent 
survival”, Nature Cell Biology, vol. 4, no. 11, pp. 833-841.
Colognato, H., Galvin, J., Wang, Z., Relucio, J., Nguyen, T., Harrison, D., Yurchenco, P.D. & ffrench-Constant, C. 
2007, “Identification of dystroglycan as a second laminin receptor in oligodendrocytes, with a role in 
myelination”, Development, vol. 134, no. 9, pp. 1723-1736.
Coman, I., Barbin, G., Charles, P., Zalc, B. & Lubetzki, C. 2005, “Axonal signals in central nervous system myelination, 
demyelination and remyelination”, Journal of the Neurological Sciences, vol. 233, no. 1-2, pp. 67-71.
Comi, G., Jeffery, D., Kappos, L., Montalban, X., Boyko, A., Rocca, M.A., Filippi, M. & ALLEGRO Study Group 2012, 
“Placebo-controlled trial of oral laquinimod for multiple sclerosis”, The New England Journal of Medicine, vol. 
366, no. 11, pp. 1000-1009.
Compston, A. & Coles, A. 2008, “Multiple sclerosis”, Lancet, vol. 372, no. 9648, pp. 1502-1517.
Confavreux, C., Hutchinson, M., Hours, M.M., Cortinovis-Tourniaire, P. & Moreau, T. 1998, “Rate of pregnancy-
related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group”, The New England Journal of 
Medicine, vol. 339, no. 5, pp. 285-291.
Connick, P., Kolappan, M., Crawley, C., Webber, D.J., Patani, R., Michell, A.W., Du, M.Q., Luan, S.L., Altmann, D.R., 
Thompson, A.J., Compston, A., Scott, M.A., Miller, D.H. & Chandran, S. 2012, “Autologous mesenchymal 
stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-
concept study”, Lancet Neurology, vol. 11, no. 2, pp. 150-156.
Crawford, A.H., Chambers, C. & Franklin, R.J. 2013, “Remyelination: the true regeneration of the central nervous 
system”, Journal of Comparative Pathology, vol. 149, no. 2-3, pp. 242-254.
Czepiel, M., Balasubramaniyan, V., Schaafsma, W., Stancic, M., Mikkers, H., Huisman, C., Boddeke, E. & Copray, S. 
2011, “Differentiation of induced pluripotent stem cells into functional oligodendrocytes”, Glia, vol. 59, no. 
6, pp. 882-892.
Czopka, T., ffrench-Constant, C. & Lyons, D.A. 2013, “Individual Oligodendrocytes Have Only a Few Hours in which 
to Generate New Myelin Sheaths In Vivo”, Developmental Cell, vol. 25, no. 6, pp. 599-609.
Czopka, T. & Lyons, D.A. 2011, “Dissecting mechanisms of myelinated axon formation using zebrafish”, Methods 
in Cell Biology, vol. 105, pp. 25-62.
Dawson, M.R., Polito, A., Levine, J.M. & Reynolds, R. 2003, “NG2-expressing glial progenitor cells: an abundant and 
widespread population of cycling cells in the adult rat CNS”, Molecular and Cellular Neurosciences, vol. 24, 
no. 2, pp. 476-488.
De Groot, C.J., Ruuls, S.R., Theeuwes, J.W., Dijkstra, C.D. & Van der Valk, P. 1997, “Immunocytochemical 
characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in 
demyelinating multiple sclerosis lesions”, Journal of Neuropathology and Experimental Neurology, vol. 56, 
no. 1, pp. 10-20.
de Monasterio-Schrader, P., Jahn, O., Tenzer, S., Wichert, S.P., Patzig, J. & Werner, H.B. 2012, “Systematic approaches 
to central nervous system myelin”, Cellular and Molecular Life Sciences, vol. 69, no. 17, pp. 2879-2894.
de Vries, H., de Jonge, J.C., Schrage, C., van der Haar, M.E. & Hoekstra, D. 1997, “Differential and cell development-
dependent localization of myelin mRNAs in oligodendrocytes”, Journal of Neuroscience Research, vol. 47, 
no. 5, pp. 479-488.
Delaney, K.H., Kwiecien, J.M., Wegiel, J., Wisniewski, H.M., Percy, D.H. & Fletch, A.L. 1995, “Familial dysmyelination 
in a Long Evans rat mutant”, Laboratory Animal Science, vol. 45, no. 5, pp. 547-553.
Demerens, C., Stankoff, B., Logak, M., Anglade, P., Allinquant, B., Couraud, F., Zalc, B. & Lubetzki, C. 1996, “Induction 
of myelination in the central nervous system by electrical activity”, Proceedings of the National Academy of 
39
Glial cells in health and multiple sclerosis
1
Sciences of the United States of America, vol. 93, no. 18, pp. 9887-9892.
Deneen, B., Ho, R., Lukaszewicz, A., Hochstim, C.J., Gronostajski, R.M. & Anderson, D.J. 2006, “The transcription 
factor NFIA controls the onset of gliogenesis in the developing spinal cord”, Neuron, vol. 52, no. 6, pp. 953-
968.
Deonarine, K., Panelli, M.C., Stashower, M.E., Jin, P., Smith, K., Slade, H.B., Norwood, C., Wang, E., Marincola, F.M. 
& Stroncek, D.F. 2007, “Gene expression profiling of cutaneous wound healing”, Journal of Translational 
Medicine, vol. 5, pp. 11.
Dian, H., Hongyu, Z., Wenjie, H. & Shihong, Z. 2011, “Rituximab for relapsing-remitting multiple sclerosis” in 
Cochrane Database of Systematic Reviews.
Dubois-Dalcq, M., Behar, T., Hudson, L. & Lazzarini, R.A. 1986, “Emergence of three myelin proteins in 
oligodendrocytes cultured without neurons”, The Journal of Cell Biology, vol. 102, no. 2, pp. 384-392.
Dugas, J.C., Cuellar, T.L., Scholze, A., Ason, B., Ibrahim, A., Emery, B., Zamanian, J.L., Foo, L.C., McManus, M.T. & 
Barres, B.A. 2010, “Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and 
myelination”, Neuron, vol. 65, no. 5, pp. 597-611.
Duncan, I.D., Brower, A., Kondo, Y., Curlee, J.F.,Jr & Schultz, R.D. 2009, “Extensive remyelination of the CNS leads 
to functional recovery”, Proceedings of the National Academy of Sciences of the United States of America, vol. 
106, no. 16, pp. 6832-6836.
Duncan, I.D., Kondo, Y. & Zhang, S.C. 2011, “The myelin mutants as models to study myelin repair in the 
leukodystrophies”, Neurotherapeutics, vol. 8, no. 4, pp. 607-624.
Durafourt, B.A., Moore, C.S., Zammit, D.A., Johnson, T.A., Zaguia, F., Guiot, M.C., Bar-Or, A. & Antel, J.P. 2012, 
“Comparison of polarization properties of human adult microglia and blood-derived macrophages”, Glia, 
vol. 60, no. 5, pp. 717-727.
Dwosh, E., Guimond, C., Duquette, P. & Sadovnick, A.D. 2003, “The interaction of MS and pregnancy: a critical 
review”, International MS journal / MS Forum, vol. 10, no. 2, pp. 38-42.
Edwards, J.P., Zhang, X., Frauwirth, K.A. & Mosser, D.M. 2006, “Biochemical and functional characterization of 
three activated macrophage populations”, Journal of Leukocyte Biology, vol. 80, no. 6, pp. 1298-1307.
Elliott, C., Lindner, M., Arthur, A., Brennan, K., Jarius, S., Hussey, J., Chan, A., Stroet, A., Olsson, T., Willison, H., Barnett, 
S.C., Meinl, E. & Linington, C. 2012, “Functional identification of pathogenic autoantibody responses in 
patients with multiple sclerosis”, Brain, vol. 135, no. Pt 6, pp. 1819-1833.
Emery, B. 2010, “Regulation of oligodendrocyte differentiation and myelination”, Science, vol. 330, no. 6005, pp. 
779-782.
Emery, B., Agalliu, D., Cahoy, J.D., Watkins, T.A., Dugas, J.C., Mulinyawe, S.B., Ibrahim, A., Ligon, K.L., Rowitch, D.H. 
& Barres, B.A. 2009, “Myelin gene regulatory factor is a critical transcriptional regulator required for CNS 
myelination”, Cell, vol. 138, no. 1, pp. 172-185.
Evangelou, N., Konz, D., Esiri, M.M., Smith, S., Palace, J. & Matthews, P.M. 2001, “Size-selective neuronal changes 
in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis”, Brain, vol. 
124, no. Pt 9, pp. 1813-1820.
Fancy, S.P., Baranzini, S.E., Zhao, C., Yuk, D.I., Irvine, K.A., Kaing, S., Sanai, N., Franklin, R.J. & Rowitch, D.H. 2009, 
“Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS”, 
Genes & Development, vol. 23, no. 13, pp. 1571-1585.
Fancy, S.P., Chan, J.R., Baranzini, S.E., Franklin, R.J. & Rowitch, D.H. 2011a, “Myelin regeneration: a recapitulation of 
development?”, Annual Review of Neuroscience, vol. 34, pp. 21-43.
Fancy, S.P., Harrington, E.P., Yuen, T.J., Silbereis, J.C., Zhao, C., Baranzini, S.E., Bruce, C.C., Otero, J.J., Huang, E.J., 
40
Chapter 1
Nusse, R., Franklin, R.J. & Rowitch, D.H. 2011c, “Axin2 as regulatory and therapeutic target in newborn brain 
injury and remyelination”, Nature Neuroscience, vol. 14, no. 8, pp. 1009-1016.
Feldmann, A., Winterstein, C., White, R., Trotter, J. & Kramer-Albers, E.M. 2009, “Comprehensive analysis of 
expression, subcellular localization, and cognate pairing of SNARE proteins in oligodendrocytes”, Journal 
of Neuroscience Research, vol. 87, no. 8, pp. 1760-1772.
Ferent, J., Zimmer, C., Durbec, P., Ruat, M. & Traiffort, E. 2013, “Sonic Hedgehog signaling is a positive 
oligodendrocyte regulator during demyelination”, The Journal of Neuroscience, vol. 33, no. 5, pp. 1759-1772.
Fernandez, M., Giuliani, A., Pirondi, S., D’Intino, G., Giardino, L., Aloe, L., Levi-Montalcini, R. & Calza, L. 2004, 
“Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory 
disease”, Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 46, 
pp. 16363-16368.
Fields, R.D. 2008, “White matter in learning, cognition and psychiatric disorders”, Trends in Neurosciences, vol. 31, 
no. 7, pp. 361-370.
Fischer, M.T., Sharma, R., Lim, J.L., Haider, L., Frischer, J.M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J. & 
Lassmann, H. 2012, “NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative 
tissue damage and mitochondrial injury”, Brain, vol. 135, no. Pt 3, pp. 886-899.
Fitzner, D., Schnaars, M., van Rossum, D., Krishnamoorthy, G., Dibaj, P., Bakhti, M., Regen, T., Hanisch, U.K. & Simons, 
M. 2011, “Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis”, Journal 
of Cell Science, vol. 124, no. Pt 3, pp. 447-458.
Fogarty, M., Richardson, W.D. & Kessaris, N. 2005, “A subset of oligodendrocytes generated from radial glia in the 
dorsal spinal cord”, Development, vol. 132, no. 8, pp. 1951-1959.
Fox, R.J., Miller, D.H., Phillips, J.T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., 
Sweetser, M.T., Viglietta, V., Dawson, K.T. & CONFIRM Study Investigators 2012, “Placebo-controlled phase 
3 study of oral BG-12 or glatiramer in multiple sclerosis”, The New England Journal of Medicine, vol. 367, no. 
12, pp. 1087-1097.
Franklin, R.J. 2003, “Remyelination by transplanted olfactory ensheathing cells”, Anatomical record.Part B, New 
anatomist, vol. 271, no. 1, pp. 71-76.
Franklin, R.J. 2002, “Why does remyelination fail in multiple sclerosis?”, Nature Reviews Neuroscience, vol. 3, no. 9, 
pp. 705-714.
Franklin, R.J. & ffrench-Constant, C. 2008, “Remyelination in the CNS: from biology to therapy”, Nature Reviews 
Neuroscience, vol. 9, no. 11, pp. 839-855.
Franklin, R.J., ffrench-Constant, C., Edgar, J.M. & Smith, K.J. 2012a, “Neuroprotection and repair in multiple 
sclerosis”, Nature Reviews Neurology, .
Franklin, R.J. & Hinks, G.L. 1999, “Understanding CNS remyelination: clues from developmental and regeneration 
biology”, Journal of Neuroscience Research, vol. 58, no. 2, pp. 207-213.
Friede, R.L. 1973, “Dating the development of human cerebellum”, Acta Neuropathologica, vol. 23, no. 1, pp. 48-58.
Frost, E., Kiernan, B.W., Faissner, A. & ffrench-Constant, C. 1996, “Regulation of oligodendrocyte precursor 
migration by extracellular matrix: evidence for substrate-specific inhibition of migration by tenascin-C”, 
Developmental Neuroscience, vol. 18, no. 4, pp. 266-273.
Frost, E.E., Buttery, P.C., Milner, R. & ffrench-Constant, C. 1999, “Integrins mediate a neuronal survival signal for 
oligodendrocytes”, Current Biology, vol. 9, no. 21, pp. 1251-1254.
Fruhbeis, C., Frohlich, D., Kuo, W.P., Amphornrat, J., Thilemann, S., Saab, A.S., Kirchhoff, F., Mobius, W., Goebbels, S., 
Nave, K.A., Schneider, A., Simons, M., Klugmann, M., Trotter, J. & Kramer-Albers, E.M. 2013, “Neurotransmitter-
41
Glial cells in health and multiple sclerosis
1
triggered transfer of exosomes mediates oligodendrocyte-neuron communication”, PLoS Biology, vol. 11, 
no. 7, pp. e1001604.
Fruttiger, M., Karlsson, L., Hall, A.C., Abramsson, A., Calver, A.R., Bostrom, H., Willetts, K., Bertold, C.H., Heath, 
J.K., Betsholtz, C. & Richardson, W.D. 1999, “Defective oligodendrocyte development and severe 
hypomyelination in PDGF-A knockout mice”, Development, vol. 126, no. 3, pp. 457-467.
Funfschilling, U., Supplie, L.M., Mahad, D., Boretius, S., Saab, A.S., Edgar, J., Brinkmann, B.G., Kassmann, C.M., 
Tzvetanova, I.D., Mobius, W., Diaz, F., Meijer, D., Suter, U., Hamprecht, B., Sereda, M.W., Moraes, C.T., Frahm, 
J., Goebbels, S. & Nave, K.A. 2012, “Glycolytic oligodendrocytes maintain myelin and long-term axonal 
integrity”, Nature, vol. 485, no. 7399, pp. 517-521.
Galea, I., Bechmann, I. & Perry, V.H. 2007, “What is immune privilege (not)?”, Trends in Immunology, vol. 28, no. 1, 
pp. 12-18.
Gallo, V., Zhou, J.M., McBain, C.J., Wright, P., Knutson, P.L. & Armstrong, R.C. 1996, “Oligodendrocyte progenitor 
cell proliferation and lineage progression are regulated by glutamate receptor-mediated K+ channel 
block”, The Journal of Neuroscience, vol. 16, no. 8, pp. 2659-2670.
Garbern, J.Y. 2007, “Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis”, Cellular and Molecular Life 
Sciences, vol. 64, no. 1, pp. 50-65.
Garcion, E., Faissner, A. & ffrench-Constant, C. 2001, “Knockout mice reveal a contribution of the extracellular 
matrix molecule tenascin-C to neural precursor proliferation and migration”, Development, vol. 128, no. 13, 
pp. 2485-2496.
Garwood, J., Garcion, E., Dobbertin, A., Heck, N., Calco, V., ffrench-Constant, C. & Faissner, A. 2004, “The 
extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required 
for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor”, The 
European Journal of Neuroscience, vol. 20, no. 10, pp. 2524-2540.
Geurts, J.J. & Barkhof, F. 2008, “Grey matter pathology in multiple sclerosis”, Lancet Neurology, vol. 7, no. 9, pp. 
841-851.
Gielen, E., Baron, W., Vandeven, M., Steels, P., Hoekstra, D. & Ameloot, M. 2006, “Rafts in oligodendrocytes: 
evidence and structure-function relationship”, Glia, vol. 54, no. 6, pp. 499-512.
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., Conway, S.J., Ng, L.G., Stanley, 
E.R., Samokhvalov, I.M. & Merad, M. 2010, “Fate mapping analysis reveals that adult microglia derive from 
primitive macrophages”, Science, vol. 330, no. 6005, pp. 841-845.
Godwin, J.W., Pinto, A.R. & Rosenthal, N.A. 2013, “Macrophages are required for adult salamander limb 
regeneration”, Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 
23, pp. 9415-9420.
Gold, R., Kappos, L., Arnold, D.L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M.T., Yang, M., 
Sheikh, S.I., Dawson, K.T. & DEFINE Study Investigators 2012, “Placebo-controlled phase 3 study of oral 
BG-12 for relapsing multiple sclerosis”, The New England Journal of Medicine, vol. 367, no. 12, pp. 1098-1107.
Goldman, S.A., Nedergaard, M. & Windrem, M.S. 2012, “Glial progenitor cell-based treatment and modeling of 
neurological disease”, Science, vol. 338, no. 6106, pp. 491-495.
Gordon, S. 2003, “Alternative activation of macrophages”, Nature Reviews Immunology, vol. 3, no. 1, pp. 23-35.
Gottle, P., Kremer, D., Jander, S., Odemis, V., Engele, J., Hartung, H.P. & Kury, P. 2010, “Activation of CXCR7 receptor 
promotes oligodendroglial cell maturation”, Annals of Neurology, vol. 68, no. 6, pp. 915-924.
Graeber, M.B. 2010, “Changing face of microglia”, Science, vol. 330, no. 6005, pp. 783-788.
Granger, N., Blamires, H., Franklin, R.J. & Jeffery, N.D. 2012, “Autologous olfactory mucosal cell transplants in 
42
Chapter 1
clinical spinal cord injury: a randomized double-blinded trial in a canine translational model”, Brain, vol. 
135, no. Pt 11, pp. 3227-3237.
Gregg, C., Shikar, V., Larsen, P., Mak, G., Chojnacki, A., Yong, V.W. & Weiss, S. 2007, “White matter plasticity and 
enhanced remyelination in the maternal CNS”, The Journal of Neuroscience, vol. 27, no. 8, pp. 1812-1823.
Gudz, T.I., Komuro, H. & Macklin, W.B. 2006, “Glutamate stimulates oligodendrocyte progenitor migration 
mediated via an alphav integrin/myelin proteolipid protein complex”, The Journal of Neuroscience, vol. 26, 
no. 9, pp. 2458-2466.
Gupta, N., Henry, R.G., Strober, J., Kang, S.M., Lim, D.A., Bucci, M., Caverzasi, E., Gaetano, L., Mandelli, M.L., Ryan, 
T., Perry, R., Farrell, J., Jeremy, R.J., Ulman, M., Huhn, S.L., Barkovich, A.J. & Rowitch, D.H. 2012, “Neural stem 
cell engraftment and myelination in the human brain”, Science Translational Medicine, vol. 4, no. 155, pp. 
155ra137.
Gutowski, N.J., Newcombe, J. & Cuzner, M.L. 1999, “Tenascin-R and C in multiple sclerosis lesions: relevance to 
extracellular matrix remodelling”, Neuropathology and Applied Neurobiology, vol. 25, no. 3, pp. 207-214.
Gyllensten, L. & Malmfors, T. 1963, “Myelinization of the optic nerve and its dependence on visual function--a 
quantitative investigation in mice”, Journal of Embryology and Experimental Morphology, vol. 11, pp. 255-
266.
Harauz, G. & Boggs, J.M. 2013, “Myelin management by the 18.5-kDa and 21.5-kDa classic myelin basic protein 
isoforms”, Journal of Neurochemistry, vol. 125, no. 3, pp. 334-361.
Harris, J.J. & Attwell, D. 2012, “The energetics of CNS white matter”, The Journal of Neuroscience, vol. 32, no. 1, pp. 
356-371.
Hawkins, B.T. & Davis, T.P. 2005, “The blood-brain barrier/neurovascular unit in health and disease”, Pharmacological 
Reviews, vol. 57, no. 2, pp. 173-185.
He, Y., Dupree, J., Wang, J., Sandoval, J., Li, J., Liu, H., Shi, Y., Nave, K.A. & Casaccia-Bonnefil, P. 2007, “The transcription 
factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation”, Neuron, vol. 55, no. 2, pp. 217-
230.
Hibbits, N., Yoshino, J., Le, T.Q. & Armstrong, R.C. 2012, “Astrogliosis during acute and chronic cuprizone 
demyelination and implications for remyelination”, ASN neuro, vol. 4, no. 6, pp. 10.1042/AN20120062.
Hirahara, Y., Matsuda, K.I., Yamada, H., Saitou, A., Morisaki, S., Takanami, K., Boggs, J.M. & Kawata, M. 2013, 
“G protein-coupled receptor 30 contributes to improved remyelination after cuprizone-induced 
demyelination”, Glia, vol. 61, no. 3, pp. 420-431.
Hirst, C., Swingler, R., Compston, D.A., Ben-Shlomo, Y. & Robertson, N.P. 2008, “Survival and cause of death in 
multiple sclerosis: a prospective population-based study”, Journal of Neurology, Neurosurgery, and 
Psychiatry, vol. 79, no. 9, pp. 1016-1021.
Hoshina, N., Tezuka, T., Yokoyama, K., Kozuka-Hata, H., Oyama, M. & Yamamoto, T. 2007, “Focal adhesion kinase 
regulates laminin-induced oligodendroglial process outgrowth”, Genes to Cells, vol. 12, no. 11, pp. 1245-
1254.
Huang, J.K., Fancy, S.P., Zhao, C., Rowitch, D.H., ffrench-Constant, C. & Franklin, R.J. 2011a, “Myelin regeneration in 
multiple sclerosis: targeting endogenous stem cells”, Neurotherapeutics, vol. 8, no. 4, pp. 650-658.
Huang, J.K., Jarjour, A.A., Nait Oumesmar, B., Kerninon, C., Williams, A., Krezel, W., Kagechika, H., Bauer, J., Zhao, 
C., Baron-Van Evercooren, A., Chambon, P., ffrench-Constant, C. & Franklin, R.J. 2011b, “Retinoid X receptor 
gamma signaling accelerates CNS remyelination”, Nature Neuroscience, vol. 14, no. 1, pp. 45-53.
Hussain, R., Ghoumari, A.M., Bielecki, B., Steibel, J., Boehm, N., Liere, P., Macklin, W.B., Kumar, N., Habert, R., 
Mhaouty-Kodja, S., Tronche, F., Sitruk-Ware, R., Schumacher, M. & Ghandour, M.S. 2013, “The neural 
43
Glial cells in health and multiple sclerosis
1
androgen receptor: a therapeutic target for myelin repair in chronic demyelination”, Brain, vol. 136, no. Pt 
1, pp. 132-146.
Ibanez, C., Shields, S.A., El-Etr, M., Baulieu, E.E., Schumacher, M. & Franklin, R.J. 2004, “Systemic progesterone 
administration results in a partial reversal of the age-associated decline in CNS remyelination following 
toxin-induced demyelination in male rats”, Neuropathology and Applied Neurobiology, vol. 30, no. 1, pp. 
80-89.
International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer, S., 
Hellenthal, G., Pirinen, M., Spencer, C.C., Patsopoulos, N.A., Moutsianas, L., Dilthey, A., Su, Z., Freeman, C., 
Hunt, S.E., Edkins, S., Gray, E., Booth, D.R., Potter, S.C., Goris, A., Band, G., Oturai, A.B., Strange, A., Saarela, J., 
Bellenguez, C., Fontaine, B., Gillman, M., Hemmer, B., Gwilliam, R., Zipp, F., Jayakumar, A., Martin, R., Leslie, 
S., Hawkins, S., Giannoulatou, E., D’alfonso, S., Blackburn, H., Martinelli Boneschi, F., Liddle, J., Harbo, H.F., 
Perez, M.L., Spurkland, A., Waller, M.J., Mycko, M.P., Ricketts, M., Comabella, M., Hammond, N., Kockum, I., 
McCann, O.T., Ban, M., Whittaker, P., Kemppinen, A., Weston, P., Hawkins, C., Widaa, S., Zajicek, J., Dronov, 
S., Robertson, N., Bumpstead, S.J., Barcellos, L.F., Ravindrarajah, R., Abraham, R., Alfredsson, L., Ardlie, K., 
Aubin, C., Baker, A., Baker, K., Baranzini, S.E., Bergamaschi, L., Bergamaschi, R., Bernstein, A., Berthele, 
A., Boggild, M., Bradfield, J.P., Brassat, D., Broadley, S.A., Buck, D., Butzkueven, H., Capra, R., Carroll, W.M., 
Cavalla, P., Celius, E.G., Cepok, S., Chiavacci, R., Clerget-Darpoux, F., Clysters, K., Comi, G., Cossburn, M., 
Cournu-Rebeix, I., Cox, M.B., Cozen, W., Cree, B.A., Cross, A.H., Cusi, D., Daly, M.J., Davis, E., de Bakker, P.I., 
Debouverie, M., D’hooghe, M.B., Dixon, K., Dobosi, R., Dubois, B., Ellinghaus, D., Elovaara, I., Esposito, F., 
Fontenille, C., Foote, S., Franke, A., Galimberti, D., Ghezzi, A., Glessner, J., Gomez, R., Gout, O., Graham, C., 
Grant, S.F., Guerini, F.R., Hakonarson, H., Hall, P., Hamsten, A., Hartung, H.P., Heard, R.N., Heath, S., Hobart, 
J., Hoshi, M., Infante-Duarte, C., Ingram, G., Ingram, W., Islam, T., Jagodic, M., Kabesch, M., Kermode, A.G., 
Kilpatrick, T.J., Kim, C., Klopp, N., Koivisto, K., Larsson, M., Lathrop, M., Lechner-Scott, J.S., Leone, M.A., Leppa, 
V., Liljedahl, U., Bomfim, I.L., Lincoln, R.R., Link, J., Liu, J., Lorentzen, A.R., Lupoli, S., Macciardi, F., Mack, T., 
Marriott, M., Martinelli, V., Mason, D., McCauley, J.L., Mentch, F., Mero, I.L., Mihalova, T., Montalban, X., 
Mottershead, J., Myhr, K.M., Naldi, P., Ollier, W., Page, A., Palotie, A., Pelletier, J., Piccio, L., Pickersgill, T., Piehl, 
F., Pobywajlo, S., Quach, H.L., Ramsay, P.P., Reunanen, M., Reynolds, R., Rioux, J.D., Rodegher, M., Roesner, S., 
Rubio, J.P., Ruckert, I.M., Salvetti, M., Salvi, E., Santaniello, A., Schaefer, C.A., Schreiber, S., Schulze, C., Scott, 
R.J., Sellebjerg, F., Selmaj, K.W., Sexton, D., Shen, L., Simms-Acuna, B., Skidmore, S., Sleiman, P.M., Smestad, 
C., Sorensen, P.S., Sondergaard, H.B., Stankovich, J., Strange, R.C., Sulonen, A.M., Sundqvist, E., Syvanen, 
A.C., Taddeo, F., Taylor, B., Blackwell, J.M., Tienari, P., Bramon, E., Tourbah, A., Brown, M.A., Tronczynska, E., 
Casas, J.P., Tubridy, N., Corvin, A., Vickery, J., Jankowski, J., Villoslada, P., Markus, H.S., Wang, K., Mathew, C.G., 
Wason, J., Palmer, C.N., Wichmann, H.E., Plomin, R., Willoughby, E., Rautanen, A., Winkelmann, J., Wittig, M., 
Trembath, R.C., Yaouanq, J., Viswanathan, A.C., Zhang, H., Wood, N.W., Zuvich, R., Deloukas, P., Langford, 
C., Duncanson, A., Oksenberg, J.R., Pericak-Vance, M.A., Haines, J.L., Olsson, T., Hillert, J., Ivinson, A.J., De 
Jager, P.L., Peltonen, L., Stewart, G.J., Hafler, D.A., Hauser, S.L., McVean, G., Donnelly, P. & Compston, A. 2011, 
“Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis”, Nature, vol. 
476, no. 7359, pp. 214-219.
Ishibashi, T., Dakin, K.A., Stevens, B., Lee, P.R., Kozlov, S.V., Stewart, C.L. & Fields, R.D. 2006, “Astrocytes promote 
myelination in response to electrical impulses”, Neuron, vol. 49, no. 6, pp. 823-832.
Jarjour, A.A., Zhang, H., Bauer, N., ffrench-Constant, C. & Williams, A. 2012, “In vitro modeling of central nervous 
system myelination and remyelination”, Glia, vol. 60, no. 1, pp. 1-12.
Jiang, F., Frederick, T.J. & Wood, T.L. 2001, “IGF-I synergizes with FGF-2 to stimulate oligodendrocyte progenitor 
entry into the cell cycle”, Developmental Biology, vol. 232, no. 2, pp. 414-423.
John, G.R., Shankar, S.L., Shafit-Zagardo, B., Massimi, A., Lee, S.C., Raine, C.S. & Brosnan, C.F. 2002, “Multiple 
sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation”, Nature 
44
Chapter 1
Medicine, vol. 8, no. 10, pp. 1115-1121.
Kamasawa, N., Sik, A., Morita, M., Yasumura, T., Davidson, K.G., Nagy, J.I. & Rash, J.E. 2005, “Connexin-47 and 
connexin-32 in gap junctions of oligodendrocyte somata, myelin sheaths, paranodal loops and Schmidt-
Lanterman incisures: implications for ionic homeostasis and potassium siphoning”, Neuroscience, vol. 136, 
no. 1, pp. 65-86.
Kang, P., Lee, H.K., Glasgow, S.M., Finley, M., Donti, T., Gaber, Z.B., Graham, B.H., Foster, A.E., Novitch, B.G., 
Gronostajski, R.M. & Deneen, B. 2012, “Sox9 and NFIA coordinate a transcriptional regulatory cascade 
during the initiation of gliogenesis”, Neuron, vol. 74, no. 1, pp. 79-94.
Kappos, L., Radue, E.W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, 
M., Zhang-Auberson, L., Burtin, P. & FREEDOMS Study Group 2010, “A placebo-controlled trial of oral 
fingolimod in relapsing multiple sclerosis”, The New England Journal of Medicine, vol. 362, no. 5, pp. 387-401.
Karadottir, R. & Attwell, D. 2007, “Neurotransmitter receptors in the life and death of oligodendrocytes”, 
Neuroscience, vol. 145, no. 4, pp. 1426-1438.
Karadottir, R., Cavelier, P., Bergersen, L.H. & Attwell, D. 2005, “NMDA receptors are expressed in oligodendrocytes 
and activated in ischaemia”, Nature, vol. 438, no. 7071, pp. 1162-1166.
Karadottir, R., Hamilton, N.B., Bakiri, Y. & Attwell, D. 2008, “Spiking and nonspiking classes of oligodendrocyte 
precursor glia in CNS white matter”, Nature Neuroscience, vol. 11, no. 4, pp. 450-456.
Kaya, F., Mannioui, A., Chesneau, A., Sekizar, S., Maillard, E., Ballagny, C., Houel-Renault, L., Dupasquier, D., 
Bronchain, O., Holtzmann, I., Desmazieres, A., Thomas, J.L., Demeneix, B.A., Brophy, P.J., Zalc, B. & Mazabraud, 
A. 2012, “Live imaging of targeted cell ablation in Xenopus: a new model to study demyelination and 
repair”, The Journal of Neuroscience, vol. 32, no. 37, pp. 12885-12895.
Kinney, M.O., McDonnell, G., Wattjes, M.P., Visser, F. & van Oosten, B.W. 2013, “Tumefactive multiple sclerosis 
lesions under fingolimod treatment”, Neurology, vol. 81, no. 4, pp. 403.
Kipp, M., Clarner, T., Dang, J., Copray, S. & Beyer, C. 2009, “The cuprizone animal model: new insights into an old 
story”, Acta Neuropathologica, vol. 118, no. 6, pp. 723-736.
Kirk, J., Plumb, J., Mirakhur, M. & McQuaid, S. 2003, “Tight junctional abnormality in multiple sclerosis white matter 
affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination”, 
The Journal of Pathology, vol. 201, no. 2, pp. 319-327.
Koch-Henriksen, N. & Sorensen, P.S. 2010, “The changing demographic pattern of multiple sclerosis epidemiology”, 
Lancet Neurology, vol. 9, no. 5, pp. 520-532.
Koehler, R.C., Roman, R.J. & Harder, D.R. 2009, “Astrocytes and the regulation of cerebral blood flow”, Trends in 
Neurosciences, vol. 32, no. 3, pp. 160-169.
Koenning, M., Jackson, S., Hay, C.M., Faux, C., Kilpatrick, T.J., Willingham, M. & Emery, B. 2012, “Myelin gene 
regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult 
CNS”, The Journal of Neuroscience, vol. 32, no. 36, pp. 12528-12542.
Kondo, T. & Raff, M. 2000, “The Id4 HLH protein and the timing of oligodendrocyte differentiation”, The EMBO 
Journal, vol. 19, no. 9, pp. 1998-2007.
Kotter, M.R., Li, W.W., Zhao, C. & Franklin, R.J. 2006, “Myelin impairs CNS remyelination by inhibiting oligodendrocyte 
precursor cell differentiation”, The Journal of Neuroscience, vol. 26, no. 1, pp. 328-332.
Kotter, M.R., Zhao, C., van Rooijen, N. & Franklin, R.J. 2005, “Macrophage-depletion induced impairment of 
experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response 
and altered growth factor expression”, Neurobiology of Disease, vol. 18, no. 1, pp. 166-175.
Kuhlmann, T., Miron, V., Cui, Q., Wegner, C., Antel, J. & Bruck, W. 2008, “Differentiation block of oligodendroglial 
45
Glial cells in health and multiple sclerosis
1
progenitor cells as a cause for remyelination failure in chronic multiple sclerosis”, Brain, vol. 131, no. Pt 7, 
pp. 1749-1758.
Kumar, S., Patel, R., Moore, S., Crawford, D.K., Suwanna, N., Mangiardi, M. & Tiwari-Woodruff, S.K. 2013, “Estrogen 
receptor beta ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes 
remyelination in a mouse model of multiple sclerosis”, Neurobiology of Disease, vol. 56, pp. 131-144.
Kutzelnigg, A., Lucchinetti, C.F., Stadelmann, C., Bruck, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, 
J.E. & Lassmann, H. 2005, “Cortical demyelination and diffuse white matter injury in multiple sclerosis”, 
Brain, vol. 128, no. Pt 11, pp. 2705-2712.
Lalmohamed, A., Bazelier, M.T., Van Staa, T.P., Uitdehaag, B.M., Leufkens, H.G., De Boer, A. & De Vries, F. 2012, 
“Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based 
cohort study”, European Journal of Neurology, vol. 19, no. 7, pp. 1007-1014.
Lampron, A., Elali, A. & Rivest, S. 2013, “Innate Immunity in the CNS: Redefining the Relationship between the CNS 
and Its Environment”, Neuron, vol. 78, no. 2, pp. 214-232.
Lassmann, H. 2011, “Review: the architecture of inflammatory demyelinating lesions: implications for studies on 
pathogenesis”, Neuropathology and Applied Neurobiology, vol. 37, no. 7, pp. 698-710.
Lassmann, H., Bruck, W. & Lucchinetti, C.F. 2007, “The immunopathology of multiple sclerosis: an overview”, Brain 
Pathology, vol. 17, no. 2, pp. 210-218.
Lassmann, H., van Horssen, J. & Mahad, D. 2012, “Progressive multiple sclerosis: pathology and pathogenesis”, 
Nature Reviews Neurology, vol. 8, no. 11, pp. 647-656.
Lau, L.W., Keough, M.B., Haylock-Jacobs, S., Cua, R., Doring, A., Sloka, S., Stirling, D.P., Rivest, S. & Yong, V.W. 2012, 
“Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination”, Annals of Neurology, vol. 
72, no. 3, pp. 419-432.
Laursen, L.S., Chan, C.W. & ffrench-Constant, C. 2009, “An integrin-contactin complex regulates CNS myelination 
by differential Fyn phosphorylation”, The Journal of Neuroscience, vol. 29, no. 29, pp. 9174-9185.
Lee, S., Leach, M.K., Redmond, S.A., Chong, S.Y., Mellon, S.H., Tuck, S.J., Feng, Z.Q., Corey, J.M. & Chan, J.R. 2012a, 
“A culture system to study oligodendrocyte myelination processes using engineered nanofibers”, Nature 
Methods, vol. 9, no. 9, pp. 917-922.
Lee, Y., Morrison, B.M., Li, Y., Lengacher, S., Farah, M.H., Hoffman, P.N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.W., 
Pellerin, L., Magistretti, P.J. & Rothstein, J.D. 2012b, “Oligodendroglia metabolically support axons and 
contribute to neurodegeneration”, Nature, vol. 487, no. 7408, pp. 443-448.
Lehnardt, S. 2010, “Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-
mediated neuronal injury”, Glia, vol. 58, no. 3, pp. 253-263.
Li, W.W., Setzu, A., Zhao, C. & Franklin, R.J. 2005, “Minocycline-mediated inhibition of microglia activation impairs 
oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination”, 
Journal of Neuroimmunology, vol. 158, no. 1-2, pp. 58-66.
Liu, A., Li, J., Marin-Husstege, M., Kageyama, R., Fan, Y., Gelinas, C. & Casaccia-Bonnefil, P. 2006, “A molecular 
insight of Hes5-dependent inhibition of myelin gene expression: old partners and new players”, The EMBO 
Journal, vol. 25, no. 20, pp. 4833-4842.
Locatelli, G., Wortge, S., Buch, T., Ingold, B., Frommer, F., Sobottka, B., Kruger, M., Karram, K., Buhlmann, C., 
Bechmann, I., Heppner, F.L., Waisman, A. & Becher, B. 2012, “Primary oligodendrocyte death does not elicit 
anti-CNS immunity”, Nature Neuroscience, vol. 15, no. 4, pp. 543-550.
Loredana, L.M., Laura, V., Carlo, D.P., George, E., Marco, R., Sten, F. & Graziella, F. 2012, “Interferon beta for secondary 
progressive multiple sclerosis” in Cochrane Database of Systematic Reviews.
46
Chapter 1
Lovatt, D., Sonnewald, U., Waagepetersen, H.S., Schousboe, A., He, W., Lin, J.H., Han, X., Takano, T., Wang, S., Sim, F.J., 
Goldman, S.A. & Nedergaard, M. 2007, “The transcriptome and metabolic gene signature of protoplasmic 
astrocytes in the adult murine cortex”, The Journal of Neuroscience, vol. 27, no. 45, pp. 12255-12266.
Lubetzki, C., Demerens, C., Anglade, P., Villarroya, H., Frankfurter, A., Lee, V.M. & Zalc, B. 1993, “Even in culture, 
oligodendrocytes myelinate solely axons”, Proceedings of the National Academy of Sciences of the United 
States of America, vol. 90, no. 14, pp. 6820-6824.
Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. & Lassmann, H. 2000, “Heterogeneity of multiple 
sclerosis lesions: implications for the pathogenesis of demyelination”, Annals of Neurology, vol. 47, no. 6, 
pp. 707-717.
Lucchinetti, C.F., Popescu, B.F., Bunyan, R.F., Moll, N.M., Roemer, S.F., Lassmann, H., Bruck, W., Parisi, J.E., 
Scheithauer, B.W., Giannini, C., Weigand, S.D., Mandrekar, J. & Ransohoff, R.M. 2011, “Inflammatory cortical 
demyelination in early multiple sclerosis”, The New England Journal of Medicine, vol. 365, no. 23, pp. 2188-
2197.
Maglione, M., Tress, O., Haas, B., Karram, K., Trotter, J., Willecke, K. & Kettenmann, H. 2010, “Oligodendrocytes in 
mouse corpus callosum are coupled via gap junction channels formed by connexin47 and connexin32”, 
Glia, vol. 58, no. 9, pp. 1104-1117.
Maier, O., Hoekstra, D. & Baron, W. 2008, “Polarity development in oligodendrocytes: sorting and trafficking of 
myelin components”, Journal of Molecular Neuroscience, vol. 35, no. 1, pp. 35-53.
Mancardi, G. 2009, “Further data on autologous haemopoietic stem cell transplantation in multiple sclerosis”, 
Lancet Neurology, vol. 8, no. 3, pp. 219-221.
Mancardi, G. & Saccardi, R. 2008, “Autologous haematopoietic stem-cell transplantation in multiple sclerosis”, 
Lancet Neurology, vol. 7, no. 7, pp. 626-636.
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.J., Card, D., Keohane, 
C., Rosenbach, M., Hale, J., Lynch, C.L., Rupprecht, K., Parsons, W. & Rosen, H. 2002, “Alteration of lymphocyte 
trafficking by sphingosine-1-phosphate receptor agonists”, Science, vol. 296, no. 5566, pp. 346-349.
Marin-Husstege, M., He, Y., Li, J., Kondo, T., Sablitzky, F. & Casaccia-Bonnefil, P. 2006, “Multiple roles of Id4 in 
developmental myelination: predicted outcomes and unexpected findings”, Glia, vol. 54, no. 4, pp. 285-
296.
Martinez, F.O., Helming, L. & Gordon, S. 2009, “Alternative activation of macrophages: an immunologic functional 
perspective”, Annual Review of Immunology, vol. 27, pp. 451-483.
Martino, G., Franklin, R.J., Baron Van Evercooren, A., Kerr, D.A. & Stem Cells in Multiple Sclerosis (STEMS) Consensus 
Group 2010, “Stem cell transplantation in multiple sclerosis: current status and future prospects”, Nature 
Reviews Neurology, vol. 6, no. 5, pp. 247-255.
Mason, J.L., Suzuki, K., Chaplin, D.D. & Matsushima, G.K. 2001, “Interleukin-1beta promotes repair of the CNS”, The 
Journal of Neuroscience, vol. 21, no. 18, pp. 7046-7052.
Mason, J.L., Toews, A., Hostettler, J.D., Morell, P., Suzuki, K., Goldman, J.E. & Matsushima, G.K. 2004, 
“Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated 
lesions”, The American Journal of Pathology, vol. 164, no. 5, pp. 1673-1682.
Matsushima, G.K. & Morell, P. 2001, “The neurotoxicant, cuprizone, as a model to study demyelination and 
remyelination in the central nervous system”, Brain Pathology, vol. 11, no. 1, pp. 107-116.
McKinnon, R.D., Matsui, T., Aranda, M. & Dubois-Dalcq, M. 1991, “A role for fibroblast growth factor in 
oligodendrocyte development”, Annals of the New York Academy of Sciences, vol. 638, pp. 378-386.
McKinnon, R.D., Matsui, T., Dubois-Dalcq, M. & Aaronson, S.A. 1990, “FGF modulates the PDGF-driven pathway of 
47
Glial cells in health and multiple sclerosis
1
oligodendrocyte development”, Neuron, vol. 5, no. 5, pp. 603-614.
McMorris, F.A. & Dubois-Dalcq, M. 1988, “Insulin-like growth factor I promotes cell proliferation and 
oligodendroglial commitment in rat glial progenitor cells developing in vitro”, Journal of Neuroscience 
Research, vol. 21, no. 2-4, pp. 199-209.
Menn, B., Garcia-Verdugo, J.M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D. & Alvarez-Buylla, A. 2006a, “Origin of 
oligodendrocytes in the subventricular zone of the adult brain”, The Journal of Neuroscience, vol. 26, no. 30, 
pp. 7907-7918.
Menn, B., Garcia-Verdugo, J.M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D. & Alvarez-Buylla, A. 2006b, “Origin of 
oligodendrocytes in the subventricular zone of the adult brain”, The Journal of Neuroscience, vol. 26, no. 30, 
pp. 7907-7918.
Metz, I., Lucchinetti, C.F., Openshaw, H., Garcia-Merino, A., Lassmann, H., Freedman, M.S., Atkins, H.L., Azzarelli, 
B., Kolar, O.J. & Bruck, W. 2007, “Autologous haematopoietic stem cell transplantation fails to stop 
demyelination and neurodegeneration in multiple sclerosis”, Brain, vol. 130, no. Pt 5, pp. 1254-1262.
Mi, S., Hu, B., Hahm, K., Luo, Y., Kam Hui, E.S., Yuan, Q., Wong, W.M., Wang, L., Su, H., Chu, T.H., Guo, J., Zhang, W., 
So, K.F., Pepinsky, B., Shao, Z., Graff, C., Garber, E., Jung, V., Wu, E.X. & Wu, W. 2007, “LINGO-1 antagonist 
promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune 
encephalomyelitis”, Nature Medicine, vol. 13, no. 10, pp. 1228-1233.
Mi, S., Miller, R.H., Lee, X., Scott, M.L., Shulag-Morskaya, S., Shao, Z., Chang, J., Thill, G., Levesque, M., Zhang, 
M., Hession, C., Sah, D., Trapp, B., He, Z., Jung, V., McCoy, J.M. & Pepinsky, R.B. 2005, “LINGO-1 negatively 
regulates myelination by oligodendrocytes”, Nature Neuroscience, vol. 8, no. 6, pp. 745-751.
Mi, S., Miller, R.H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C.B., Zhang, Y., Miklasz, S., Shea, D., Mason, 
J., Franklin, R.J., Ji, B., Shao, Z., Chedotal, A., Bernard, F., Roulois, A., Xu, J., Jung, V. & Pepinsky, B. 2009, 
“Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte 
precursor cells”, Annals of Neurology, vol. 65, no. 3, pp. 304-315.
Mi, S., Pepinsky, R.B. & Cadavid, D. 2013, “Blocking LINGO-1 as a therapy to promote CNS repair: from concept to 
the clinic”, CNS drugs, vol. 27, no. 7, pp. 493-503.
Michailov, G.V., Sereda, M.W., Brinkmann, B.G., Fischer, T.M., Haug, B., Birchmeier, C., Role, L., Lai, C., Schwab, M.H. 
& Nave, K.A. 2004, “Axonal neuregulin-1 regulates myelin sheath thickness”, Science, vol. 304, no. 5671, pp. 
700-703.
Minkiewicz, J., de Rivero Vaccari, J.P. & Keane, R.W. 2013, “Human astrocytes express a novel NLRP2 inflammasome”, 
Glia, .
Miron, V.E., Boyd, A., Zhao, J.W., Yuen, T.J., Ruckh, J.M., Shadrach, J.L., van Wijngaarden, P., Wagers, A.J., Williams, 
A., Franklin, R.J. & ffrench-Constant, C. 2013, “M2 microglia and macrophages drive oligodendrocyte 
differentiation during CNS remyelination”, Nature Neuroscience, vol. 16, no. 9, pp. 1211-1218.
Najm, F.J., Lager, A.M., Zaremba, A., Wyatt, K., Caprariello, A.V., Factor, D.C., Karl, R.T., Maeda, T., Miller, R.H. & Tesar, 
P.J. 2013, “Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic 
oligodendrocyte progenitor cells”, Nature Biotechnology, vol. 31, no. 5, pp. 426-433.
Nave, K.A. 2010a, “Myelination and support of axonal integrity by glia”, Nature, vol. 468, no. 7321, pp. 244-252.
Nave, K.A. 2010b, “Myelination and the trophic support of long axons”, Nature Reviews Neuroscience, vol. 11, no. 
4, pp. 275-283.
Nedergaard, M. & Verkhratsky, A. 2012, “Artifact versus reality--how astrocytes contribute to synaptic events”, 
Glia, vol. 60, no. 7, pp. 1013-1023.
Nicholas, R.S., Wing, M.G. & Compston, A. 2001, “Nonactivated microglia promote oligodendrocyte precursor 
48
Chapter 1
survival and maturation through the transcription factor NF-kappa B”, The European Journal of Neuroscience, 
vol. 13, no. 5, pp. 959-967.
Niehaus, A., Shi, J., Grzenkowski, M., Diers-Fenger, M., Archelos, J., Hartung, H.P., Toyka, K., Bruck, W. & Trotter, 
J. 2000, “Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing 
oligodendrocyte progenitor cell surface protein: implications for remyelination”, Annals of Neurology, vol. 
48, no. 3, pp. 362-371.
Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. 2005, “Resting microglial cells are highly dynamic surveillants of 
brain parenchyma in vivo”, Science, vol. 308, no. 5726, pp. 1314-1318.
Nistor, G.I., Totoiu, M.O., Haque, N., Carpenter, M.K. & Keirstead, H.S. 2005, “Human embryonic stem cells 
differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation”, Glia, 
vol. 49, no. 3, pp. 385-396.
Nylander, A. & Hafler, D.A. 2012, “Multiple sclerosis”, The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1180-
1188.
Odoardi, F., Sie, C., Streyl, K., Ulaganathan, V.K., Schlager, C., Lodygin, D., Heckelsmiller, K., Nietfeld, W., Ellwart, J., 
Klinkert, W.E., Lottaz, C., Nosov, M., Brinkmann, V., Spang, R., Lehrach, H., Vingron, M., Wekerle, H., Flugel-
Koch, C. & Flugel, A. 2012, “T cells become licensed in the lung to enter the central nervous system”, Nature, 
vol. 488, no. 7413, pp. 675-679.
Oleszak, E.L., Zaczynska, E., Bhattacharjee, M., Butunoi, C., Legido, A. & Katsetos, C.D. 1998, “Inducible nitric oxide 
synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in 
chronic, multiple sclerosis”, Clinical and Diagnostic Laboratory Immunology, vol. 5, no. 4, pp. 438-445.
O’Meara, R.W., Michalski, J.P. & Kothary, R. 2011, “Integrin signaling in oligodendrocytes and its importance in 
CNS myelination”, Journal of Signal Transduction, vol. 2011, pp. 354091.
Ortega, F., Gascon, S., Masserdotti, G., Deshpande, A., Simon, C., Fischer, J., Dimou, L., Chichung Lie, D., Schroeder, 
T. & Berninger, B. 2013, “Oligodendrogliogenic and neurogenic adult subependymal zone neural stem cells 
constitute distinct lineages and exhibit differential responsiveness to Wnt signalling”, Nature Cell Biology, 
vol. 15, no. 6, pp. 602-613.
Ortega, M.C., Bribian, A., Peregrin, S., Gil, M.T., Marin, O. & de Castro, F. 2012, “Neuregulin-1/ErbB4 signaling 
controls the migration of oligodendrocyte precursor cells during development”, Experimental Neurology, 
vol. 235, no. 2, pp. 610-620.
Ousman, S.S. & Kubes, P. 2012, “Immune surveillance in the central nervous system”, Nature Neuroscience, vol. 15, 
no. 8, pp. 1096-1101.
PA, R.G., Barbara, I., M., M.L., George, E., Chris, P., Roberto, D., Elena, P. & Graziella, F. 2001, “Interferon in relapsing-
remitting multiple sclerosis” in Cochrane Database of Systematic Reviews.
Patel, J.R., Williams, J.L., Muccigrosso, M.M., Liu, L., Sun, T., Rubin, J.B. & Klein, R.S. 2012, “Astrocyte TNFR2 is 
required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation 
within the adult CNS”, Acta Neuropathologica, vol. 124, no. 6, pp. 847-860.
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P.S., Bruck, W., 
Lucchinetti, C. & Lassmann, H. 2006, “Remyelination is extensive in a subset of multiple sclerosis patients”, 
Brain, vol. 129, no. Pt 12, pp. 3165-3172.
Penderis, J., Shields, S.A. & Franklin, R.J. 2003, “Impaired remyelination and depletion of oligodendrocyte 
progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous 
system”, Brain, vol. 126, no. Pt 6, pp. 1382-1391.
Perkins, G.A., Sosinsky, G.E., Ghassemzadeh, S., Perez, A., Jones, Y. & Ellisman, M.H. 2008, “Electron tomographic 
analysis of cytoskeletal cross-bridges in the paranodal region of the node of Ranvier in peripheral nerves”, 
49
Glial cells in health and multiple sclerosis
1
Journal of Structural Biology, vol. 161, no. 3, pp. 469-480.
Peterson, J.W., Bo, L., Mork, S., Chang, A. & Trapp, B.D. 2001, “Transected neurites, apoptotic neurons, and reduced 
inflammation in cortical multiple sclerosis lesions”, Annals of Neurology, vol. 50, no. 3, pp. 389-400.
Piaton, G., Gould, R.M. & Lubetzki, C. 2010, “Axon-oligodendrocyte interactions during developmental 
myelination, demyelination and repair”, Journal of Neurochemistry, vol. 114, no. 5, pp. 1243-1260.
Polman, C.H., O’Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., Phillips, J.T., Lublin, F.D., 
Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M.A., Sandrock, A.W. & AFFIRM Investigators 2006, 
“A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis”, The New England 
Journal of Medicine, vol. 354, no. 9, pp. 899-910.
Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, 
M., Kappos, L., Lublin, F.D., Montalban, X., O’Connor, P., Sandberg-Wollheim, M., Thompson, A.J., Waubant, 
E., Weinshenker, B. & Wolinsky, J.S. 2011, “Diagnostic criteria for multiple sclerosis: 2010 revisions to the 
McDonald criteria”, Annals of Neurology, vol. 69, no. 2, pp. 292-302.
Poser, C.M. & Brinar, V.V. 2007, “The accuracy of prevalence rates of multiple sclerosis: a critical review”, 
Neuroepidemiology, vol. 29, no. 3-4, pp. 150-155.
Preston, M., Gong, X., Su, W., Matsumoto, S.G., Banine, F., Winkler, C., Foster, S., Xing, R., Struve, J., Dean, J., 
Baggenstoss, B., Weigel, P.H., Montine, T.J., Back, S.A. & Sherman, L.S. 2013, “Digestion products of the PH20 
hyaluronidase inhibit remyelination”, Annals of Neurology, vol. 73, no. 2, pp. 266-280.
Pringle, N.P., Mudhar, H.S., Collarini, E.J. & Richardson, W.D. 1992, “PDGF receptors in the rat CNS: during late 
neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte 
lineage”, Development, vol. 115, no. 2, pp. 535-551.
Qi, Y., Cai, J., Wu, Y., Wu, R., Lee, J., Fu, H., Rao, M., Sussel, L., Rubenstein, J. & Qiu, M. 2001, “Control of oligodendrocyte 
differentiation by the Nkx2.2 homeodomain transcription factor”, Development, vol. 128, no. 14, pp. 2723-
2733.
Rafalski, V.A., Ho, P.P., Brett, J.O., Ucar, D., Dugas, J.C., Pollina, E.A., Chow, L.M., Ibrahim, A., Baker, S.J., Barres, B.A., 
Steinman, L. & Brunet, A. 2013, “Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation 
in the adult brain”, Nature Cell Biology, vol. 15, no. 6, pp. 614-624.
Ransohoff, R.M. & Brown, M.A. 2012, “Innate immunity in the central nervous system”, The Journal of Clinical 
Investigation, vol. 122, no. 4, pp. 1164-1171.
Ransohoff, R.M. & Cardona, A.E. 2010, “The myeloid cells of the central nervous system parenchyma”, Nature, vol. 
468, no. 7321, pp. 253-262.
Ransohoff, R.M. & Engelhardt, B. 2012, “The anatomical and cellular basis of immune surveillance in the central 
nervous system”, Nature Reviews Immunology, vol. 12, no. 9, pp. 623-635.
Rawji, K.S. & Yong, V.W. 2013, “The benefits and detriments of macrophages/microglia in models of multiple 
sclerosis”, Clinical & Developmental Immunology, vol. 2013, pp. 948976.
Reynolds, R., Dawson, M., Papadopoulos, D., Polito, A., Di Bello, I.C., Pham-Dinh, D. & Levine, J. 2002, “The 
response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS”, Journal 
of Neurocytology, vol. 31, no. 6-7, pp. 523-536.
Rhodes, K.E., Raivich, G. & Fawcett, J.W. 2006, “The injury response of oligodendrocyte precursor cells is induced 
by platelets, macrophages and inflammation-associated cytokines”, Neuroscience, vol. 140, no. 1, pp. 87-
100.
Richardson, W.D., Young, K.M., Tripathi, R.B. & McKenzie, I. 2011, “NG2-glia as multipotent neural stem cells: fact or 
fantasy?”, Neuron, vol. 70, no. 4, pp. 661-673.
50
Chapter 1
Rivera, F.J. & Aigner, L. 2012, “Adult mesenchymal stem cell therapy for myelin repair in multiple sclerosis”, 
Biological Research, vol. 45, no. 3, pp. 257-268.
Rivers, L.E., Young, K.M., Rizzi, M., Jamen, F., Psachoulia, K., Wade, A., Kessaris, N. & Richardson, W.D. 2008, “PDGFRA/
NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice”, Nature 
Neuroscience, vol. 11, no. 12, pp. 1392-1401.
Robins, S.C., Villemain, A., Liu, X., Djogo, T., Kryzskaya, D., Storch, K.F. & Kokoeva, M.V. 2013, “Extensive regenerative 
plasticity among adult NG2-glia populations is exclusively based on self-renewal”, Glia, vol. 61, no. 10, pp. 
1735-1747.
Rowitch, D.H. & Kriegstein, A.R. 2010, “Developmental genetics of vertebrate glial-cell specification”, Nature, vol. 
468, no. 7321, pp. 214-222.
Roy, N.S., Wang, S., Harrison-Restelli, C., Benraiss, A., Fraser, R.A., Gravel, M., Braun, P.E. & Goldman, S.A. 1999, 
“Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells 
from the adult human subcortical white matter”, The Journal of Neuroscience, vol. 19, no. 22, pp. 9986-9995.
Ruckh, J.M., Zhao, J.W., Shadrach, J.L., van Wijngaarden, P., Rao, T.N., Wagers, A.J. & Franklin, R.J. 2012, “Rejuvenation 
of regeneration in the aging central nervous system”, Cell Stem Cell, vol. 10, no. 1, pp. 96-103.
Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W., Lublin, F.D., Weinstock-Guttman, 
B., Wynn, D.R., Lynn, F., Panzara, M.A., Sandrock, A.W. & SENTINEL Investigators 2006, “Natalizumab plus 
interferon beta-1a for relapsing multiple sclerosis”, The New England Journal of Medicine, vol. 354, no. 9, pp. 
911-923.
Safarinejad, M.R. 2008, “Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in 
multiple sclerosis”, Journal of Neuroendocrinology, vol. 20, no. 12, pp. 1368-1375.
Samanta, J. & Kessler, J.A. 2004, “Interactions between ID and OLIG proteins mediate the inhibitory effects of 
BMP4 on oligodendroglial differentiation”, Development, vol. 131, no. 17, pp. 4131-4142.
Satoh, J.I., Tabunoki, H. & Yamamura, T. 2009, “Molecular network of the comprehensive multiple sclerosis brain-
lesion proteome”, Multiple Sclerosis, vol. 15, no. 5, pp. 531-541.
Scholz, J., Klein, M.C., Behrens, T.E. & Johansen-Berg, H. 2009, “Training induces changes in white-matter 
architecture”, Nature Neuroscience, vol. 12, no. 11, pp. 1370-1371.
Schonrock, L.M., Kuhlmann, T., Adler, S., Bitsch, A. & Bruck, W. 1998, “Identification of glial cell proliferation in early 
multiple sclerosis lesions”, Neuropathology and Applied Neurobiology, vol. 24, no. 4, pp. 320-330.
Schulz, K., Kroner, A. & David, S. 2012, “Iron efflux from astrocytes plays a role in remyelination”, The Journal of 
Neuroscience, vol. 32, no. 14, pp. 4841-4847.
Serafini, B., Muzio, L., Rosicarelli, B. & Aloisi, F. 2013, “Radioactive in situ hybridization for Epstein-Barr virus-
encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain”, Brain, 136/7/
e233
Simons, M., Snaidero, N. & Aggarwal, S. 2012, “Cell polarity in myelinating glia: from membrane flow to diffusion 
barriers”, Biochimica et biophysica acta, vol. 1821, no. 8, pp. 1146-1153.
Simons, M. & Trajkovic, K. 2006, “Neuron-glia communication in the control of oligodendrocyte function and 
myelin biogenesis”, Journal of Cell Science, vol. 119, no. Pt 21, pp. 4381-4389.
Simons, M. & Trotter, J. 2007, “Wrapping it up: the cell biology of myelination”, Current Opinion in Neurobiology, 
vol. 17, no. 5, pp. 533-540.
Sirko, S., Behrendt, G., Johansson, P.A., Tripathi, P., Costa, M., Bek, S., Heinrich, C., Tiedt, S., Colak, D., Dichgans, M., 
Fischer, I.R., Plesnila, N., Staufenbiel, M., Haass, C., Snapyan, M., Saghatelyan, A., Tsai, L.H., Fischer, A., Grobe, 
K., Dimou, L. & Gotz, M. 2013, “Reactive glia in the injured brain acquire stem cell properties in response to 
51
Glial cells in health and multiple sclerosis
1
sonic hedgehog glia”, Cell Stem Cell, vol. 12, no. 4, pp. 426-439.
Skripuletz, T., Hackstette, D., Bauer, K., Gudi, V., Pul, R., Voss, E., Berger, K., Kipp, M., Baumgartner, W. & Stangel, M. 
2013, “Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced 
demyelination”, Brain, vol. 136, no. Pt 1, pp. 147-167.
Smith, C.M., Cooksey, E. & Duncan, I.D. 2013, “Myelin loss does not lead to axonal degeneration in a long-lived 
model of chronic demyelination”, The Journal of Neuroscience, vol. 33, no. 6, pp. 2718-2727.
Smith, P.M. & Jeffery, N.D. 2006, “Histological and ultrastructural analysis of white matter damage after naturally-
occurring spinal cord injury”, Brain Pathology, vol. 16, no. 2, pp. 99-109.
Sobel, R.A. & Ahmed, A.S. 2001, “White matter extracellular matrix chondroitin sulfate/dermatan sulfate 
proteoglycans in multiple sclerosis”, Journal of Neuropathology and Experimental Neurology, vol. 60, no. 12, 
pp. 1198-1207.
Sobel, R.A. & Mitchell, M.E. 1989, “Fibronectin in multiple sclerosis lesions”, The American Journal of Pathology, vol. 
135, no. 1, pp. 161-168.
Sofroniew, M.V. & Vinters, H.V. 2010, “Astrocytes: biology and pathology”, Acta Neuropathologica, vol. 119, no. 1, 
pp. 7-35.
Soldan, M.M. & Pirko, I. 2012, “Biogenesis and significance of central nervous system myelin”, Seminars in 
Neurology, vol. 32, no. 1, pp. 9-14.
Spassky, N., de Castro, F., Le Bras, B., Heydon, K., Queraud-LeSaux, F., Bloch-Gallego, E., Chedotal, A., Zalc, B. & 
Thomas, J.L. 2002, “Directional guidance of oligodendroglial migration by class 3 semaphorins and 
netrin-1”, The Journal of Neuroscience, vol. 22, no. 14, pp. 5992-6004.
Srivastava, R., Aslam, M., Kalluri, S.R., Schirmer, L., Buck, D., Tackenberg, B., Rothhammer, V., Chan, A., Gold, R., 
Berthele, A., Bennett, J.L., Korn, T. & Hemmer, B. 2012, “Potassium channel KIR4.1 as an immune target in 
multiple sclerosis”, The New England Journal of Medicine, vol. 367, no. 2, pp. 115-123.
Stancic, M., Slijepcevic, D., Nomden, A., Vos, M.J., de Jonge, J.C., Sikkema, A.H., Gabius, H.J., Hoekstra, D. & Baron, 
W. 2012, “Galectin-4, a novel neuronal regulator of myelination”, Glia, vol. 60, no. 6, pp. 919-935.
Stevens, B. 2003, “Glia: much more than the neuron’s side-kick”, Current Biology : CB, vol. 13, no. 12, pp. R469-72.
Stevens, B., Porta, S., Haak, L.L., Gallo, V. & Fields, R.D. 2002, “Adenosine: a neuron-glial transmitter promoting 
myelination in the CNS in response to action potentials”, Neuron, vol. 36, no. 5, pp. 855-868.
Stoffels, J.M., de Jonge, J.C., Stancic, M., Nomden, A., van Strien, M.E., Ma, D., Siskova, Z., Maier, O., ffrench-
Constant, C., Franklin, R.J., Hoekstra, D., Zhao, C. & Baron, W. 2013, “Fibronectin aggregation in multiple 
sclerosis lesions impairs remyelination”, Brain, vol. 136, no. Pt 1, pp. 116-131.
Stolt, C.C., Lommes, P., Sock, E., Chaboissier, M.C., Schedl, A. & Wegner, M. 2003, “The Sox9 transcription factor 
determines glial fate choice in the developing spinal cord”, Genes & Development, vol. 17, no. 13, pp. 1677-
1689.
Stolt, C.C., Schlierf, A., Lommes, P., Hillgartner, S., Werner, T., Kosian, T., Sock, E., Kessaris, N., Richardson, W.D., 
Lefebvre, V. & Wegner, M. 2006, “SoxD proteins influence multiple stages of oligodendrocyte development 
and modulate SoxE protein function”, Developmental Cell, vol. 11, no. 5, pp. 697-709.
Stys, P.K., Zamponi, G.W., van Minnen, J. & Geurts, J.J. 2012, “Will the real multiple sclerosis please stand up?”, 
Nature reviews.Neuroscience, vol. 13, no. 7, pp. 507-514.
Swiss, V.A., Nguyen, T., Dugas, J., Ibrahim, A., Barres, B., Androulakis, I.P. & Casaccia, P. 2011, “Identification of a 
gene regulatory network necessary for the initiation of oligodendrocyte differentiation”, PloS one, vol. 6, 
no. 4, pp. e18088.
Takahashi, K. & Yamanaka, S. 2006, “Induction of pluripotent stem cells from mouse embryonic and adult 
52
Chapter 1
fibroblast cultures by defined factors”, Cell, vol. 126, no. 4, pp. 663-676.
Talbott, J.F., Loy, D.N., Liu, Y., Qiu, M.S., Bunge, M.B., Rao, M.S. & Whittemore, S.R. 2005, “Endogenous Nkx2.2+/
Olig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the 
absence of astrocytes”, Experimental Neurology, vol. 192, no. 1, pp. 11-24.
Tartaglia, L.A., Weber, R.F., Figari, I.S., Reynolds, C., Palladino, M.A.,Jr & Goeddel, D.V. 1991, “The two different 
receptors for tumor necrosis factor mediate distinct cellular responses”, Proceedings of the National 
Academy of Sciences of the United States of America, vol. 88, no. 20, pp. 9292-9296.
Tatsumi, K., Takebayashi, H., Manabe, T., Tanaka, K.F., Makinodan, M., Yamauchi, T., Makinodan, E., Matsuyoshi, H., 
Okuda, H., Ikenaka, K. & Wanaka, A. 2008, “Genetic fate mapping of Olig2 progenitors in the injured adult 
cerebral cortex reveals preferential differentiation into astrocytes”, Journal of Neuroscience Research, vol. 
86, no. 16, pp. 3494-3502.
Tauber, H., Waehneldt, T.V. & Neuhoff, V. 1980, “Myelination in rabbit optic nerves is accelerated by artificial eye 
opening”, Neuroscience Letters, vol. 16, no. 3, pp. 235-238.
Taveggia, C., Zanazzi, G., Petrylak, A., Yano, H., Rosenbluth, J., Einheber, S., Xu, X., Esper, R.M., Loeb, J.A., Shrager, P., 
Chao, M.V., Falls, D.L., Role, L. & Salzer, J.L. 2005, “Neuregulin-1 type III determines the ensheathment fate of 
axons”, Neuron, vol. 47, no. 5, pp. 681-694.
Tchelingerian, J.L., Monge, M., Le Saux, F., Zalc, B. & Jacque, C. 1995, “Differential oligodendroglial expression of 
the tumor necrosis factor receptors in vivo and in vitro”, Journal of Neurochemistry, vol. 65, no. 5, pp. 2377-
2380.
Tomassini, V., Onesti, E., Mainero, C., Giugni, E., Paolillo, A., Salvetti, M., Nicoletti, F. & Pozzilli, C. 2005, “Sex 
hormones modulate brain damage in multiple sclerosis: MRI evidence”, Journal of Neurology, Neurosurgery, 
and Psychiatry, vol. 76, no. 2, pp. 272-275.
Trajkovic, K., Dhaunchak, A.S., Goncalves, J.T., Wenzel, D., Schneider, A., Bunt, G., Nave, K.A. & Simons, M. 2006, 
“Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites”, The Journal 
of Cell Biology, vol. 172, no. 6, pp. 937-948.
Trapp, B.D., Bo, L., Mork, S. & Chang, A. 1999, “Pathogenesis of tissue injury in MS lesions”, Journal of 
Neuroimmunology, vol. 98, no. 1, pp. 49-56.
Trapp, B.D. & Nave, K.A. 2008, “Multiple sclerosis: an immune or neurodegenerative disorder?”, Annual Review of 
Neuroscience, vol. 31, pp. 247-269.
Tremlett, H., Paty, D. & Devonshire, V. 2006, “Disability progression in multiple sclerosis is slower than previously 
reported”, Neurology, vol. 66, no. 2, pp. 172-177.
Trotter, J., Karram, K. & Nishiyama, A. 2010, “NG2 cells: Properties, progeny and origin”, Brain Research Reviews, vol. 
63, no. 1-2, pp. 72-82.
Tsai, H.H., Li, H., Fuentealba, L.C., Molofsky, A.V., Taveira-Marques, R., Zhuang, H., Tenney, A., Murnen, A.T., Fancy, 
S.P., Merkle, F., Kessaris, N., Alvarez-Buylla, A., Richardson, W.D. & Rowitch, D.H. 2012, “Regional astrocyte 
allocation regulates CNS synaptogenesis and repair”, Science, vol. 337, no. 6092, pp. 358-362.
Tsunoda, I. & Fujinami, R.S. 2010, “Neuropathogenesis of Theiler’s murine encephalomyelitis virus infection, an 
animal model for multiple sclerosis”, Journal of Neuroimmune Pharmacology, vol. 5, no. 3, pp. 355-369.
Tzartos, J.S., Khan, G., Vossenkamper, A., Cruz-Sadaba, M., Lonardi, S., Sefia, E., Meager, A., Elia, A., Middeldorp, 
J.M., Clemens, M., Farrell, P.J., Giovannoni, G. & Meier, U.C. 2012, “Association of innate immune activation 
with latent Epstein-Barr virus in active MS lesions”, Neurology, vol. 78, no. 1, pp. 15-23.
Uchida, N., Chen, K., Dohse, M., Hansen, K.D., Dean, J., Buser, J.R., Riddle, A., Beardsley, D.J., Wan, Y., Gong, X., 
Nguyen, T., Cummings, B.J., Anderson, A.J., Tamaki, S.J., Tsukamoto, A., Weissman, I.L., Matsumoto, S.G., 
53
Glial cells in health and multiple sclerosis
1
Sherman, L.S., Kroenke, C.D. & Back, S.A. 2012, “Human neural stem cells induce functional myelination in 
mice with severe dysmyelination”, Science Translational Medicine, vol. 4, no. 155, pp. 155ra136.
Vallstedt, A., Klos, J.M. & Ericson, J. 2005, “Multiple dorsoventral origins of oligodendrocyte generation in the 
spinal cord and hindbrain”, Neuron, vol. 45, no. 1, pp. 55-67.
van der Knaap, M.S., Pronk, J.C. & Scheper, G.C. 2006, “Vanishing white matter disease”, Lancet Neurology, vol. 5, 
no. 5, pp. 413-423.
van der Star, B.J., Vogel, D.Y., Kipp, M., Puentes, F., Baker, D. & Amor, S. 2012, “In vitro and in vivo models of multiple 
sclerosis”, CNS & Neurological Disorders Drug Targets, vol. 11, no. 5, pp. 570-588.
van Horssen, J., Bo, L., Dijkstra, C.D. & de Vries, H.E. 2006, “Extensive extracellular matrix depositions in active 
multiple sclerosis lesions”, Neurobiology of Disease, vol. 24, no. 3, pp. 484-491.
van Noort, J.M. & Bsibsi, M. 2009, “Toll-like receptors in the CNS: implications for neurodegeneration and repair”, 
Progress in Brain Research, vol. 175, pp. 139-148.
Vana, A.C., Flint, N.C., Harwood, N.E., Le, T.Q., Fruttiger, M. & Armstrong, R.C. 2007, “Platelet-derived growth factor 
promotes repair of chronically demyelinated white matter”, Journal of Neuropathology and Experimental 
Neurology, vol. 66, no. 11, pp. 975-988.
Van’t Veer, A., Du, Y., Fischer, T.Z., Boetig, D.R., Wood, M.R. & Dreyfus, C.F. 2009, “Brain-derived neurotrophic factor 
effects on oligodendrocyte progenitors of the basal forebrain are mediated through trkB and the MAP 
kinase pathway”, Journal of Neuroscience Research, vol. 87, no. 1, pp. 69-78.
Viehover, A., Miller, R.H., Park, S.K., Fischbach, G. & Vartanian, T. 2001, “Neuregulin: an oligodendrocyte growth 
factor absent in active multiple sclerosis lesions”, Developmental Neuroscience, vol. 23, no. 4-5, pp. 377-386.
Vogel, D.Y., Vereyken, E.J., Glim, J.E., Heijnen, P.D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C.E., van Horssen, 
J. & Dijkstra, C.D. 2013, “Macrophages in inflammatory multiple sclerosis lesions have an intermediate 
activation status”, Journal of Neuroinflammation, vol. 10, pp. 35-2094-10-35.
Wake, H., Lee, P.R. & Fields, R.D. 2011, “Control of local protein synthesis and initial events in myelination by action 
potentials”, Science, vol. 333, no. 6049, pp. 1647-1651.
Wake, H., Moorhouse, A.J., Miyamoto, A. & Nabekura, J. 2013, “Microglia: actively surveying and shaping neuronal 
circuit structure and function”, Trends in Neurosciences, vol. 36, no. 4, pp. 209-217.
Wang, S., Sdrulla, A.D., diSibio, G., Bush, G., Nofziger, D., Hicks, C., Weinmaster, G. & Barres, B.A. 1998, “Notch 
receptor activation inhibits oligodendrocyte differentiation”, Neuron, vol. 21, no. 1, pp. 63-75.
Wang, S.S., Shultz, J.R., Burish, M.J., Harrison, K.H., Hof, P.R., Towns, L.C., Wagers, M.W. & Wyatt, K.D. 2008, “Functional 
trade-offs in white matter axonal scaling”, The Journal of Neuroscience, vol. 28, no. 15, pp. 4047-4056.
Wang, Z., Chen, J., Qin, Z. & Zhang, J. 1998, “The research of myelinization of normal fetal brain with magnetic 
resonance imaging”, Chinese Medical Journal, vol. 111, no. 1, pp. 71-74.
Watanabe, M., Hadzic, T. & Nishiyama, A. 2004, “Transient upregulation of Nkx2.2 expression in oligodendrocyte 
lineage cells during remyelination”, Glia, vol. 46, no. 3, pp. 311-322.
Wegner, M. 2008, “A matter of identity: transcriptional control in oligodendrocytes”, Journal of Molecular 
Neuroscience : MN, vol. 35, no. 1, pp. 3-12.
Weinshenker, B.G. 1994, “Natural history of multiple sclerosis”, Annals of Neurology, vol. 36 Suppl, pp. S6-11.
White, R., Gonsior, C., Kramer-Albers, E.M., Stohr, N., Huttelmaier, S. & Trotter, J. 2008, “Activation of oligodendroglial 
Fyn kinase enhances translation of mRNAs transported in hnRNP A2-dependent RNA granules”, The Journal 
of Cell Biology, vol. 181, no. 4, pp. 579-586.
Williams, A., Piaton, G., Aigrot, M.S., Belhadi, A., Theaudin, M., Petermann, F., Thomas, J.L., Zalc, B. & Lubetzki, C. 




Windrem, M.S., Schanz, S.J., Guo, M., Tian, G.F., Washco, V., Stanwood, N., Rasband, M., Roy, N.S., Nedergaard, M., 
Havton, L.A., Wang, S. & Goldman, S.A. 2008, “Neonatal chimerization with human glial progenitor cells can 
both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse”, Cell Stem Cell, vol. 2, 
no. 6, pp. 553-565.
Wolswijk, G. 2002, “Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord”, Brain, vol. 
125, no. Pt 2, pp. 338-349.
Wolswijk, G. 1998, “Chronic stage multiple sclerosis lesions contain a relatively quiescent population of 
oligodendrocyte precursor cells”, The Journal of Neuroscience, vol. 18, no. 2, pp. 601-609.
Wong, A.W., Xiao, J., Kemper, D., Kilpatrick, T.J. & Murray, S.S. 2013, “Oligodendroglial expression of TrkB 
independently regulates myelination and progenitor cell proliferation”, The Journal of Neuroscience, vol. 
33, no. 11, pp. 4947-4957.
Woodruff, R.H. & Franklin, R.J. 1999, “Demyelination and remyelination of the caudal cerebellar peduncle of 
adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-
galactocerebroside: a comparative study”, Glia, vol. 25, no. 3, pp. 216-228.
Xiao, L., Guo, D., Hu, C., Shen, W., Shan, L., Li, C., Liu, X., Yang, W., Zhang, W. & He, C. 2012, “Diosgenin promotes 
oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to 
accelerate remyelination”, Glia, vol. 60, no. 7, pp. 1037-1052.
Xin, M., Yue, T., Ma, Z., Wu, F.F., Gow, A. & Lu, Q.R. 2005, “Myelinogenesis and axonal recognition by oligodendrocytes 
in brain are uncoupled in Olig1-null mice”, The Journal of Neuroscience, vol. 25, no. 6, pp. 1354-1365.
Yang, N., Zuchero, J.B., Ahlenius, H., Marro, S., Ng, Y.H., Vierbuchen, T., Hawkins, J.S., Geissler, R., Barres, B.A. & 
Wernig, M. 2013, “Generation of oligodendroglial cells by direct lineage conversion”, Nature Biotechnology, 
vol. 31, no. 5, pp. 434-439.
Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L. & Karin, N. 1992, “Prevention of experimental 
autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin”, Nature, vol. 356, no. 6364, 
pp. 63-66.
Yoshida, T. & Nakagawa, M. 2012, “Clinical aspects and pathology of Alexander disease, and morphological and 
functional alteration of astrocytes induced by GFAP mutation”, Neuropathology, vol. 32, no. 4, pp. 440-446.
Young, K.M., Psachoulia, K., Tripathi, R.B., Dunn, S.J., Cossell, L., Attwell, D., Tohyama, K. & Richardson, W.D. 2013, 
“Oligodendrocyte Dynamics in the Healthy Adult CNS: Evidence for Myelin Remodeling”, Neuron, vol. 77, 
no. 5, pp. 873-885.
Yuen, T.J., Johnson, K.R., Miron, V.E., Zhao, C., Quandt, J., Harrisingh, M.C., Swire, M., Williams, A., McFarland, H.F., 
Franklin, R.J. & ffrench-Constant, C. 2013, “Identification of endothelin 2 as an inflammatory factor that 
promotes central nervous system remyelination”, Brain, vol. 136, no. Pt 4, pp. 1035-1047.
Zalc, B., Goujet, D. & Colman, D. 2008, “The origin of the myelination program in vertebrates”, Current Biology : CB, 
vol. 18, no. 12, pp. R511-2.
Zawadzka, M., Rivers, L.E., Fancy, S.P., Zhao, C., Tripathi, R., Jamen, F., Young, K., Goncharevich, A., Pohl, H., Rizzi, M., 
Rowitch, D.H., Kessaris, N., Suter, U., Richardson, W.D. & Franklin, R.J. 2010, “CNS-resident glial progenitor/
stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination”, Cell 
Stem Cell, vol. 6, no. 6, pp. 578-590.
Zeinstra, E., Wilczak, N., Streefland, C. & De Keyser, J. 2000, “Astrocytes in chronic active multiple sclerosis plaques 
express MHC class II molecules”, Neuroreport, vol. 11, no. 1, pp. 89-91.
Zhang, H., Vutskits, L., Calaora, V., Durbec, P. & Kiss, J.Z. 2004, “A role for the polysialic acid-neural cell adhesion 
55
Glial cells in health and multiple sclerosis
1
molecule in PDGF-induced chemotaxis of oligodendrocyte precursor cells”, Journal of Cell Science, vol. 117, 
no. Pt 1, pp. 93-103.
Zhao, C., Fancy, S.P., Franklin, R.J. & ffrench-Constant, C. 2009, “Up-regulation of oligodendrocyte precursor cell 
alphaV integrin and its extracellular ligands during central nervous system remyelination”, Journal of 
Neuroscience Research, vol. 87, no. 15, pp. 3447-3455.
Zhao, C., Li, W.W. & Franklin, R.J. 2006, “Differences in the early inflammatory responses to toxin-induced 
demyelination are associated with the age-related decline in CNS remyelination”, Neurobiology of Aging, 
vol. 27, no. 9, pp. 1298-1307.
Zhao, X., He, X., Han, X., Yu, Y., Ye, F., Chen, Y., Hoang, T., Xu, X., Mi, Q.S., Xin, M., Wang, F., Appel, B. & Lu, Q.R. 2010, 
“MicroRNA-mediated control of oligodendrocyte differentiation”, Neuron, vol. 65, no. 5, pp. 612-626.
Zhou, Q. & Anderson, D.J. 2002, “The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial 
subtype specification”, Cell, vol. 109, no. 1, pp. 61-73.
Zhu, X., Bergles, D.E. & Nishiyama, A. 2008, “NG2 cells generate both oligodendrocytes and gray matter astrocytes”, 
Development, vol. 135, no. 1, pp. 145-157.
Zhu, X., Hill, R.A. & Nishiyama, A. 2008, “NG2 cells generate oligodendrocytes and gray matter astrocytes in the 
spinal cord”, Neuron Glia Biology, vol. 4, no. 1, pp. 19-26.
56
57
Josephine M. J. Stoffels1
Jenny C. de Jonge1
Mirjana Stancic1
Anita Nomden1









1Department of Cell Biology, University Medical Centre Groningen, 
University of Groningen, The Netherlands
2Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, 
VU University Medical Centre, The Netherlands
3Wellcome Trust - Medical Research Council Stem Cell Institute and Department 
of Veterinary Medicine, University of Cambridge, UK
4) MRC Centre for Regenerative Medicine, 
Centre for Multiple Sclerosis Research, UK
Brain 2013; 136: 116-131
Fibronectin aggregation in multiple 





Remyelination following central nervous system demyelination is essential to prevent axon 
degeneration. However, remyelination ultimately fails in demyelinating diseases such as multiple 
sclerosis. This failure of remyelination is likely mediated by many factors, including changes in the 
extracellular signalling environment. Here, we examined the expression of the extracellular matrix 
molecule fibronectin on demyelinating injury and how this affects remyelination by oligodendrocytes 
progenitors. In toxin-induced lesions undergoing efficient remyelination, fibronectin expression 
was transiently increased within demyelinated areas and declined as remyelination proceeded. 
Fibronectin levels increased both by leakage from the blood circulation and by production from 
central nervous system resident cells. In chronically demyelinated multiple sclerosis lesions, 
fibronectin expression persisted in the form of aggregates, which may render fibronectin resistant 
to degradation. Aggregation of fibronectin was similarly observed at the relapse phase of chronic 
experimental autoimmune encephalitis, but not on toxin-induced demyelination, suggesting 
that fibronectin aggregation is mediated by inflammation-induced demyelination. Indeed, the 
inflammatory mediator lipopolysaccharide induced fibronectin aggregation by astrocytes. Most 
intriguingly, injection of astrocyte-derived fibronectin aggregates in toxin-induced demyelinated 
lesions inhibited oligodendrocyte differentiation and remyelination, and fibronectin aggregates 
are barely expressed in remyelinated multiple sclerosis lesions. Therefore, these findings suggest 
that fibronectin aggregates within multiple sclerosis lesions contribute to remyelination failure. 
Hence, the inhibitory signals induced by fibronectin aggregates or factors that affect fibronectin 
aggregation could be potential therapeutic targets for promoting remyelination.
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INTRODUCTION
Inflammation-mediated loss of myelin (demyelination) and incomplete remyelination are 
pathological hallmarks of multiple sclerosis. Remyelination is essential for both restoration of saltatory 
conduction and axonal protection (Franklin, ffrench-Constant 2008). Although remyelination occurs 
in early stages of multiple sclerosis, it declines as the disease progresses, resulting in chronically 
demyelinated plaques and axonal loss (Goldschmidt et al. 2009). Oligodendrocyte progenitors, the 
cells responsible for CNS remyelination (Zawadzka et al. 2010), are present in most multiple sclerosis 
lesions, but ultimately fail to differentiate into mature myelinating oligodendrocytes, which results 
in remyelination failure (Franklin, ffrench-Constant 2008, Kuhlmann et al. 2008). 
Migration and proliferation of oligodendrocyte progenitor cells and their differentiation into 
myelinating oligodendrocytes are regulated by many factors, including the extracellular matrix 
(Baron, Colognato & ffrench-Constant 2005). For example, laminin-2 provides oligodendrocytes with 
signals for both survival (Colognato et al. 2002, Baron et al. 2003) and myelination (Buttery, ffrench-
Constant 1999, Relvas et al. 2001, Siskova et al. 2006). In contrast, fibronectin promotes proliferation, 
but reduces myelin-like membrane formation (Baron, Colognato & ffrench-Constant 2005, Buttery, 
ffrench-Constant 1999, Siskova et al. 2006, Maier et al. 2005, Siskova et al. 2009). Following CNS 
injury, the extracellular matrix is extensively remodelled, which is reflected in altered expression 
profiles of extracellular matrix molecules (Sobel, Mitchell 1989, Gutowski, Newcombe & Cuzner 
1999, Back et al. 2005, van Horssen et al. 2005, van Horssen et al. 2006, Satoh, Tabunoki & Yamamura 
2009). Therefore, aberrant extracellular matrix signals in the injury environment may inhibit 
oligodendrocyte maturation, contributing to remyelination failure in multiple sclerosis lesions. 
Indeed, while absent from healthy adult human tissue, expression of fibronectin is upregulated in 
multiple sclerosis lesions, particularly around blood vessels (Sobel, Mitchell 1989, van Horssen et al. 
2005), and also in the CNS parenchyma (van Horssen et al. 2006). Furthermore, astrocyte-derived 
high molecular weight hyaluronan, which inhibits oligodendrocyte maturation, appears in chronic 
demyelinating multiple sclerosis lesions (Back et al. 2005). Laminin expression is also increased in 
multiple sclerosis lesions (van Horssen et al. 2005). Therefore, the overall effects of lesion-induced 
changes in the extracellular matrix on oligodendrocyte progenitor cells remain to be established. 
Here, we further characterized the nature of fibronectin signaling to oligodendrocyte progenitor 
cells in multiple sclerosis lesions, and how this fibronectin signalling might affect remyelination. We 
show that fibronectin specifically localizes in areas of demyelination, and identify cellular sources 
for its expression. In experimental demyelination, fibronectin is cleared on remyelination, whereas 
fibronectin aggregates and therefore persists in chronic multiple sclerosis lesions and chronic 
relapsing experimental autoimmune encephalomyelitis (EAE). Importantly, intralesion injection of 
fibronectin aggregates inhibits oligodendrocyte differentiation and remyelination in toxin-induced 
demyelinated lesions, which implies that aggregation of fibronectin contributes to remyelination 





Tissues were obtained from the Netherlands Brain Bank, Netherlands Institute for Neuroscience, 
Amsterdam. Studies were performed on brain material taken at autopsy from nine healthy subjects 
(without clinical or histological signs of neurological disease), eight subjects with (chronic) active 
multiple sclerosis lesions, nine with chronic inactive multiple sclerosis lesions and two with multiple 
sclerosis shadow plaques (Maier, Baron & Hoekstra 2007). Samples were selected according to 
their activity status as determined by MRI, split in half and either immediately frozen in liquid 
nitrogen or fixed in formaldehyde and paraffin embedded. Control white matter did not show any 
histological signs of inflammation and demyelination. Demyelinated lesions were identified by 
Luxol fast blue histochemistry and proteolipid protein staining. Active lesions were characterized 
by their indistinct margin, hypercellularity, intense perivascular T lymphocyte infiltration (CD3) and 
presence of hypertrophic astrocytes (glial fibrillary acidic protein, GFAP) and macrophages (CD68) 
in the centre of the lesions. Chronic active lesions were classified on the basis of a hypocellular 
lesion centre with fibrous astrocytes and some macrophages, sharp lesion border and a broad rim of 
macrophages. Chronic inactive lesions contained a hypocellular centre without macrophages and 
lymphocytes, and a sharp lesion border. Shadow plaques were characterized by a slightly reduced 
proteolipid protein expression compared with the surrounding normal-appearing white matter, 
without abundant expression of CD68. Notably, remyelinated areas, as determined by Luxol fast 
blue or proteolipid protein staining, were not visible in the other multiple sclerosis lesions analysed. 
For immunohistochemical analysis, sections were deparaffinized and subjected to antigen retrieval 
followed by fluorescent detection as described previously (Stancic et al. 2011). Control sections from 
which the primary antibody was omitted showed low non-specific binding. Sections were analysed 
using a conventional fluorescence microscope (Olympus AX70) equipped with analySIS software. 
For western blot and reverse transcription–PCR analysis, samples were homogenized and extracted 
for protein and total RNA as described (Maier, Baron & Hoekstra 2007). All material was collected 
from donors whose written informed consent for brain autopsy and the use of the material and 
clinical information for research purposes has been obtained by the Netherlands Brain Bank.
Toxin-induced demyelination
Lesions were induced in spinal cord white matter or in the caudal cerebral peduncle of 8–10-week-old 
female Sprague Dawley rats (Harlan) by injection of 1 ml of 1% lysolecthin (Sigma Aldrich) or 4 ml of 
0.01% ethidium bromide (VWR), respectively (Fancy, Zhao & Franklin 2004, Zhao, Li & Franklin 2006). 
At the desired time points, animals were sacrificed and tissue processed as described previously 
(Fancy, Zhao & Franklin 2004, Zhao, Li & Franklin 2006, Woodruff, Franklin 1999). The control spinal 
cord tissues consisted of similar fragments from unlesioned thoracic segments of spinal cord. The 
intralesion injection of fibronectin aggregates was performed at 7 days post lesion into lysolecithin-
induced lesions in rat dorsal funiculus of spinal cord. A volume of 2 ml of fibronectin aggregates (0.3 
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mg/ml) was injected using a Hamilton syringe with a pulled glass tip attached. These animals were 
sacrificed 7 days after aggregate injection, i.e. 14 days post lesion. Experiments were performed in 
compliance with UK Home Office regulations.
Chronic relapsing experimental autoimmune encephalomyelitis
Chronic relapsing EAE was induced with recombinant rat myelin oligodendrocyte glycoprotein 
in adult male Dark Agouti rats (Harlan, weight 230–250 g) as described previously (Ledeboer et 
al. 2003). Briefly, the rats were anaesthetized with isoflurane and immunized intradermally in the 
dorsal tail base with 75 mg of recombinant rat myelin oligodendrocyte glycoprotein (rrMOG1–125) 
emulsified in incomplete Freund’s adjuvant (Difco) together with 10mM NaAc (pH 3.0). Control rats 
received incomplete Freund’s adjuvant and NaAc only. Rats were weighed and examined daily for 
neurological symptoms of EAE that were scored on the following scale: 0, no clinical disease; 0.5, 
partial loss of tail tone; 1, complete tail atony; 2, paresis, partial hind limb paralysis; 3, complete 
paralysis of the hind limbs and/or lower part of the body; 4, moribund or dead due to EAE. Chronic 
relapsing EAE and incomplete Freund’s adjuvant control animals were sacrificed when chronic 
relapsing EAE rats reached the peak clinical symptoms during the relapse (~25 days post injection) 
and spinal cords were processed as previously described (Maier et al. 2005, Ledeboer et al. 2003). All 
experimental procedures were approved of by the Animal Ethical Committee of the VU University. 
Cell cultures
Primary glial cells: Primary glial cultures were generated from 1 to 3-day-old Wistar rats (Harlan) as 
described previously (Bsibsi et al. 2012). Isolated microglia and astrocytes were cultured in Dulbecco’s 
modified Eagle medium/10% foetal calf serum in 10 cm dishes (1.0 x 10^6/dish) or 8-well Permanox 
chamber slides (15.000 cells/well; Nunc). Cells were left untreated or activated with 200 ng/ml 
ultrapure lipopolysaccharide (InvivoGen) for 48 h. Deposited astroglial matrices were prepared by 
water-lysis of astrocytes for 2 h at 37ºC. Isolated oligodendrocyte progenitor cells were cultured 
in Sato medium (Maier et al. 2005) in poly-L-lysine-coated 10 cm dishes (1.0 x 10^6/dish) or 8-well 
chamber slides (15.000 cells/well) with wells coated with astroglial matrices (see later in the text). 
The oligodendrocyte progenitor cells were first synchronized in Sato medium supplemented with 
platelet-derived growth factor AA (Peprotech; 10 ng/ml) and fibroblast growth factor-2 (Peprotech, 
10 ng/ml) for 2 days. Differentiation was induced by growth factor withdrawal and cells were grown 
for 7 days in Sato medium containing 0.5% foetal calf serum.
Human astrocytes: Adult human astrocytes were isolated from post-mortem subcortical white matter 
of well-documented healthy subjects and patients with multiple sclerosis, as described previously 
(Bsibsi et al. 2012). Purity of the cultures was routinely verified by staining for GFAP (astrocytes). 
Astrocyte cultures used were at least 97% pure. The cells were plated in 10 cm dishes (1.0 x 10^6/
dish) or 8-well chamber slides (10.000/well). Deposited astroglial matrices were prepared by water-




Toxin-induced lesions: Frozen sections (12 mm) of spinal cord and caudal cerebral peduncle were 
permeabilized and blocked with phosphate-buffered saline (PBS) containing 5% normal donkey 
serum and 0.3% TritonTM X-100. Sections were incubated with the appropriate primary antibodies 
(Table 1) diluted in PBS containing 3% normal donkey serum overnight at 4ºC. For double labelling 
immunohistochemistry, primary antibodies were incubated sequentially. After washing in PBS, 
the sections were incubated with appropriate Alexa Fluor© (488 or 594)-conjugated secondary 
antibodies (Invitrogen 1:500) at room temperature for 2 h, followed by 4’,6-diamidino-2-phenylindole 
(DAPI) to visualize cell nuclei. Following immunostaining, some slides were incubated in 0.1% 
Sudan Black solution (made in 70% ethanol) for 5 min at room temperature to stain myelin. Pale 
areas in the white matter indicate loss of myelin. Sudan Black staining has no detrimental effect on 
immunofluorescence. Sections were analysed with a Zeiss Axio Observer A1 fluorescent microscope. 
Chronic relapsing experimental autoimmune encephalomyelitis: Fresh frozen rat spinal cord 
sections (12 mm) were fixed with acetone for 20 min, washed in Tris-buffered saline, blocked in 5% 
milk in Tris-buffered saline with 0.5% TritonTM X-100 and 0.03% H2O2 and incubated with primary 
antibodies (Table 1) overnight at 4ºC, followed by appropriate Alexa Fluor© (488 or 594)-conjugated 
secondary antibodies (1:400) for immunofluorescence. Sections were examined with a Leica 
confocal laser scanning microscope. For peroxidase-based analysis, sections were washed in 
Table 1: Primary antibodies used during IHC, ICC and WB
manufacturer dilution WB dilution IHC/ICC
anti-actin (mAb) Sigma 1:1000 n.a.
anti-APC (CC1, mAb) Calbiochem n.a. 1:200
anti-CD3 (mAb) Zymed n.a. 1:100
anti-CD11b (MAC1, mAb) Serotec n.a. 1:100
anti-CD68 (mAb) DAKO n.a. 1:100
anti-CNP (mAb) Sigma 1:500 n.a.
anti-EIIIA-fibronectin (IST9) Abcam n.a. 1:200
anti-fibronectin (pAb) Millipore 1:1000 1:50-1:100
anti-GFAP (mAb) Millipore 1:1000 1:500
anti-GFAP (pAb) DAKO n.a. 1:500
anti-laminin 1+2 (pAb) Abcam 1:500 n.a.
anti-MBP (mAb) Chemicon 1:100 1:25
anti-Nkx2.2 (mAb) Hybridoma Bank Iowa n.a. 1:100
anti-Olig2 (pAb) Millipore n.a. 1:1000
anti-OX6 (mAb) Serotec n.a. 1:1000
anti-PLP (mAb) Serotec n.a. 1:3000
TuJ1 (mAb) kind gift of A. Frankfurter1 1:2000 n.a.
anti-vWF (mAb) Serotec n.a. 1:50
anti-vWF (pAb) DAKO n.a. 1:200
n.a., not applicable; mAb, monoclonal antibody; pAb, polyclonal antibody; 1) (Lee et al. 1990)
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Tris-buffered saline and incubated for 2 h at room temperature with secondary biotinylated IgGs 
(Jackson ImmunoResearch, 1:400), followed by washes in Tris-buffered saline and incubation for 1 
h at room temperature with avidin–biotin–peroxidase complex (Vector Laboratories, 1:400). After 
washes in Tris-buffered saline and 50mM Tris–HCl (pH 7.6), immunoreactivity was visualized using 
0.5 mg/ml of diaminobenzidene (Sigma) in 50mM Tris–HCl (pH 7.6). 
Immunocytochemical analysis 
Oligodendrocytes were fixed with 4% paraformaldehyde for 20 min and permeabilized with ice-
cold methanol for 10 min. After a 30-min block with 4% bovine serum albumin, cells were incubated 
for 60 min with primary antibodies (Table 1) in 4% bovine serum albumin. Cells were washed three 
times with ice-cold PBS and incubated for 25 min with appropriate tetramethyl rhodamine iso-
thiocyanateconjugated antibodies (Jackson ImmunoResearch). Nuclei were stained with DAPI (1 
mg/ml) and 1,4-diazabicyclo[2.2.2]octane-containing mounting medium was added to prevent 
image fading. For staining of astroglial matrices, fixation and permeabilization steps were omitted. 
Oligodendrocytes were characterized by their morphology, and in each experiment at least 500 cells 
were scored as myelin basic protein (MBP)-positive or -negative. In addition, positive cells bearing 
MBP-positive membranous structures spread between the cellular processes were identified as 
membrane sheet forming, irrespective of the extent of sheet formation. 
Reverse transcription–polymerase chain reaction 
Total RNA was isolated from cells and tissue homogenates using the RNeasy_ Mini kit (Qiagen). Total 
RNA from tissue (0.5 mg) or cells (1.0 mg) was reverse transcribed in the presence of oligo(dT)12–18 
and dNTPs (Invitrogen) with SuperScript_ II reverse transcriptase (Invitrogen) according to the 
manufacturer’s instructions. The resulting complementary DNA was amplified using primers 
specific to the different proteins (Table 2). Cycling conditions were optimized and PCR products 
were resolved by agarose gel electrophoresis. Changes in gene expression were analysed by Scion 
Image Software. 
Table 2.  Primer sequences used during RT-PCR
sense anti-sense length (bp)
Actin Hs/Rn ACCACACAGCTGAGAGGGAAATC GGTCTTTACGGATGTCAACG 276
CD68 Hs TATTGCTTTCTGCATCATCC TTTAGTAGAGACAGGGTTTCAC 303
Cyclophilin Rn CTCGTGACCCCTCTTTCC CAT TATTTTCCTCATTTCCCCT 522
Fn1 Hs GAGGAGAGTGGAAGTGTGAG TTGTGGTTGTTGTATAGGAAGG 496
Fn1 Rn AGCCC TTACAGTTCCAAGTTCC CCATT CAATTCATTGCATCG 1077
GFAP Hs CTCCAACTAACAAGAAACTCAC GGCTCCAATCTATAATCCCA 412




To generate a complementary RNA probe for fibronectin, complementary DNA acquired using 
fibronectin primers (Table 2) was cloned by reverse transcription–PCR and inserted into the pCRII-
TOPO plasmid, using the TOPO© TA Cloning© Kit (Invitrogen) according to the manufacturer’s 
instruction. The probe is expected to recognize all variants of fibronectin messenger RNA. The 
digoxigenin-labelled proteolipid protein probe was generated as described (Chari et al. 2006). The 
details for probe labelling and staining procedures have been described in previous studies (Sim et 
al. 2002, Zhao et al. 2008).
Deoxycholate (in)solubility assays and preparation of fibronectin aggregates
Tissue homogenates (multiple sclerosis and chronic relapsing EAE) were incubated with deoxycholate 
buffer [2% deoxycholate and Complete Mini protease inhibitor cocktail (Roche) in 20mM Tris–HCl, 
pH 8.3], for 30 min on ice. Proteins from lysolecithin-induced lesions were extracted from 30-mm 
thick slices through oscillation for at least 3 h in deoxycholate buffer. Deposited astroglial matrices 
were prepared by water-lysis of astrocytes for 2 h at 37ºC. The efficiency of lysis was verified by 
DAPI staining, and only matrices without visible nuclei were used. Deposits were scraped in ice-
cold deoxycholate buffer and further solubilized for 30 min on ice. Protein concentrations were 
determined by a Bio-Rad DC protein assay (Bio-Rad Laboratories) using bovine serum albumin as 
standard. For biochemical analysis, deoxycholate-soluble and -insoluble fractions from equal protein 
amounts of the deoxycholate extracts were separated by centrifugation at 13.000 rpm for 20 min at 
4ºC. The deoxycholate-insoluble pellets were dissolved in 2% SDS in 20mM Tris–HCl, pH 8.8, whereas 
the deoxycholate-soluble supernatant was concentrated by trichloroacetic acid precipitation. For 
intralesion injections, the aggregates present in the deoxycholate-insoluble fraction were dialyzed 
against PBS for 24 h at 4ºC. After dialysis, the protein content was determined and the presence of 
aggregates confirmed by western blot.
Lactate dehydrogenase and MTT assay
Oligodendrocyte progenitor cells were plated in 24-well plates (Nunc) at a density of 50.000 cells 
in 500 ml culture medium. Oligodendrocytes were treated with fibronectin aggregates (5.0 mg/
ml of the deoxycholate-insoluble fraction of rat astrocyte-derived deposits dialyzed against PBS) at 
the onset of differentiation (oligodendrocyte progenitor cells), 3 days (immature oligodendrocytes) 
or 7 days (mature oligodendrocytes) after initiating differentiation. After 3 days, the medium 
(lactate dehydrogenase assay) and cells [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; MTT] were analysed. To determine the cytotoxicity of deoxycholateinsoluble fibronectin 
aggregates, the release of lactate dehydrogenase into the medium was measured using a 
commercial lactate dehydrogenase assay kit (Roche) according to manufacturer’s instructions. The 
effect on cell viability was determined with an MTT assay. Briefly, after medium was removed for the 
lactate dehydrogenase assay, cells were incubated with MTT diluted in culture medium (0.5 mg/ml, 
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Sigma) for 3–4 h. MTT-formazan crystals were collected in dimethyl sulphoxide and absorption was 
measured at 560 nm. Cytotoxicity (lactate dehydrogenase) and cell viability (MTT) are expressed as 
the percentage of vehicle-treated (PBS) cells, which was set at 100%.
Electron microscopy analysis
The animals were perfused with 4% glutaraldehyde and lesion containing spinal cord was coronally 
sliced at ~1mm thickness and fixed with osmium tetroxide overnight before being subjected to a 
standard protocol of epoxy resin embedding (Zhao et al. 2008). Ultrathin sections of the lesion site 
were produced at transverse orientation and examined with a Hitachi H-600 electron microscope. 
Myelination of axons in the lesion was analysed for g-ratio, which is calculated as the diameter of 
axons divided by the diameter of axons with surrounding myelin sheaths.
Sodium dodecyl sulphate–polyacrylamide gel electrophoresis and western blotting
Equal amounts of proteins (tissue homogenates, cultured cells and reducing conditions) or volume 
[deoxycholate-(in)solubility assays, non-reducing conditions] were loaded onto 6 or 8% SDS-PAGE 
gels and subjected to western blot analysis as described previously (Bsibsi et al. 2012). The signals 
were detected using the Odyssey© Infrared Imaging System (Li-Cor Biosciences) and analysed using 
Odyssey V3.0 analysis software.
RESULTS
Cellular fibronectin expression is transiently increased in toxin-induced demyelination
Fibronectin effects on regeneration have been studied in various tissues (Scanzello, Plaas & Crow 
2008). To assess whether on demyelination, changes in the extracellular matrix environment 
include fibronectin, we first examined the profile of fibronectin expression following toxin-induced 
demyelination. Injection of lysolecithin into spinal cord white matter creates focally demyelinated 
lesions without significant axonal loss (Blakemore, Franklin 2008). These lesions undergo spontaneous 
remyelination, involving the activation of oligodendrocyte progenitor cells and their recruitment 
into the demyelinated area (0–10 days post lesion), and their subsequent differentiation and myelin 
sheath formation (10–21 days post lesion) (Zhao, Li & Franklin 2006). In this model, the lesion area is 
characterized by an increased cellularity, which reflects well the area of demyelination as visualized 
with a Sudan Black myelin stain (Fig. 1A). Therefore, the demyelinated areas were identified based 
on their hypercellularity using DAPI staining for nuclei. Immunohistochemical analysis showed that 
fibronectin expression was highly detectable in demyelinated areas at 3 and 5 days post lesion, 
but progressively reduced at 10 and 15 days post lesion (Fig. 1B). Western blot analysis confirmed 
a clear and significant increase in fibronectin protein expression at 5 days post lesion, followed by 
a significant decrease at 14 days post lesion (Fig. 1C). Demyelination and ongoing remyelination 
of the lesions were confirmed by reduced expression levels of MBP at 5 days post lesion compared 
with unlesioned control, and increased MBP expression at 14 days post lesion as compared with 5 
66
Chapter 2
days post lesion, respectively (Fig. 1C). Transient expression of fibronectin was also observed using 
a second model of toxin-induced demyelination, in which ethidium bromide is injected into the 
caudal cerebral peduncle of rats (Supplementary Fig. 1; (Woodruff, Franklin 1999)). 
Fibronectin has two major variants: (i) plasma fibronectin, a soluble dimer that is secreted into 
the circulation by hepatocytes; and (ii) cellular fibronectin, which is produced by resident cells. On 
CNS injury, and likely also on toxin-induced demyelination, plasma fibronectin enters the brain 
owing to blood–brain barrier disruption (Sobel, Mitchell 1989, van Horssen et al. 2005). To examine 
whether cells also express cellular fibronectin following CNS demyelination, we analysed fibronectin 
messenger RNA expression in lysolecithin-induced demyelination via reverse transcriptase–PCR. As 
shown in Fig. 1D, total fibronectin messenger RNA levels increased significantly at demyelination (5 
days post lesion) compared with unlesioned spinal cord, and decreased again in early remyelination 
(14 days post lesion). To assess cellular fibronectin protein expression, we performed double 
immunohistochemistry with anti-fibronectin and anti-EIIIA (IST9) specific antibodies. EIIIA-
fibronectin, i.e. cellular fibronectin, was expressed in acute lysolecithin-induced demyelination, 
where it was confined to the lesioned area and mostly located around blood vessels (Fig. 1E). 
Notably, fibronectin expression was more widespread throughout the demyelinated area than 
EIIIAfibronectin. Importantly, EIIIA-fibronectin protein expression was increased as early as 1 day 
post lesion and downregulated at 14 days post lesion (Supplementary Fig. 2), concomitant to the 
decrease of total fibronectin expression (Fig. 1B and C). Hence, these findings reveal that fibronectin 
expression was transiently upregulated on toxin-induced demyelination, and the detection of 
fibronectin messenger RNA and EIIIA-fibronectin indicate that CNS resident cells synthesize 
fibronectin in response to demyelination, which prompted us to identify these cells.
Multiple cell types express cellular fibronectin in toxin-induced demyelination
The cellular distribution of fibronectin messenger RNA in toxin-induced demyelination sections 
was examined by in situ hybridization. Fibronectin messenger RNA expression was confined to the 
demyelinated area (Fig. 2A), consistent with fibronectin protein expression (Fig. 1A). Macrophages/
microglia were identified as a possible source by two-colour double labelling in situ hybridization 
for fibronectin and osteopontin messenger RNA, a marker for cells of the macrophage/microglia 
lineage particularly in toxin-induced lesions (Zhao et al. 2008). There was clear colocalization at 1 
day post lesion (Fig. 2B; 68.2 ± 11.2%) that was decreased at 5 days post lesion (Fig. 2C; 23 ± 5.8%), 
which might reflect the transition from monocytes/microglia to phagocytotic macrophages (Zhao 
et al., 2006). This is supported by double labelling with anti-fibronectin and anti-CD11b (MAC1) 
antibodies, showing fibronectin expression in a substantial number of MAC1-positive microglia/
macrophages (Fig. 2D, 5 days post lesion). Fibronectin messenger RNA (Fig. 2E) and protein (Fig. 2F) 
was further detected in GFAP-positive astrocytes, indicating that astrocytes are another source of 
cellular fibronectin. Co-labelling with anti-Olig2 antibodies (Fig. 2G; 2.9 ± 1.0% fibronectin messenger 
RNA/Olig2 double positive), as a marker for the oligodendrocytes lineage and antibodies against 
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Figure 1. Expression of cellular fibronectin in lysolecithin-induced demyelination. Lesioned and 
non-lesioned tissues were analyzed for the expression of Fn protein and mRNA using fluorescent 
immunohistochemistry (B, E), Western blot (C) and RT-PCR (D) analysis. Focal demyelination of the rat spinal cord 
was induced by lysolecithin injection. In A-E, representative images, blots and gels are shown of 3-4 animals 
per condition. A. Demyelinated areas, as visualized with a Sudan black myelin stain, were identified based on 
their hypercellularity (DAPI staining). Images were taken at 5 days post lesion (DPL). Scale bars are 1000 µm 
(black) and 100 µm (white), respectively. B. Fn expression (red) is abundant at demyelination (3 and 5 DPL, and 
cleared upon remyelination (10 and 15 DPL). The baseline expression of Fn was very low upon immunostaining 
of unlesioned control spinal cord and normal appearing tissue around lesions. Scale bar is 20 µm. C, D. Fn protein 
(C) and mRNA (D) is upregulated in demyelination (5 DPL vs CTRL), but downregulated upon remyelination (14 
DPL vs 5 DPL). Data were quantified by normalizing the optical densities of Fn protein against actin (C), and Fn 
mRNA against the housekeeping gene cyclophilin (D). Data are expressed as value of the mean + the standard 
deviation (* p<0.05, *** p<0.0001 at one-way ANOVA followed by Tukey’s HSD test, 3-4 animals per condition). 
Demyelination of the lesions was confirmed by lower expression levels of the myelin protein MBP. E. Fn (red) and 
EIIIA-Fn (IST9, green) expression in lysolecithin-induced demyelination (5 DPL). Scale bar is 20 µm. EIIIA-Fn and 
Fn particularly co-localize (yellow) around blood vessels.
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Nkx2.2 (Fig. 2H), as a marker for oligodendrocyte progenitor cells, demonstrated little colocalization 
with fi bronectin messenger RNA and protein, respectively. Finally, some fi bronectin messenger 
RNA–expressing cells occurred in association with blood vessels and had the morphology and 
arrangement of endothelial cells (Fig. 2I, inset). Double labelling with antibodies against fi bronectin 
and von Willebrand factor, a marker for endothelial cells, showed that some fi bronectin co-localized 
with oval-shaped von Willebrand factor-positive cells (Fig. 2I, inset). This indicated that endothelial 
cells may also produce cellular fi bronectin, as suggested before by the localization of EIIIA-
fi bronectin (Fig. 1), and co-localization of IST9 with von Willebrand factor (data not shown). Hence, 
macrophages/ microglia, astrocytes and endothelial cells, but not cells of the oligodendrocytes 
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Figure 2. Expression of fi bronectin by a variety of cell types in toxin-induced demyelination. Fn mRNA 
in lesioned areas is expressed in microglia/macrophages (B), astrocytes (E) and endothelial cells (inset I), but 
not oligodendrocytes (G). Sections from non-lesioned (inset A), CCP-lesions (A, E, F) and spinal cord lesions 
(lysolecithin, B-D, G-I) at 1 DPL (B), 2 DPL (A), and 5 DPL (C-I) were single (A, inset A and I) or double (B-I) labeled 
for either Fn protein (green, D, F, I and red, H), or Fn mRNA (A-C, E, G, inset I, blue) together with OPN mRNA (B, C, 
magenta) and MAC1 (D, red) as markers for microglia/macrophages, GFAP (D, E, red), as a marker for astrocytes, 
Olig-2 (G, red) as a marker for the oligodendrocyte lineage, Nkx2.2 (H, green) as a marker for OPCs, and Von 
Willebrand factor (vWF, I, red), as a marker for endothelial cells. Protein and mRNA were visualized by indirect 
fl uorescent immunohistochemistry and in situ hybridization, respectively. Lesioned areas were identifi ed by 
hypercellularity, i.e., DAPI (blue) staining. Representative images of 3-4 animals per condition are shown. DPL is 
days post lesion. Scale bar is 50 µm for A, E and H, and 20 µm for B-D, F, G and I.
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Fibronectin assembles into aggregates in demyelinated multiple sclerosis lesions 
Previous studies suggest the expression of fibronectin in chronically demyelinated multiple sclerosis 
lesions (Sobel, Mitchell 1989, van Horssen et al. 2005, Satoh, Tabunoki & Yamamura 2009). However, 
these studies do not provide information on fibronectin levels, its origin or its form. We therefore 
biochemically characterized fibronectin expression in white matter brain homogenates of healthy 
subjects (control white matter, n = 9), (chronic) active multiple sclerosis lesions (n = 8) and chronic 
inactive multiple sclerosis lesions (n = 9). In chronic inactive lesions, fibronectin was expressed 
around blood vessels (Fig. 3D), whereas an increased number of smaller fibronectin deposits were 
present throughout (chronic) active multiple sclerosis lesions (Fig. 3B and C). However, in control 
white matter, obtained from subjects without clinical or pathological signs of neurological disease, 
fibronectin was scarcely detectable and limited to the vasculature (Fig. 3A). Western blot analysis 
under reducing conditions confirmed the increased fibronectin expression in multiple sclerosis 
lesions as compared with control white matter (Fig. 3E).  Although control white matter showed 
a variation in fibronectin levels among individual subjects, the amount of fibronectin in white 
matter homogenates of active and inactive multiple sclerosis lesions was generally higher (Fig. 3F). 
Therefore, our data provide quantitative evidence of fibronectin accumulation in multiple sclerosis 
lesions. Analysis of fibronectin messenger RNA expression via reverse transcriptase–PCR revealed 
low levels (Supplementary Fig. 3) that do not seem to be in line with the increased fibronectin protein 
levels in multiple sclerosis lesions (Fig. 3B), but could well be explained by the chronic status of these 
lesions. Accordingly, fibronectin messenger RNA might have been initially upregulated at the onset 
of demyelination, but downregulated over time, whereas the protein has not been degraded and 
subjected to post-transcriptional and post-translational modification, which we examined next.
Fibronectin normally appears as a disulphide-bound dimer with subunits of 220–250 kDa, 
but can assemble into a complex network of fibrils of high molecular weight aggregates, which 
are insoluble in the detergent deoxycholate (Wierzbicka-Patynowski, Schwarzbauer 2003, Mao, 
Schwarzbauer 2005). Under non-reducing SDS-PAGE conditions, fibronectin aggregates remain 
either in the stacking gel or just penetrate the resolving gel in lower percentage SDS cells. To 
examine whether fibronectin aggregates in multiple sclerosis lesions, we performed detergent 
deoxycholate (in)solubility assays. High molecular weight fibronectin complexes were observed 
in the deoxycholate-insoluble fraction from homogenates of multiple sclerosis lesions, whereas 
fibronectin dimers were the main form in control white matter (Fig. 3G). This suggests that 
fibronectin aggregates are predominantly present in both active and inactive multiple sclerosis 
lesions, and hardly in control white matter. Given our previous findings that fibronectin perturbs 
myelin-like membrane formation (Buttery, ffrench-Constant 1999, Siskova et al. 2006, Maier et al. 
2005, Siskova et al. 2009) and given that clearance of fibronectin in toxin-induced demyelination 
preceded remyelination (Fig. 1), the detection of fibronectin aggregates in chronically demyelinated 
multiple sclerosis lesions led us to hypothesize that they may contribute to remyelination failure. 
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Figure 3. Fibronectin protein expression and biochemical characterization in human CWM, MS 
lesions, cr-EAE and toxin-induced lesions. A-D. Fn expression (green) is abundant within the parenchyma 
of demyelinated MS lesion areas in aMS (B, arrows) and caMS (arrow), and nearly absent from control white 
matter (CWM). In ciMS, Fn is abundantly expressed in association with blood vessels (D). Nuclei were 
counterstained with DAPI (blue). Representative images of CWM (A, ) and centers of active (aMS, B), chronic 
active (caMS, C) and chronic inactive (ciMS, D) MS lesions are shown. Scale bar is 20 µm. E. Expression levels 
of Fn and the other indicated proteins in 50 µg of brain white matter homogenates of human CWM (4), (c)
aMS (5) and ciMS (5) lesions as determined by Western blot under reducing conditions (monomers). 
Demyelination of the lesions was confirmed by lower expression levels of the myelin protein MBP compared 
to CWM. Decreased CNP-levels, mostly in active MS lesions, and decreased TuJ1-levels, particularly in 
inactive lesions, were likely indicative of OLG and axonal loss, respectively. The constant levels of actin in the 
samples served as internal controls. F. Variation of Fn expression in individual human white matter tissue. 
G. Fn aggregates (Fn AGG) are abundantly present in (c)aMS and ciMS lesions homogenates as compared 
to CWM homogenates. 100 µg of homogenates were subjected to DOC-(in)solubility assays, and DOC-
insoluble (I) and -soluble (S) fractions were analyzed by Western blotting under non-reducing conditions. 
H. Fn aggregates are virtually absent from lysolecithin-induced demyelinated lesions. DOC-insoluble (I) and 
-soluble (S) fractions from 50 µg tissue were analyzed by Western blotting under non-reducing conditions. 3 
animals per condition were analyzed. (Legends continue on the next page.)
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Deoxycholate (in)solubility assays followed by SDS-PAGE under non-reducing conditions revealed 
that fibronectin aggregation was minimal in toxin-lesioned tissues (Fig. 3H). Hence, fibronectin 
expression was transiently upregulated on toxin-induced demyelination, but does not extensively 
aggregate. A major difference between multiple sclerosis and toxin-induced lesions is the 
mechanism of demyelination. In multiple sclerosis, demyelination results mainly from activity of the 
adaptive immune system, whereas in toxin-induced models, demyelination is caused by the toxin 
and this initiates a secondary inflammatory response, mainly involving the innate immune system. 
To assess whether fibronectin aggregation is mediated by chronic inflammation, we next examined 
fibronectin expression and aggregation in chronic relapsing EAE, an animal model of immune-
mediated demyelination that resembles many clinical and pathological features of relapsing-
remitting multiple sclerosis (Furlan, Cuomo & Martino 2009, Pachner 2011). On immunization with 
a myelin oligodendrocyte glycoprotein peptide, the animals suffer from neurological symptoms, 
usually restricted to the hind body, that develop in a relapsing-remitting pattern (Supplementary 
Fig. 4A). During the relapse phase, Major Histocompatibility Complex class II inflammatory infiltrates 
can be observed in the rat spinal cord (Supplementary Fig. 4B), whereas demyelinated areas can 
be observed in the lumbar and sacral region of the spinal cord (Ledeboer et al. 2003, Storch et al. 
1998). Total fibronectin expression was increased at the relapse phase in chronic relapsing EAE by 
~9-fold (Fig. 3I) compared with incomplete Freund’s adjuvant control. Furthermore, deoxycholate-
(in)solubility assays showed that fibronectin aggregated in chronic relapsing EAE (Fig. 3J), 
similar to multiple sclerosis  lesions (Fig. 3B). EIIIA-fibronectin expression was also evident at the 
relapse in chronic relapsing EAE (Fig. 3K), suggesting that cellular fibronectin was increased as 
an immediate response on inflammation-mediated demyelination. Hence, whereas fibronectin 
was transiently expressed and remained predominantly soluble in toxin-induced demyelination 
undergoing remyelination, fibronectin aggregates were formed in lesions of inflammation-induced 
demyelination, where remyelination often fails. Therefore, we next examined whether   inflammatory 
mediators induce fibronectin aggregation in vitro.
Fig. 3 continued. Fibronectin protein expression and biochemical characterization in human CWM, MS lesions, 
cr-EAE and toxin-induced lesions. (...) I. Fn expression is upregulated in cr-EAE animals as compared to IFA 
controls. Spinal cord homogenates (20 µg) of control and cr-EAE (relapse phase) were analyzed by Western 
blotting under reducing conditions (monomers). Data were quantified by normalizing the optical densities of 
Fn protein against actin, and expressed as mean + the standard deviation (** p < 0,01 at Student’s t-test, 3 
animals per group). J. Fn aggregates at the relapse phase in cr-EAE. DOC-insoluble (I) and -soluble (S) fractions 
from 100 µg tissue were analyzed by Western blotting under non-reducing  conditions. K. Fn (red) and EIIIA-Fn 
(IST9, green) expression at the relapse phase of cr-EAE. Scale bar is 20 µm. EIIIA-Fn and Fn particularly co-localize 
(yellow) around blood vessels.
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Fibronectin aggregation by cultured astrocytes is induced by the inflammatory mediator 
lipopolysaccharide
Having identified multiple cellular sources in vivo, we first examined which of these cells express 
fibronectin messenger RNA and protein in (primary) monoculture in vitro. Only cultured astrocytes 
produced fibronectin messenger RNA and fibronectin protein in considerable amounts (Fig. 4A), 
which corroborate previous findings that astrocytes produce fibronectin (Price, Hynes 1985, Liesi, 
Kirkwood & Vaheri 1986, Oh, Yong 1996). However, fibronectin expression by the other cell types 
may occur in other, particular activation states. Water-lysis of the cultured astrocytes showed 
that untreated astrocytes deposited fibronectin in an evenly distributed diffuse pattern, whereas 
astrocytes exposed to the inflammatory mediator lipopolysaccharide deposited a more localized 
fibrillar fibronectin matrix (Fig. 4B, rat). Similar results were obtained when astrocytes were removed 
by EDTA-mediated detachment (data not shown). Notably, an increase in fibronectin messenger 
RNA and a slight increase in protein expression were observed in astrocytes treated with the 
inflammatory mediator lipopolysaccharide (Fig. 4A). Fibronectin aggregation also markedly 
increased after treatment with lipopolysaccharide in ratastrocyte-derived matrices, as detected 
by deoxycholate-(in)solubility assays (Fig. 4C). Likewise, cultured human astrocytes isolated from 
patients with multiple sclerosis displayed the ability to deposit and to arrange fibronectin in fibrillar 
networks, whereas human astrocytes from healthy subjects deposited fibronectin in smaller more 
diffuse structures (Fig. 4B, human). In addition, astrocytes from multiple sclerosis tissue synthesized 
slightly more fibronectin and similar levels of laminin, which is a myelination permissive extracellular 
matrix molecule (Buttery, ffrench-Constant 1999, Siskova et al. 2006, Colognato, ffrench-Constant & 
Feltri 2005) compared with astrocytes from healthy subjects (Fig. 4D). Furthermore, multiple sclerosis 
astroglial matrices, but not those from healthy astrocytes, showed a clear band at the position of 
aggregated fibronectin in the deoxycholate-insoluble fraction (Fig. 4E), whereas deposited laminin 
appeared in the deoxycholate-soluble fraction (Fig. 4E). Also, preliminary proteomic analysis 
demonstrated that the deoxycholate-insoluble fraction mainly consists of fibronectin, i.e. ~10% 
of total protein, and does not contain other extracellular matrix proteins, such as hyaluronan and 
proteoglycans. These findings demonstrate that, although cultured astrocytes synthesize and 
deposit fibronectin, they do not induce aggregation unless additional factors, such as those linked 
to chronic inflammation, are present. This could explain why fibronectin aggregates were found at 
the relapse phase in chronic relapsing EAE and multiple sclerosis lesions, but not in toxin-induced 
demyelination. Because fibronectin aggregates in multiple sclerosis lesions, where remyelination 
fails, and not in toxin-induced lesions, where remyelination is complete, we next examined whether 
fibronectin aggregates contribute directly to remyelination failure.
Astrocyte-derived fibronectin aggregates inhibit remyelination
We first studied whether astrocyte-derived fibronectin aggregates altered progression within 
the oligodendrocytes lineage in vitro. To allow investigation of cell–matrix interactions as such, 
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oligodendrocyte progenitor cells were plated onto astroglial matrices obtained from untreated (Fig. 
4B) or lipopolysaccharide-treated rat astrocytes (Fig. 4B). The astrocytes were removed by
water-lysis, so that the effect of live astrocytes and their soluble factors on oligodendrocyte progenitor 
cells was eliminated. When oligodendrocyte progenitor cells were cultured on the astrocytederived 
matrices for 7 days, a small increase in the number of MBP-positive cells, indicative for differentiation, 
was observed (Fig. 5A and B). Myelin-like membrane formation, as defined by cells bearing MBP-
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Figure 4. Fibronectin expression and aggregation in cultured cells. A. Cultured astrocytes synthesize 
Fn protein in abundant levels. Primary rat oligodendrocyte progenitors (OPC), mature rat oligodendrocytes 
(OLG), rat microglia (M), rat LPS-activated microglia (aM), rat astrocytes (A), rat LPS-activated astrocytes (aA), 
bone-marrow derived macrophages (MP), rat cortical neurons (N) (de Jong et al., 2005), and the human brain 
endothelial cell line hCEMC/D3 (E) (Weksler et al. 2005) were analyzed for Fn mRNA and protein expression using 
RT-PCR and Western blot analysis (reducing conditions, monomers). A representative blot of 3 independent 
experiments is shown. B. Astroglial matrices from both LPS-activated rat astrocytes (LPS) and human MS 
astrocytes (MS) contained fibrillar Fn structures, whereas control astrocytes (CTRL) showed a more diffuse 
deposition of Fn. Cultured astrocytes were water-lysed and remaining deposits were analyzed for Fn deposition 
by immunofluorescence. Scale bar is 20 µm. Representative images of 3-4 independent experiments are shown. 
C. Fn aggregates (Fn AGG) are present in the matrix of LPS-stimulated (+ LPS), but not in the matrix of non-
stimulated (-) rat astrocytes. 10 µg deposits were subjected to DOC-(in)solubility assays, and DOC-insoluble (I) 
and -soluble (S) fractions were analyzed by Western blotting under non-reducing conditions. Representative 
blots and images of 3-4 independent experiments are shown. D. Fn and laminin (Ln) are expressed by cultured 
human astrocytes from healthy subjects (CTRL, 4) and MS patients (3). Total cell lysates (10 µg) were analyzed 
for Fn and Ln expression by Western blotting under reducing conditions (monomers). Data were quantified by 
normalizing the optical densities of Fn and Ln protein against actin, and expressed as mean + the standard 
deviation (p > 0,05 at Student´s t-test). E. Presence of Fn aggregates is increased in the DOC-insoluble fraction 
of MS astrocytes (MS) as compared to normal astrocytes (CTRL), whereas laminin is DOC-soluble. 10 µg deposits 
were subjected to DOC-(in)solubility assays, and DOC-insoluble (I) and -soluble (S) fractions were analyzed by 
Western blotting under non-reducing conditions. Representative blots of the deposits of astrocyte cultures 
analyzed in D are shown.  
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positive membranous structures spread between the cellular processes, however, was prevented 
on astroglial matrices from lipopolysaccharide-stimulated astrocytes, i.e. containing fibronectin 
aggregates, compared with oligodendrocyte progenitor cells cultured on astroglial matrices from 
untreated rat astrocytes (Fig. 5A and B). To further examine whether fibronectin aggregates in 
the total astroglial matrix indeed impair remyelination in vivo, enriched fibronectin aggregates, 
obtained from the deoxycholate-insoluble fraction of  deposits from cultured rat astrocytes, were 
intralesionally injected in lysolecithin-induced demyelinated lesions at 7 days post lesion. Following 
fibronectin aggregate injection, the density of cells expressing the oligodendrocytes marker Olig2 
seemed slightly reduced at 14 days post lesion, i.e. 7 days post aggregate injection, compared with 
saline-injected lesions (Fig. 5C and D), though not statistically significant. Notably, in saline-injected 
lesions, substantial fibronectin staining was still present, which is likely due to the response of fresh 
trauma by the (second) injection, although to a much lesser extent comparing with fibronectin 
aggregate–injected  esions (Supplementary Fig. 5A and B). The number of cells expressing the 
oligodendrocyte progenitor cell marker Nkx2.2 in the lesions was also not altered by fibronectin 
aggregates (Fig. E and F). Cells expressing oligodendrocyte differentiation markers APC protein (CC1) 
and proteolipid protein messenger RNA were, however, significantly decreased (Fig. 5G–J). Electron 
microscopy analysis at 14 days post lesion revealed that remyelination was impaired on fibronectin 
aggregate injection (Fig. 5K), which was reflected by a significant increase in the g-ratios (P50.05, 
Fig. 5L). To examine whether the reduction of mature oligodendrocytes was due to direct toxicity of 
fibronectin aggregates, the viability of oligodendrocyte cell lineage cells was assessed in vitro with 
Figure 5. Effects of fibronectin aggregates on oligodendrocytes in vitro and in vivo. A, B OPCs differentiate 
to MBP-expressing oligodendrocytes on control (ECM CTRL) and Fn aggregate (ECM LPS) astroglial matrices, but 
myelin-like membrane formation was retarded on Fn aggregates (Fn AGG). This is confirmed by quantification of 
MBP-positive cells (B, differentiation), and the amount of MBP-positive cells elaborating myelin-like membranes 
(B, ´myelination´). Astroglial matrices were obtained by water-lysis of astrocytes. In each experiment, at least 
500 cell/wells were counted. To compare different independent experiments, the data are expressed as % of 
control, i.e., values obtained from CTRL were set to 100. Each bar represents the mean + SEM of 3 independent 
experiments. Statistical differences were assessed with a Student´s t-test, and are indicated by asterisks (* p 
<0.05, ** p <0.01). Representative images of 3 independent experiments are shown (A). Scale bar is 20 µm. C-L. 
Fn aggregates impair OLG differentiation and remyelination in vivo. DOC-insoluble Fn aggregates obtained 
from rat astrocyte-derived deposits were intralesionally injected into demyelinated lesions of rats, 7 days after 
lysolecithin-induced demyelination, and the analyzed at 14 DPL, i.e., 7 days post injection. C-J. Images in C, 
E, G and I are representative images of demyelinated areas upon saline (left) and Fn aggregate injection. The 
outline of the lesions was measured using AxoVision software on the basis of the increase in DAPI staining. 
The numbers of Olig2 (C), NKX2.2 (E), CC1 (G), or PLP mRNA (I) positive cells were manually counted 3 times. 
There are 3-4 animals per group, 3 lesions per animal at a distance of about 120 μM apart from each other. 
The quantifications are shown in D, F, H and J, respectively. Each bar represents the mean + SEM. Statistical 
differences were assessed with a Student’s t-test, and are indicated by asterisks (* p <0.05). Scale bar is 100 μm. 
K, L. Images are representative electromicrographs of demyelinated areas upon saline (left) and Fn aggregate 
injection. The g-ratio of individual axons from saline injected (red circles) and Fn aggregate (black circles) were 
plotted against the corresponding axon diameters. The average g-ratio in Fn aggregated injected demyelinated 
areas is significantly higher than upon saline injection (p<0.05, Student´s t-test, 3 animals per group). Scale bar 
in K is 2 µm.
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a lactate dehydrogenase and MTT assay. Oligodendrocyte viability was not affected by addition of 
fibronectin aggregates to different maturation stages (Supplementary Fig. 5C and D), indicating that 
fibronectin aggregates are apparently not toxic to cultured oligodendrocytes. Therefore, these data 
indicate that astrocytederived fibronectin aggregates predominantly perturbed oligodendrocytes 
differentiation in vivo and impaired remyelination.
These findings would imply that fibronectin aggregates must be absent from remyelinated 
multiple sclerosis lesions, i.e. shadow plaques, which were examined next.
Fibronectin aggregates are present at low level in remyelinated multiple sclerosis lesions
To assess whether fibronectin aggregates are expressed at remyelinating conditions, homogenates 
of remyelinated multiple sclerosis shadow plaque containing brain tissue were subjected to 
deoxycholate-(in)solubility assays. The status of shadow plaques was confirmed by the Netherlands 
Brain Bank, showing a slightly reduced expression of proteolipid protein compared with the 
surrounding normal-appearing white matter, without abundant expression of CD68. Fibronectin 
aggregates were weakly expressed in the examined multiple sclerosis shadow plaques, whereas 
fibronectin is mainly present as a deoxycholate-soluble dimer (Fig. 6A). Furthermore, western 
blot analysis at reducing conditions revealed that fibronectin levels are slightly increased in 
remyelinated multiple sclerosis lesions compared with control white matter, but to a lesser extent 
than in (chronic) active multiple sclerosis lesions (Fig. 6B). Fibronectin staining around blood vessels 
can be discerned throughout the shadow plaques (Fig. 6C), and seemed higher than fibronectin 
staining in surrounding normal-appearing white matter (data not shown). However, fibronectin 
is barely detectable in the parenchyma of the emyelinated area. Thus, fibronectin aggregates are 
present at a low level in remyelinated multiple sclerosis lesions, which corroborate the findings that 
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Figure 6. Fibronectin protein expression and biochemical characterization in remyelinated MS lesions.  
A. Expression levels of Fn aggregates (Fn AGG) and dimers in remyelinated MS lesions (rMS). 100 µg of 
homogenates were subjected to DOC-(in)solubility assays, and DOC-insoluble (I) and -soluble (S) fractions were 
analyzed by Western blotting under non-reducing conditions. B. Total Fn expression in remyelinated MS lesions 
(rMS), as compared to control white matter (CWM), and (chronic) active MS [(c)aMS]. Expression levels of Fn and 
the other indicated proteins were detected by subjecting 50 µg of human brain white matter homogenates to 
Western blot analysis under reducing conditions. D. Immunohistochemistry for Fn in MS shadow plaque lesions, 
where Fn was detected in a shape typical for blood vessels. A representative image of two different remyelinated 
lesions is shown. Scale bar is 20 µm.
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DISCUSSION
Remyelination is crucial for functional recovery in demyelinating diseases, such as multiple sclerosis 
(Duncan et al. 2009). Here, we show that the extracellular matrix component fibronectin, which 
is largely absent from healthy adult white matter, rapidly accumulates as an acute response to 
demyelination, but disappears on remyelination. However, in multiple sclerosis lesions where 
remyelination fails, a persistent accumulation of stable aggregated fibronectin occurs. These 
fibronectin aggregates are most likely generated by astrocytes on engagement with inflammatory 
mediators, and most relevantly, these aggregates impair remyelination. 
Aggregation of fibronectin is likely associated with the process of inflammation. This was 
suggested by the absence of fibronectin aggregates from toxin-induced demyelination, where 
an innate immune response is secondary to demyelination, compared with the abundance 
of fibronectin aggregates in chronic relapsing EAE and multiple sclerosis lesions, where 
demyelination is caused by the adaptive immune response. Also, our in vitro experiments with 
primary rat astrocytes suggest a role for inflammatory mediators in fibronectin aggregation. 
Astrocytes exposed to the inflammatory mediator lipopolysaccharide deposit fibronectin in fibril-
like structures, whereas untreated astrocytes deposit fibronectin in a more diffuse pattern. This 
structural difference in fibronectin appearance is monitored by conversion from a deoxycholate-
soluble dimeric form to deoxycholate-insoluble fibronectin aggregates. Fibrillar fibronectin 
assembly is primarily initiated by binding of soluble fibronectin dimers to integrin α5β1, followed 
by assembly into high molecular weight fibronectin that is cross-linked by non-covalent bonds 
(Wierzbicka-Patynowski, Schwarzbauer 2003, Wu et al. 1993, Wu et al. 1995, Ohashi, Erickson 2009). 
Integrin α5β1 is expressed on astrocytes (King, McBride & Priestley 2001), neurons (King, McBride 
& Priestley 2001) and activated microglia (Milner et al. 2007), but not on oligodendrocytes (Milner, 
ffrench-Constant 1994). In addition to fibril formation, fibronectin can be covalently cross-linked 
by enzymes. Tumor necrosis factor-α, for example, increases fibronectin aggregation in endothelial 
cell layers by an enhanced transglutaminase activity on their surface (Chen et al. 2000), a process 
that might be active in multiple sclerosis lesions (van Strien et al. 2011). Hence, both persistent and 
recurring inflammation as well as concomitant astrogliosis could gradually result in conformation 
and accumulation of aggregated fibronectin in multiple sclerosis lesions.
Fibronectin expression in multiple sclerosis lesions was previously suggested to result from 
blood–brain barrier disruption (Sobel, Mitchell 1989, van Horssen et al. 2005). Our data reveal that 
on CNS injury, CNS resident cells also contribute to the fibronectin pool. This conclusion is supported 
by at least three observations: (i) next to a typical vasculature ocalization, small fibronectin deposits 
are present in multiple sclerosis, chronic relapsing EAE and toxin-induced lesions, suggesting 
additional sources to plasma leakage; (ii) fibronectin messenger RNA is upregulated in toxininduced 
demyelination; and (iii) EIIIA-fibronectin protein is detected at the lesion site. The lack of fibronectin 
messenger RNA, likely due to the chronic disease status, precluded elucidation of cellular sources 
in multiple sclerosis lesions. However, in situ hybridization co-localization studies in toxin-induced 
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lesion revealed that astrocytes, microglia/macrophages and endothelial cells likely synthesize 
fibronectin. Whether these cells also secrete and actively deposit fibronectin in vivo is rather difficult 
to determine. In vitro, fibronectin aggregation is dependent on astrocytes, as only astrocytes 
actively synthesize and deposit fibronectin, and plasma fibronectin alone, i.e. in the absence of 
astrocytes, does not aggregate (our unpublished observations). However, plasma fibronectin likely 
incorporates into astrocyte-derived fibronectin aggregates (McKeown-Longo, Mosher 1983, Peters 
et al. 1990).
Importantly, our data revealed that aggregated fibronectin impairs remyelination.  Fibronectin 
aggregates are hardly present in remyelinated multiple sclerosis shadow plaques, and injection of 
astrocyte-derived fibronectin aggregates into lysolecithin-induced demyelinated lesions resulted 
in a significant decrease of differentiated oligodendrocytes and concomitant increase in g-ratio 
compared with saline-injected lesions. Myelin-like membrane formation in vitro is inhibited by 
astrocyte-derived matrix that contains fibronectin aggregates, but not by astrocyte-derived 
matrix that contains dimeric fibronectin. This might be explained by the presence of additional 
(extracellular matrix) molecules that reside in the total astroglial matrix, such as laminin ((Liesi, 
Dahl & Vaheri 1983, Liesi et al. 1984); Fig. 4D and E). These additional molecules could overcome 
the myelination-inhibiting effect of dimeric fibronectin that has been observed previously (Buttery, 
ffrench-Constant 1999, Siskova et al. 2006, Maier et al. 2005, Siskova et al. 2009). Indeed, laminin 
signals are known to dominate over dimeric plasma fibronectin inhibitory signals (Buttery, ffrench-
Constant 1999). The presence of additional proteins in total astrocyte deposits may therefore 
also explain why fibronectin aggregates affect oligodendrocyte differentiation only in vivo, as 
the intralesionally injected aggregates were deoxycholate-insoluble, therefore lacking laminin 
and other glycoproteins (Fig. 4D and E). The inhibitory effect of fibronectin aggregates may occur 
through different mechanisms. First, fibronectin aggregates could directly affect oligodendrocyte 
progenitor cells through the classical fibronectin receptors, αv integrins, which they upregulate 
in toxin-induced lesions (Zhao et al. 2009). Alternatively, the interaction of aggregates with other 
cell types in vivo might indirectly affect oligodendrocyte differentiation and remyelination. Finally, 
fibronectin aggregation likely involves biochemical restructuring of fibronectin (Johnson et al. 1999, 
Baneyx, Baugh & Vogel 2002), which could expose different conformation-dependent binding sites 
that provoke altered signalling properties (Morla, Zhang & Ruoslahti 1994, Pasqualini et al. 1996, 
Sottile, Hocking & Swiatek 1998).
In conclusion, myelin regeneration following demyelination is a dynamic process, and requires 
a spatial and timely balanced response of the extracellular microenvironment.  Temporal dimeric 
fibronectin expression by astrocytes might be important in regulating remyelination at earlier 
stages. Pathological fibronectin aggregates as observed in multiple sclerosis lesions do, however, 
likely contribute to remyelination failure. Therefore, strategies to promote remyelination should 
not aim at preventing fibronectin deposition, but at interfering with fibronectin aggregation and 
clearance. In addition, the effects of persistent fibronectin  aggregates on other CNS cells, including 
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microglia and neurons, as well as the mechanisms of how aggregation is mediated, warrant further 
investigation, particularly because protein  aggregation is likely central to the pathology of several 
other neurodegenerative diseases (Jucker, Walker 2011).
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Supplementary Figure 1. Expression of fibronectin in caudal cerebral peduncle demyelinated lesions. A-D. 
Fibronectin (Fn) is abundantly expressed in demyelination (B,C, 5-14 DPL), and cleared upon remyelination (D, 
21 DPL). Sections from non-lesioned (A, CTRL) and ethidium bromide-lesioned rat brain at different days post 
lesion (DPL) were immunostained for total Fn. In caudal cerebral peduncle demyelinated lesions, virtually no 
remyelination can be detected at 0-14 DPL (Zhao C, Li WW, Franklin RJM, 2006). Representative images of 3 
animals per time points are shown. Scale bar is 20 μm.  
 IST9 - 1 DPL 14 DPL
A B
Supplementary Figure 2. Expression of EIIIA-fibronectin in lysolecithin-induced demyelinated lesions. 
EIIIA-fibronectin (EIIIA-Fn) is expressed as early as 1 day post lesion (DPL), and is cleared at 14 DPL. Sections 
of lysolecithin-induced lesioned areas at 1 (A) and 14 (B) DPL were immunostained for EIIIA-Fn (IST9, red). 
Representative images are shown. Scale bar is 20 μm.
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Supplementary Figure 3. Fibronectin mRNA expression in human CWM and MS lesions. Fibronectin mRNA 
(Fn) is virtually absent from chronic active [(c)aMS] and chronic inactive (ciMS) MS lesions. Analysis of Fn, CD68 
(activated microglia/macrophages), GFAP (astrocyte) mRNA levels (primers in table 1) in CWM, (c)aMS and ciMS 
homogenates. Actin mRNA served as an internal control. Two out of eight (chronic) active lesions showed Fn 
mRNA, whereas Fn mRNA was scarcely detectable in any of the seven chronic inactive MS lesions examind. Fn 
mRNA was also detected in three out of nine CWM tissues.
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Supplementary Figure 4. Clinical scores and monocyte infiltration at the relapse phase of rat chronic 
experimental allergic encefalitis. A. Clinical scores of chronic experimental allergic encefalitis (cr-EAE) rats and 
incomplete Freund’s adjuvant (IFA) controls. Cr-EAE animals were scored on the following scale: 
0, no clinical disease; 0.5, partial loss of tail tone; 1, complete tail atony; 2, paresis, partial hind limb paralysis; 3, 
complete paralysis of the hind limbs and/or lower part of the body; 4, moribund or dead due to EAE. Data are 
represented as mean + S.E.M, with n=8 animals per group. B. Immunohistochemical staining for MHC class II 
positive macrophages (Ox6), showing a clear increase in cr-EAE animals as compared to IFA controls. Stainings 
were performed on the cervical part of the spinal cord from 3 representative animals, with average clinical scores 
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Supplementary Figure 5. Fibronectin expression in lysolecithin lesions upon fibronectin aggregate injection, 
and assessment of the toxicity of fibronectin aggregates. Sections of lysolecithin-lesioned areas at 7 days post 
saline (A) or fibronectin aggregate (B) (Fn AGG) injection were immunostained for fibronectin (Fn). Representative 
images are shown. Scale bar is 20 μM. C, D. Fn aggregates were added to cultured rat oligodendrocytes at a 
final concentration of 5,0 μg/mL in various stages of oligodendrocyte maturation. Three days after Fn aggregate 
addition, LDH (C) and MTT (D) assays were performed. Relative cytotoxicity and viability were calculated against 
unstimulated control cells. Data are represented as the mean + the standard deviation. Statistical analyses were 
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Central nervous system remyelination by oligodendrocyte progenitor cells (OPCs) ultimately fails 
in the majority of multiple sclerosis (MS) lesions. Remyelination failure is mediated in part by the 
aberrant expression of factors that impair OPC differentiation, including fibronectin (Fn) aggregates. 
Fn is present in demyelinated lesions in two major forms; plasma Fn (pFn), deposited following 
blood-brain barrier disruption, and cellular Fn (cFn), synthesized by resident glial cells and containing 
alternatively spliced domains EIIIA and EIIIB. Here, we investigated the distinctive roles that cFn 
and pFn play in remyelination. We used an inducible Cre-lox recombination strategy to selectively 
remove pFn, astrocyte-derived cFn or both from mice, and examined the impact on remyelination 
of toxin-induced demyelinated lesions of spinal cord white matter. This approach revealed that cFn 
from astrocytes is a major source of Fn in demyelinated lesions. Furthermore, following astrocyte-
derived cFn conditional knockout, the number of OPCs recruited to the demyelinated lesion 
decreased significantly, whereas OPC numbers were unaltered following pFn conditional knockout. 
However, remyelination completed normally following conditional knockout of astrocyte-derived 
cFn and pFn. Both the EIIIA and EIIIB domains of cFn were expressed following demyelination, and 
in vitro assays demonstrated that the EIIIA domain of cFn promotes proliferation of OPCs, but not 
migration. Therefore, although the EIIIA domain from cFn facilitated OPC recruitment following 
demyelination, cFn is not essential for successful remyelination. Since previous findings indicated 
that astrocyte-derived Fn aggregates in chronic MS lesions inhibit remyelination, cFn removal may 
benefit therapeutic strategies to promote remyelination in MS.
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INTRODUCTION
Multiple sclerosis (MS) is a central nervous system (CNS) disease, of which inflammation, 
demyelination, and axonal loss are the main pathological features. Regeneration of myelin 
(remyelination) involves proliferation and migration of activated oligodendrocyte progenitor 
cells (OPCs) to demyelinated lesions, and their subsequent differentiation into myelinating 
oligodendrocytes (Franklin and ffrench-Constant, 2008; Zawadzka et al., 2010). The extent of 
remyelination in MS is variable, but often is insufficient to prevent chronic axonal loss (Patrikios et 
al., 2006; Franklin et al., 2012). Promoting endogenous remyelination provides a means to reduce 
axonal degeneration and thereby slow progression of clinical disability (Franklin et al., 2012; Duncan 
et al., 2009). 
Fibronectin (Fn) is an extracellular matrix (ECM) protein, that is essential for embryonic 
development (George et al., 1993). In healthy adults, Fn is continuously produced by hepatocytes 
and circulates in the plasma. Fn is absent from the healthy CNS, but expressed in demyelinated 
lesions. Plasma Fn (pFn) leaks across a disrupted blood-brain barrier (Sobel and Mitchell, 1989; van 
Horssen et al., 2005; Satoh et al., 2009), and cellular Fn (cFn) is primarily synthesized by astrocytes 
(Hibbits et al., 2012; Stoffels et al., 2013b), but also by microglia/macrophages and endothelial cells 
(Stoffels et al., 2013a). In contrast to pFn, cFn may contain alternatively spliced domains, named 
EIIIA, EIIIB and the V-region in rodents (EDA, EDB and IIICS, respectively, in humans) (Paul et al., 1986; 
Schwarzbauer et al., 1987). In vitro, Fn stimulates migration and proliferation of OPCs via αv integrin 
receptors, the only integrin receptors for Fn present on OPCs (Milner and ffrench-Constant, 1994; 
Milner et al., 1996; Blaschuk et al., 2000; Baron et al., 2002). The expression of both Fn and αv integrins 
is transiently increased in demyelinated lesions (Zhao et al., 2009). Therefore, Fn may contribute to 
remyelination by promoting OPC recruitment. However, removal of Fn is required for remyelination 
to proceed to completion, since Fn inhibits myelin sheet formation (Buttery and ffrench-Constant, 
1999; Maier et al., 2005; Siskova et al., 2006; Siskova et al., 2009). In addition, Fn aggregates impair 
OPC differentiation in vivo, and likely contribute to remyelination failure in MS (Stoffels et al., 2013a). 
Here, we explored the role of Fn in more depth by asking what distinctive roles the two Fn variants, 
pFn and astrocyte-derived cFn, play in remyelination. Using an inducible Cre-lox recombination 
strategy to selectively remove pFn, astrocyte-derived cFn or both (Sakai et al., 2001; Hirrlinger et 
al., 2006) in combination with a well-established model of CNS de- and remyelination (Blakemore 
and Franklin, 2008), we found that cFn from astrocytes, but not pFn, promotes recruitment of 
OPCs. In vitro analysis revealed that this was likely mediated by the EIIIA domain, which enhances 
OPC proliferation. However, although conditional knockout of astrocyte cFn was associated with 
reduced OPC recruitment following demyelination, it was not sufficient to affect remyelination 
outcome. The translational implication of our data therefore is that elimination of astrocyte-derived 
cFn may be attempted in MS to prevent Fn aggregation, which will likely be beneficial in promoting 






Animals were housed under standard conditions. All experiments were performed in compliance 
with United Kingdom Home Office regulations. Female Sprague Dawley rats at 8-10 weeks of age 
were obtained from Harlan, UK. Plasma Fn (pFn) inducible, conditional knockout mice (hereafter 
referred to as pFncKO) were a kind gift from Dr. R. Fässler, Max Planck Institute for Biochemistry, 
Martinsried, Germany. Inducible, conditional knockout (hereafter referred to as ‘conditional 
knockout’) of pFn was created as described (Sakai et al., 2001). Briefly, floxed Fn mice were crossed 
with mice expressing Cre recombinase under the control of the polyinosinic-polycitidic acid (poly I:C) 
responsive Mx promoter (Mx-Cre). On Cre-mediated recombination at the loxP sites, the start codon, 
signal sequence and the exon/intron border of exon 1 are removed from the Fn gene to generate 
the null allele (Sakai et al., 2001). Cre-mediated recombination was induced in hepatocytes from 
the 6-week old mice carrying Mx-Cre by two intraperitoneal injections of poly I:C (GE Healthcare, 
Amersham, UK) with a 48 h interval as previously described (Sakai et al., 2001). Control animals 
received vehicle only (PBS). Mice were subjected to lysolecithin-induced demyelination at 2-3 weeks 
following induction of the knockout. 
Conditional knockout mice devoid of astrocyte-derived Fn (astrocyte Fn; aFncKO) were created by 
crossing Fn floxed mice with mice expressing Cre recombinase driven by human glial fibrilary acid 
protein (GFAP), with its nucleus translocation controlled by a modified estrogen receptor (hGFAP-
CreERT2) (Hirrlinger et al., 2006). The hGFAP-CreERT2 mice were a kind gift from Dr. F. Kirchhoff, Max 
Planck Institute of Experimental Medicine, Goettingen, Germany. To induce conditional knockout of 
Fn from astrocytes, tamoxifen (100 mg/kg in corn oil, Sigma-Aldrich, Gillingham, UK) was injected 
intraperitoneally daily for 5 consecutive days, starting from 10 days prior to demyelination (Hirrlinger 
et al., 2006; Leone et al., 2003). The control group was injected with corn oil.
Compound astrocyte and pFn conditional knockout (a+pFncKO) was achieved by breeding 
mice heterozygous for MxCre and hGFAP-CreERT2, and homozygous for the floxed Fn gene. The 
induction protocol for these mice was the combination of that described for single conditional 
knockout strains above. 
Lysolecithin-induced demyelination of the spinal cord and tissue processing
Surgery and tissue processing were performed as described (Zawadzka et al., 2010; Zhao et al., 
2006). Briefly, animals at about 9-10 weeks old were anaesthetized with isoflurane, and spinal cord 
lesions were created by direct injection of 1 µL 1% lysolecithin into the ventral funiculus through 
a gap between two thoraco-lumbar vertebrae. In the conditional knockout animals, lesions were 
induced 1-2 weeks after completing the induction protocol. Blood samples were obtained for 
isolating plasma from the tail at the time of lesion, and collected in citrate-dextrose solution (Sigma-
Aldrich, Dorset, UK), then stored at -80ºC until use.
At the designated time post lesion, animals were euthanized by intravenous injection of 
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pentobarbital followed by appropriate protocols of tissue processing. For immunohistochemistry and 
in situ hybridization, animals were perfusion fixed with 4% phosphate-buffered paraformaldehyde 
(PFA) solution via the left ventricle, after which dissected spinal cord containing the lesions was 
treated with 20% sucrose in phosphate-buffered saline (PBS) overnight. Cords were embedded 
in OCT (Thermo Fisher Raymond Lamb, Loughborough, UK), and cut in coronal sections at 12 µm 
thickness. These sections were mounted on poly-L-lysine coated slides (Polysciences Europe GmbH 
Eppelheim, Germany) and stored at -80ºC until further use. For resin embedding and semithin 
sectioning, animals were perfused with 4% phosphate-buffered gluteraldehyde and subjected to 
a standard resin embedding process (Zhao et al., 2006). Semithin sections of 1 µm were cut and 
stained with alkaline toluidine blue. Ranking analysis on semithin sections of remyelinated lesions 
was performed by two independent, blinded researchers as described (Ibanez et al., 2004). 
Glial cell cultures 
Primary glial cell cultures were generated from 1-2-day old Wistar rats (Harlan, the Netherlands) 
as previously described (Baron et al., 2002; Bsibsi et al., 2012). Briefly, after 10-12 days in culture on 
poly-l-lysine (5 µg/mL, Sigma-Aldrich, St. Louis, MO) coated flasks, OPCs and astrocytes were isolated 
via a shake-off procedure (McCarthy and de Vellis, 1980). Contaminating microglia were removed 
by shaking the flasks at 150 rpm for 1 h at 37°C on an orbital shaker. Subsequently, flasks were 
shaken at 240 rpm overnight at 37°C. Floating OPCs were further purified by differential adhesion. 
Then, OPCs were cultured in defined Sato medium (Maier et al., 2005) on appropriate cell culture 
plastics for the different assays (see below). Purity of the OPC cultures was routinely assessed by 
immunocytochemistry for Olig2 (1:1000; Millipore, Billerica, MA) and cultures used were > 97% pure. 
To obtain astrocytes, a subsequent overnight shake off was performed at 240 rpm and the 
remaining astrocyte monolayer was removed by trypsin. Astrocytes were cultured in T162 flasks 
(Corning Costar, Lowell, MA) in DMEM (Life Technologies, Paisley, UK) containing 10% fetal calf 
serum (FCS; Bodinco, Alkmaar, The Netherlands) and antibiotic supplements (Life Technologies), 
and passaged once before experimental use. Regular immunocytochemistry for glial fibrillary acidic 
protein (GFAP; Millipore; 1:500) was performed to assure sufficient purity of the astrocyte cultures 
(>97%).
Plasma and cellular fibronectin coatings 
To obtain cFn, astrocytes were cultured on 10 cm dishes (Corning) for 48 h, followed by water-lysis at 
37°C. The remaining astroglial matrix was scraped in sterile PBS containing Complete Mini protease 
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), followed by protein concentration 
determination with Bio-Rad DC protein assay (Bio-Rad Laboratories, Hercules, CA) using bovine 
serum albumin as standard. Then, 8-well chamber-slides were incubated with 8 µg pFn from bovine 
serum (Sigma-Aldrich) or 8 µg astroglial matrix protein (‘cFn’) per well in PBS for 3 h at 37°C. Similarly, 
both sides of membranes on transwell microchambers (Becton-Dickinson Labware, Bedford, MA) 
92
Chapter 3
were coated with 10 µg of pFn or cFn per well, and 3.5 µg pFn or cFn was used per well of a 96-wells 
plate. When indicated, Fn coatings were incubated with functional blocking antibodies (2 µg/mL) for 
1 h at 37°C, followed by a gentle wash with PBS and seeding of OPCs. Blocking antibodies used were: 
mouse anti-Fn IST9 (directed against the EIIIA domain, Abcam, Cambridge, UK) and mouse anti-Fn 
C6 (directed against the EIIIB domain, Abcam). Notably, the astrocyte-derived cFn preparation also 
contains other astroglial matrix proteins, such as laminin (Liesi et al., 1984; Liesi et al., 1983) and 
chondroitin sulphate proteoglycans (Lau et al., 2012), but although these proteins may affect OPC 
adhesion, proliferation and migration also (Milner et al., 1996; Lau et al., 2012; Hu et al., 2009), EIIIA 
and EIIIB are exclusively present in cFn.
SDS-PAGE and Western blotting
Equal amounts of plasma from pFncKO and a+pFncKO mice and their controls were mixed with 
standard SDS sample buffer, heated for 10 min at 95ºC, and separated by electrophoresis on 
SDS-PAGE gels (8%, Expedeon, Cambridge, UK) for 1 h at 150 V. Protein was transferred to a PVDF 
membrane (Invitrogen, Paisly, UK) using a wet blotting system (Expedeon, Cambridge, UK) and 
according glycine-Tris-methanol buffer. After three washes with 0.1% Tween-20 in PBS, membranes 
were blocked with 5% non-fat milk solution and incubated with a rabbit anti-Fn antibody (Millipore, 
Watford, UK; 1:10,000) in blocking buffer, overnight at 4ºC. Membranes were washed, and incubated 
with HRP-conjugated anti-rabbit antibody (Roche, Lewes, UK; 1:1000) in washing buffer. Signals 
were detected using enhanced chemiluminescence plus (ECL plus; GE Healthcare, Amersham, UK) 
followed by exposure on suitable X-ray film (Thermo Scientific, Rockford, IL). For detection of mouse 
IgG as a control, membranes were washed and incubated with biotinylated donkey anti-mouse 
IgG antibody (Jackson ImmunoResearch Laboratories Inc, Newmarket, UK; 1:1000) for 1 h, after 
which the Vectastain ABC Elite kit (Vector Laboraties, Peterborough, UK) was used according to the 
manufacturer’s instructions, and signals were developed as described above.
Immunochemistry
Frozen spinal cord sections were air dried for approximately 1 h and immunohistochemistry was 
performed as described (Stoffels et al., 2013a) using antibodies against Fn (Millipore; 1:1000), 
Olig2 (Millipore, 1:1000; R&D Systems, Abingdon, UK; 1:200), Sox2 (Santa Cruz Biotechnology Inc, 
Dallas, TX; 1:500), KI67 (Abcam; 1:1000), and Iba1 (Abcam; 1:500). Antigen retrieval was performed 
before immunostaining with Olig2, using target retrieval solution (DAKO, Ely, UK) at 95ºC for 20 
min. Immunochemistry on coated cFn was performed as described (Stoffels et al., 2013a), using 
antibodies against Fn (1:50), IST9 (1:50) and C6 (1:50). Secondary antibodies used were appropriate 
Alexa Fluor© (488 or 594)-conjugated secondary antibodies (Invitrogen; 1:500). 
For immunohistochemistry using primary antibodies generated in mice on mouse tissue, 
a modified protocol was used. This protocol was applied for primary antibodies against Nkx2.2 
(Hybridoma Bank Iowa, Iowa City, IA; 1:100), CC1 (Millipore; 1:100) and Aldh1L1 (NeuroMab, Davis, 
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CA; 1:100) and secondary antibodies used were Alexa Fluor© 488-conjugated-anti IgG2b (for Nkx2.2 
and CC1) or -anti IgG1 (for Aldh1L1) (Invitrogen; 1:400). Sections were first permeabilized with 1% 
Triton-X-100 in 0.05 M Tris-buffered saline (TBS) for 30 min. Then, sections were blocked for 30 min in 
TBS with 10% normal goat serum (NGS) and 0.25% Triton-X-100, followed by another blocking step 
for 1 h using mouse-on-mouse Ig solution (Vector Laboratories) according to the manufacturer’s 
instructions. Primary antibodies were appropriately diluted in TBS containing 2% NGS and 0.3% 
Triton-X-100, and applied for 1 h. Secondary antibodies were appropriately diluted in TBS with 1% 
NGS, 0.1% Triton-X-100 and DAPI (1 µg/mL), and applied for 15 min, followed by a 10 min incubation 
in 0.1% Sudan Black in 70% ethanol. All incubations were at room temperature. After each step, 
sections were washed in 0.05 M TBS with 0.1% Tween-20 (VWR, Lutterworth, UK) 3 times 2 min. 
Images from immunohistochemistry with either protocol were acquired using a Zeiss Observer 
A1 fluorescent microscope, and images from immunochemistry on coatings were acquired using a 
Zeiss Axioskop 2 microscope with Leica Application Suite V3 software. For counting cell numbers, in 
each animal 3 demyelinated lesions were selected, spanning the centre of lesions, at approximately 
120 µm distance from each other. The outline of each lesion was defined based on the increase 
in DAPI cellularity inside the lesion using Zeiss Axovision 4.8 software (Stoffels et al., 2013a). The 
numbers of marker-positive cells inside the lesions were manually counted 3 times and averaged 
for each lesion. There were 4-5 animals per group. Individual Fn- and Iba1-immunereactive cells 
could not be discerned reliably, hence these were quantified by measuring the optical densities 
from immunofluorescence using FIJI software. 
Reverse transcription-PCR
Total RNA was isolated from tissue homogenates using the RNeasy Mini kit (Qiagen). Reverse 
transcription of 0.5 µg total RNA was performed in the presence of oligo(dT)12–18 and 
dNTPs (Invitrogen) with SuperScript_II reverse transcriptase (Invitrogen) according to the 
manufacturer’s instructions. The resulting complementary DNA was amplified using Microzone 
MegaMix Blue (Microzone Ltd, West Sussex, UK) and the following primers: for EIIIA; forward: 
5’-AAACAGAAATGACCATTGAAGTTTG-3’, reverse: 5’-TTGATTTCTTTCATTGGTCCTGTCTT-3’; for EIIIB; 
forward: 5’-TTACACTGTCAAAGATGACAAGGAAA-3’, reverse: 5’-TGACATCAGAAGAATCAAAACCAGTT-3’ 
(optimized from: (Magnuson et al., 1991; Vitale et al., 1994), and for cyclophilin; forward: 
CTCGTGACCCCTCTTTCC, reverse: CATTATTTTCCTCATTTCCCCT (Stoffels et al., 2013a; Zhao et al., 
2006). Cycling conditions were optimized, with all cycle numbers falling within the linear production 
range, and PCR products were resolved by agarose gel electrophoresis. Changes in gene expression 
were analyzed by Scion Image Software. The EIIIA and EIIIB primers generate two products: a band 
that includes the alternatively spliced domain (526 bp for EIIIA, 640 bp for EIIIB) and another band 
when these domains are spliced out (256 bp for EIIIA, 367 bp for EIIIB) (Vitale et al., 1994). Therefore, 
the upper bands were used for quantifications. Hereto, optical densities were normalized against 




OPCs were plated on 8-well Permanox chamber-slides (Nunc, Naperville, IL), pre-coated with 5 
µg/mL poly-l-lysine followed by appropriate cFn or pFn coatings (described above), at a density 
of 30,000 cells per well. OPCs were allowed to incorporate 5-bromo-2-deoxyuridine (BrdU; 10 µM; 
Roche) for 24 h in the presence of 10 ng/mL PDGF-AA and 10 ng/mL FGF-2. Then, cells were fixed in 
4% PFA for 20 min, and additionally fixed in 5% acetic acid in ethanol for 20 min. BrdU was detected 
using reagents from the BrdU Labelling and Detection Kit I (Roche) according to the manufacturer’s 
instructions with the addition of the oligodendrocyte lineage marker Olig2 (Abcam) and Alexa 
Fluor© 546-conjugated anti-rabbit antibody, and visualization of nuclei with DAPI (1 µg/mL). To 
compare the percentages of BrdU-incorporating cells between the conditions, the numbers of 
double BrdU- and Olig2-positive cells were counted relative to the Olig2-positive cells (at least 150 
cells per condition) from images captured with a Leica TCS SP8 Confocal Laser Scanning Microscope. 
Transwell migration assay
OPCs were seeded on polyethylene terephthalate membranes of 8 µm pore size (Becton-Dickinson 
Labware) in 12-well modified Boyden transwell microchambers at a density of 80,000 cells per insert. 
OPCs were allowed to migrate through the coated (described above) membranes for 4 h using 10 
ng/mL PDGF-AA as a chemoattractant in the bottom of the well. Non-migrating cells were removed 
from the top compartment with a cotton swab. Remaining cells in the membranes were fixed for 
20 min in 5% acetic acid in ethanol and nuclei were visualized using DAPI (1 µg/mL) in PBS for 30 
min. After washing in PBS, membranes were mounted on glass slides and images of DAPI-positive, 
migrated cells were captured using a Zeiss Axioskop 2 plus microscope with Leica Application Suite 
v3 software (15 X20 fields per membrane). The numbers of cells were assessed using FIJI software. 
Adhesion assay
Coated 96-wells plates (Nunc) were blocked for 30 min with 1% heat-inactivated BSA at 37°C. Then, 
wells were left untreated or treated with the Fn blocking antibodies against EIIIA or EIIIB (mouse 
anti-Fn IST9; Abcam and anti-Fn C6; Abcam). After washing, 10,000 OPCs in 50 ml Sato medium per 
well were allowed to adhere for 1 h at 37°C. For integrin blocking experiments, OPCs were pre-
incubated with anti-integrin β1 (Becton Dickinson Pharmingen, Breda, NL; 1:200), anti-integrin 
β3 (Becton Dickinson Pharmingen; 1:200) or anti-integrin β5 (Millipore, Chemicon, Temecula, CA; 
1:200) antibodies for 30 min at 37°C. The cells were washed two times with PBS, and adhered cells 
were fixed for 15 min with ice-cold methanol. Cells were stained with 0.2% crystal violet (in 2% 
ethanol; Sigma), then washed several times with water, after which the stain was solubilised in 1% 
SDS. Adhesion was quantified by measuring the absorbance at 570 nm after 30 min. Adhesion is 
expressed as percentage of the corresponding untreated substrate control resulting from triplicate 
determinations. 
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In situ hybridization
The DIG-labeled PLP probe was generated as described (Chari et al., 2006). Briefly, mouse PLP cDNA 
(a kind gift from I.R. Griffiths, Glasgow, UK) was used, subcloned into the pGEM4 plasmid (Promega, 
Southampton, UK). The probe was labelled using a DIG RNA labelling kit (Roche, Lewes, UK).  In situ 
hybridization was performed as described previously (Sim et al., 2000; Zhao et al., 2008). Methods of 
quantification for the in situ hybridized sections are described under ‘immunochemistry’, except that 
measurements of the outlines of the lesions were based on the darker, lesioned tissue background.
Statistical analyses
Statistical analyses were performed in GraphPad Prism (GraphPad Inc, La Jolle, CA). First, the 
Kolmogorov-Smirnov test was applied to test for a normal distribution of the data. Multiple group 
comparisons of data, which could thus be assumed to have a normal distribution (data sets of FncKO 
animals, derived from immunohistochemistry and in situ hybridization studies, except for the data 
describing immunofluorescence intensity of Fn- and Iba1-staining), were performed using one-
way ANOVA followed by Tukey’s Multiple Comparison Test (* p < 0.05; ** p < 0.01; *** p < 0.001). 
Multiple group comparisons of data that were not compatible with a normal distribution (data sets 
derived from in vitro assays and reverse transcription PCR on demyelinated tissue, as well as of the 
data describing immunofluorescence intensity of Fn and Iba1 stainings) were performed using the 
Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test (* p < 0.05; ** p < 0.01; *** p < 
0.001). Non-parametric ranking data, derived from blindly ranking alkaline toluidine blue stained 
resin sections for estimated degrees of remyelination, were statistically analysed using the Mann-
Whitney test (Ibanez et al., 2004). For the in vivo rodent data from immunohistochemistry, in situ 
hybridization and reverse transcription PCR studies, a representative graph of 2-3 independent 
experiments is shown, displaying absolute means of 3-4 animals per group and 3 lesions per 
animal, each approximately 120 µm from each other, with the exception of immunochemistry for 
Iba1, data of which are shown as a relative to the mean immunofluorescence levels of littermate 
controls, set at 100% for each independent experiment. Quantification methods are described 
under ‘immunochemistry’. For in vitro proliferation, migration and adhesion assays, graphs display 
mean values relative to a control condition (cFn or pFn) from 3-5 independent experiments. All error 
bars represent standard deviations. 
RESULTS
Fibronectin in demyelinated lesions is predominantly produced by astrocytes
Transient Fn expression during demyelination is hypothesized to benefit remyelination (Hibbits et 
al., 2012; Stoffels et al., 2013a; Zhao et al., 2009), whereas the persistent presence of Fn aggregates, 
inhibit OPC differentiation and impairs remyelination (Stoffels et al., 2013a). The aim of the present 
study was therefore to better define the potential involvement and underlying mechanism(s) of 
the different Fn sources in remyelination. We used a well-established rodent model of experimental 
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demyelination, in which focal, primary demyelination is created by the injection of lysolecithin 
into the white matter of the spinal cord ventral funiculus (Zawadzka et al., 2010; Blakemore and 
Franklin, 2008). Spontaneous and complete remyelination of these lesions proceeds over a period 
of approximately 21-28 days in young adult rodents, which involves proliferation and migration of 
local, activated OPCs to the demyelinated lesions (‘recruitment’; 1-10 days post lesion (DPL)) (Franklin 
and ffrench-Constant, 2008; Zawadzka et al., 2010), followed by differentiation of oligodendrocytes 
and myelin sheath formation (10-21 DPL) (Zhao et al., 2006). In order to eliminate pFn and cFn from 
lysolecithin-demyelinated lesions, we used Cre/lox technology, creating conditional knockout 
adult mice devoid of plasma Fn (pFncKO), astrocyte Fn (aFncKO) or both (a+pFncKO). The pFn null allele 
was generated by activation of the Mx-Cre promoter with poly I:C as described (Sakai et al., 2001), 
which removes the start codon, signal sequence and the exon/intron border of exon 1 from the 
pFn gene. In order to remove cFn, we targeted astrocytes, because these are considered a major 
source of Fn in the CNS following injury, and synthesize pathological Fn aggregates in MS (Hibbits 
et al., 2012; Stoffels et al., 2013a). We thus used mice expressing Cre recombinase under control of 
a GFAP promoter, which was rendered active by exposure to tamoxifen via a modified estrogen 
receptor. The induction efficiency was tested in a reporter line, as described in a previous report 
(Hirrlinger et al., 2006). In our own experiments, this approach showed that at 5 days after a course 
of tamoxifen administration in unlesioned adult mice, of astrocytes in spinal cord white matter on 
average 78.5% ± 2.4% SD (n=4) expressed the reporter (yellow fluorescent protein), indicating an 
efficient recombination.
Using this approach, pFn was successfully eliminated from plasma in pFncKO mice, as revealed 
by Western blot analysis (Fig. 1A). Similar results were obtained on plasma from a+pFncKO mice, 
whereas pFn remained present in the plasma of aFncKO mice as expected (Fig. 1B). Given the virtual 
absence of cFn from the healthy CNS and its increased expression on demyelination (Stoffels et al., 
2013a; Zhao et al., 2009), we assessed local Fn expression in the CNS of aFncKO and a+pFncKO mice by 
immunohistochemistry of lysolecithin-induced demyelinated lesions. As shown in Fig. 1C and 1D, 
Fn expression was increased in demyelinated lesions of control animals at 5 DPL as reported in rat 
models (Stoffels et al., 2013a; Zhao et al., 2009). In pFncKO mice, Fn immunostaining was unaltered 
compared to expression in littermate controls (Fig. 1C,D), despite the strong reduction in Fn plasma 
levels (Fig. 1A). These data indicate that either pFn is not a major source of Fn expression within 
lesions, or that cFn may compensate for the absence of pFn. In contrast, Fn expression was markedly 
reduced in demyelinated lesions of aFncKO and a+pFncKO mice (Fig. 1C,D), corroborating astrocytes as 
a major source of cFn after demyelination. Having reduced Fn levels from plasma and astrocytes, we 
next analyzed how remyelination was affected at both the recruitment and differentiation stages of 
remyelination.
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Proliferation of oligodendrocyte progenitor cells in response to demyelination is decreased 
in astrocyte fi bronectin conditional knockout animals 
To determine whether recruitment of OPCs to the demyelinated area is aff ected by pFncKO and/or 
aFncKO, we analyzed OPC numbers after lysolecithin-induced demyelination in the diff erent FncKO 
mice. Immunostaining for Olig2 was used as a marker for oligodendrocyte lineage cells (Arnett et al., 
2004; Fancy et al., 2009) and Sox2 and Olig2 double immunohistochemistry to identify OPCs (Kondo 
and Raff , 2004; Shen et al., 2008) (Fig 2A). This approach revealed a small, signifi cant reduction in 
Olig2-positive (Olig2+) cells and Sox2+Olig2+ cells after aFncKO, but not pFncKO at 5 DPL (Fig. 2A-C). A 
similar reduction in Olig2+ and Sox2+Olig2+ cells was detected after a+pFncKO (Fig. 2A-C), indicating 
that the decrease in OPC numbers was associated with the decrease in astrocyte cFn. An additional 
decrease in pFn levels in a+pFncKO did not further reduce the number of OPCs. In support of these 
observations, by determining OPC numbers using the transcription factor Nkx2.2 as a marker 
(Watanabe et al., 2004), we similarly detected that OPC numbers were reduced after aFncKO and 
Figure 1. Fibronectin in demyelinated lesions is predominantly produced by astrocytes. A,B. Western blot 
analysis for fi bronectin (Fn) and immunoglobulin M (IgM) on plasma of littermate controls (CTRL) and after 
conditional knockout of Fn from plasma (pFncKO), astrocytes (aFncKO) or astrocytes and plasma (a+pFncKO). Note 
the virtual absence of Fn from plasma after pFncKO and a+pFncKO. C. Immunohistochemistry for Fn on lysolecithin-
demyelinated spinal cord lesions at 5 days post lesion (DPL) after pFncKO, aFncKO, a+pFncKO or in CTRL mice. D. 
Quantifi cation of immunofl uorescent staining intensities in (C) from 3 animals per group, and 3 lesions per 
animal, approximately 120 µm distant from each other from images that were taken on the same day using the 
exact same camera settings. Note the reduction in intensity of immunofl uorescence relative to CTRL after aFncKO 
and a+pFncKO, but not following pFncKO. Bars represent means. Error bars show standard deviations. Statistical 
analysis was performed using the Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test (* p < 0.05; ** 
p < 0.01; *** p < 0.001). Demyelinated lesion outlines were measured in Zeiss Axovision 4.8 software based on 
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a+pFncKO (Fig. 2D). The lesions were of comparable sizes in the diff erent FncKO samples relative to 
controls (data not shown). In tissue culture, pFn promotes OPC migration and proliferation (Milner 
et al., 1996; Baron et al., 2002; Hu et al., 2009). To examine whether the reduction in OPC numbers 
in aFncKO animals refl ected an impairment in proliferation, we next analyzed the numbers of 
proliferating OPCs at 5 DPL, determined by co-labelling with Olig2 and the cell proliferation marker 
KI67 (Gerdes et al., 1983). This revealed a signifi cant reduction in KI67+Olig2+ cells in aFncKO and 
a+pFncKO, but not pFncKO (Fig. 2E,F), indicating that the decrease in OPC numbers is, at least partly, a 
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Figure 2. Proliferation of oligodendrocyte progenitor cells is reduced after conditional knockout of 
astrocyte fibronectin, but not after plasma fibronectin conditional knockout alone. A-I. After 5-days post 
lysolecithin-induced demyelination (5 DPL) of the mouse spinal cord ventral funiculus, the density of Olig2-
positive (‘Olig2+’, B), Sox2+Olig2+ (A,C), Nkx2.2+ (D), KI67+Olig2+ (E,F) Iba1+ (G,H), and Aldh1L1+ (I) cells were 
determined by immunohistochemistry. Note the decrease in Olig2+, Sox2+Olig2+, Nkx2.2+ and KI67+Olig2+ 
cells number after conditional knockout of fibronectin from astrocytes (aFncKO) or from astrocytes and plasma 
(a+pFncKO), but not from plasma alone (pFncKO) relative to littermate controls (CTRL). Images in A,E and G are 
representative images of demyelinated areas in the different groups. Insets show higher power magnifications 
of the double positive cells that were counted, with the blue color representing DAPI staining. The outline of 
the demyelinated lesions was measured in Zeiss Axovision 4.8 software based on increased DAPI stainings 
inside lesions and outlines are represented by dashed white lines. Double (A,C,E,F) or single (B,D,G-I) positive cell 
numbers were manually counted 3 times for 4 animals per group, and 3 lesions per animal, approximately 120 
µm distant from each other. Representative graphs of 2-3 independent experiments are shown. Bars represent 
means. Error bars show standard deviations. Statistical analyses were performed using one-way ANOVA, followed 
by Tukey’s Multiple Comparison Test (* p < 0.05; ** p<0.01; *** p < 0.001; NS: not significant). Scale bars are 50 µm.
result of impaired proliferation. In contrast, we did not observe a substantial change in microglia/
macrophage numbers after FncKO, as assessed by immunohistochemistry for ionized calcium-
binding adaptor molecule 1 (Iba1) (Imai et al., 1996) (Fig. 2G,H). Similarly, astrocyte numbers were 
not significantly affected by FncKO, as reflected by comparable intense immunofluorescence levels 
of aldehyde dehydrogenase 1, member L1 (Aldh1L1) (Lovatt et al., 2007; Cahoy et al., 2008) (Fig. 
2I). Hence, aFncKO resulted in a reduced number of OPCs after demyelination, whereas microglia/
macrophage and astrocyte cell numbers were unaffected.
Oligodendrocyte differentiation and remyelination are not affected by conditional knockout 
of fibronectin from astrocytes
We next examined whether the decreased OPC numbers observed in aFncKO and a+pFncKO during 
demyelination resulted in altered CNS remyelination following lysolecithin-induced demyelination. 
Oligodendrocyte lineage cell numbers were analyzed by immunohistochemistry for Olig2 at 14 days 
post lysolecithin-induced demyelination (Zhao et al., 2006). As shown in Fig. 3A and 3B, Olig2+ cells 
were still significantly decreased in a+pFncKO and aFncKO as compared to littermate controls. In pFncKO 
animals, Olig2+ cell numbers did not differ from the control animals in the lesions. Furthermore, 
analysis of differentiated oligodendrocytes, determined by immunohistochemical staining for CC1 
(Bhat et al., 1996), showed that the numbers of CC1+ cells were identical in all groups (Fig. 3C). 
This was confirmed using an alternative marker of mature oligodendrocytes, in situ hybridization 
for proteolipid protein (PLP) mRNA, a major myelin protein, which revealed no differences in PLP 
mRNA+ cells (Fig. 3D,E). Therefore, despite a reduction of OPCs after demyelination in aFncKO and 
a+pFncKO, this was not sufficient to result in an impairment of oligodendrocyte generation at 14 DPL. 
To assess whether myelin sheath formation was affected, we examined toluidine blue stained 










































































































Figure 3. Oligodendrocyte diff erentiation and remyelination are not aff ected by conditional knockout of 
astrocyte fi bronectin. A-E. At 14 days post lysolecithin-induced demyelination (14 DPL) of the spinal cord ventral 
funiculus, immunohistochemistry (A-C) and in situ hybridization (D,E) were applied to determine the numbers of 
Olig2+ (A,B), CC1+ (C) and PLP mRNA+ (D,E) cells after conditional knockout of fi bronectin from plasma (pFncKO), 
astrocytes (aFncKO), or astrocytes and plasma (a+pFncKO). Note the signifi cant decrease of Olig2+ oligodendrocyte 
lineage cells after aFncKO and a+pFncKO (A,B), whereas the numbers of diff erentiating oligodendrocytes dot not 
diff er from littermate controls (CTRL) (C-E). Images in A and D are representative images of demyelinated areas in 
the diff erent groups. Insets show higher power magnifi cations of the positive cells that were counted, with the 
blue color representing DAPI staining. Outlines of demyelinated lesions were measured in Zeiss Axovision 4.8 
software based on the increase in DAPI staining inside lesions, and outlines are represented by dashed lines. Cell 
numbers were manually counted 3 times from 4 animals per group, and 3 lesions per animal, approximately 120 
µm distant from each other. Representative graphs of 2-3 independent experiments are shown. Bars represent 
means. Error bars show standard deviations. Statistical analyses were performed using one-way ANOVA, followed 
by Tukey’s Multiple Comparison Test (** < 0.01; *** < 0.001; NS: not signifi cant). Scale bars are 50 µm. F,G. At 21 
DPL, semi-thin sections of resin-embedded CTRL and a+pFncKO animals were stained with alkalin toluidin blue 
to analyze the myelin structure (F), and blindly ranked according to estimated percentage of remyelination by 
two independent researchers, after which statistical diff erences were analyzed using the Mann Whitney test (G). 
Scale bar is 100 μm. NS means ‘not signifi cant’
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any gross morphological differences between remyelinated lesions from control and a+pFncKO 
animals (Fig. 3F). Ranking analysis of the degree of remyelination (Ibanez et al., 2004) did not reveal 
significant differences between controls and a+pFncKO lesions either (Fig. 3G). Therefore, cFn from 
astrocytes, although contributing to OPC proliferation, is not essential for remyelination. 
Expression of the alternatively spliced domains EIIIA and EIIIB mRNA of cellular fibronectin is 
increased following demyelination
We next investigated the specific contribution of the alternatively spliced domains EIIIA and EIIIB, 
exclusively localized within the cFn structure (Paul et al., 1986; Schwarzbauer et al., 1987) in the 
regulation of OPC proliferation following demyelination. We first determined the expression of 
both domains following demyelination by semi-quantitative analysis of mRNA expression. Using 
primers against exons flanking the alternatively spliced domains, two bands were detected: a long 
product containing the alternatively spliced domain (used for quantification) and a short product 
lacking the alternatively spliced domain (Magnuson et al., 1991; Vitale et al., 1994) (Fig. 4A). Relative 
to unlesioned tissue, EIIIA and EIIIB mRNA levels were increased in demyelinated tissue at 5 DPL (Fig. 
4A-C), similar to our previous report for total Fn protein and Fn EIIIA protein (Stoffels et al., 2013a). 

















































 CTRL   5 DPL   14 DPL
Figure 4. Enhanced expression of fibronectin 
alternatively spliced domains EIIIA and EIIIB 
mRNA after lysolecithin-induced demyelination. 
A. Reverse transcription PCR on spinal cord RNA from 
control (CTRL) rats or at 5 days (5 DPL) or 14 days 
(14 DPL) post lysolecithin -induced demyelination, 
showing an increase in fibronectin EIIIA and EIIIB 
mRNA at 5 DPL (upper bands). Note that, whereas 
fibronectin EIIIB mRNA decreases at ongoing 
remyelination (14 DPL), upregulation of fibronectin 
EIIIA mRNA is sustained. B,C. Quantifications of A for 
EIIIA (B) and EIIIB (C) fibronectin mRNA. Relative optical 
densities were normalized against the housekeeping 
gene cyclophilin (A) for 3-4 animals per condition. 
Representative graph of a duplicate experiment 
is shown. Statistical analysis was performed using 
the Kruskal-Wallis Test, followed by Dunn’s Multiple 
Comparison Test (* p < 0.05; ** < 0.01).
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unlesioned tissue (Fig. 4A,C; 14 DPL), whereas EIIIA levels remained increased for longer (Fig. 4A,B; 
14 DPL). The high EIIIA mRNA levels at 14 DPL contrasted with the reduced levels of EIIIA protein 
as compared to 5 DPL that we previously reported (Stoffels et al., 2013a), implying translational 
regulation. Because both EIIIA and EIIIB mRNA levels are increased at 5 DPL, when OPCs are recruited, 
and since these elements are exclusively present in cFn, we next examined the extent to which cFn 
EIIIA, EIIIB or both are involved in proliferation and/or migration of OPCs.
The EIIIA domain of astrocyte-derived fibronectin promotes proliferation of oligodendrocyte 
progenitor cells, but not their migration and adhesion. 
To examine the effect of pFn and cFn on OPC proliferation, we used commercially available pFn 
from bovine plasma and cFn derived from extracellular deposits of primary astrocytes (Fig. 5A, ‘Fn’). 
The astrocyte-derived cFn preparation contained the alternatively spliced domain EIIIA (Fig. 5A, 
‘EIIIA’) and EIIIB (Fig. 5A, ‘EIIIB’), as confirmed by immunostaining with domain-specific antibodies. 
Functional blocking antibodies against EIIIA (‘IST9’, Liao et al., 1999) and EIIIB (‘C6’, Balza et al., 
2009) were used to eliminate signals from these domains. OPCs were allowed to proliferate on 
the different substrates in the presence of PDGF-AA and FGF-2 for 24 h, after which percentages 
of BrdU-incorporating Olig2+ cells were determined by immunochemistry as a measure of OPC 
proliferation. OPCs proliferated equally well on either cFn (16% ± 5% SD) or pFn (15% ± 8% SD) (Fig. 
5B). However, proliferation of OPCs was markedly reduced when the cells were cultured on cFn with 
the EIIIA domain blocked (Fig. 5B; ‘cFn+IST9’). In contrast, addition of the EIIIA blocking antibody 
to pFn did not affect OPC proliferation (Fig. 5B; ‘pFn+IST9’), indicating that the reduction in OPC 
proliferation following the blocking of EIIIA with the IST9 antibody was attributable to the specific 
effect(s) of the antibody. Moreover, blocking EIIIB from cFn (Fig. 5A; ‘EIIIB’) with the C6 antibody (Fig. 
5B; ‘cFn+C6’) did not affect OPC proliferation. To determine whether EIIIA and/or EIIIB of cFn are 
also important for OPC migration, we allowed OPCs to migrate through transwell microchambers, 
containing membranes coated with pFn or cFn on both sides, using PDGF-AA as an attractant in 
the bottom well. As shown in Fig. 5C, migration of OPCs was similar on cFn and pFn, and was not 
affected by blocking the EIIIA or EIIIB domains. These experiments demonstrate that EIIIA, but not 
EIIIB, is primarily required for proliferation of OPCs and that neither domain is essential for migration 
of OPCs on astrocyte-derived cFn. 
Proliferation of OPCs on pFn is largely mediated by the integrin receptors αvβ3 and αvβ1 (Milner 
et al., 1996; Blaschuk et al., 2000; Baron et al., 2002). Although EIIIA does not directly bind to αvβ1 
or αvβ3, it has been reported that EIIIA may indirectly promote adhesion of cFn to these integrins, 
thereby facilitating proliferation (Manabe et al., 1999). To test this possibility, we assessed whether 
adhesion of OPCs to cFn indirectly involved integrin β binding by using blocking antibodies against 
integrins β1, β3 and β5, and whether such adhesion was facilitated by functional EIIIA and EIIIB 
domains. Adhesion of OPCs to cFn was only modestly reduced when the integrins β3 (Fig. 5D; ‘cFn+ 
β3’) and β5 (Fig. 5D; ‘cFn+ β5’) were blocked, when compared to adhesion to pFn (Fig. 5D; ‘pFn+ 
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Figure 5. The EIIIA domain of astrocyte-derived fibronectin promotes proliferation of oligodendrocyte 
progenitor cells, but not their migration and adhesion. A. Astroglial matrix derived from neonatal rat 
astrocytes (cFn) immunostained for total fibronectin (‘Fn’), and the alternatively spliced EIIIA (‘EIIIA’) or EIIIB (‘EIIIB’) 
domains. Scale bar is 50 µM. B. Oligodendrocyte progenitor cells (OPCs) from neonatal rats were cultured for 24 
h on plasma fibronectin (pFn) or cFn, alone or in the presence of blocking antibodies against the EIIIA or EIIIB 
domains and subjected to a BrdU incorporation assay combined with Olig2 immuncytochemistry. On cFn, 16% 
of OPCs proliferated on average ± 5% SD. Note that addition of an EIIIA blocking antibody (‘cFn+IST9’) decreased 
the number of Olig2+ OPCs incorporating BrdU on cFn, but not on pFn (‘pFn+IST9’), and BrdU incorporation did 
not differ between the other conditions. C. OPCs were allowed to migrate through transwell inserts coated with 
cFn or pFn for 4 h, alone or in the presence of blocking antibodies against EIIIA (‘pFn+IST9’; ‘cFn+IST9’) or EIIIB 
(‘cFn+C6’) antibodies. Note that the numbers of migrated cells did not differ between the conditions. D,E. OPCs 
were allowed to adhere to pFn or cFn in the presence of blocking antibodies against integrins β1 (‘pFn+ β1’, ‘cFn+ 
β1’), β3 (‘pFn+ β3’, ‘cFn+ β3’) or β5 (‘pFn+ β5’, ‘cFn+ β5’) (D) or after blocking the EIIIA (‘cFn+IST9’) or EIIIB (‘cFn+C6’) 
(E) domains of cFn. Note that whereas integrins β3 and β5 likely mediate adhesion of OPCs, particularly to cFn 
(D), adhesion does not require a functional EIIIA or EIIIB domain on cFn (E). Bars in the graphs represent means 
of 3-4 independent experiments relative to cFn, which was set at 100% (dashed line) or pFn for the OPCs grown 
on pFn in figure 5D. Error bars show standard deviations. Statistical analyses were performed using the Kruskal-
Wallis Test, followed by Dunn’s Multiple Comparison Test (** p < 0.01; NS: not significant).
104
Chapter 3
β3’, ‘pFn+ β5’). In contrast, integrin β1 had no effect on adhesion of OPCs to both pFn and cFn (Fig. 
5D; ‘pFn+ β1’, ‘cFn+ β1’). Furthermore, functional blocking of EIIIA and EIIIB domains did not alter 
adhesion of OPCs to cFn (Fig. 5E). Thus, whereas the integrin β3 and β5 receptors likely mediate 
adhesion of OPCs to cFn, adhesion of OPCs does not require functional EIIIA or EIIIB domains of cFn. 
DISCUSSION
In this study, we investigated how Fn, derived from plasma (pFn) or cellular fibronectin (cFn) derived 
from astrocytes, modulates remyelination following CNS demyelination. After conditional knockout 
of Fn from plasma (pFncKO), astrocytes (aFncKO) or both (a+pFncKO), astrocyte-derived cFn, but not pFn, 
promotes recruitment of OPCs following demyelination. Our in vitro analyses of OPCs, cultured on 
either pFn or astrocyte-derived cFn, revealed that the alternatively spliced EIIIA domain, exclusively 
present in cFn, is instrumental in stimulating proliferation. Our data further showed that this control 
of proliferation by the EIIIA domain was likely not related to an ability of EIIIA to enhance adhesion 
of OPCs, although integrins β3 and β5 mediate adhesion of OPCs to cFn. Furthermore, we did not 
observe an effect of cFn on migration of OPCs. Despite a reduction in oligodendrocyte lineage 
cells on a+pFncKO at later stages of the remyelination process, both pFn and astrocyte cFn were not 
required for oligodendrocyte differentiation and complete remyelination. 
Although both EIIIA and EIIIB are largely absent from healthy tissue after embryonic 
development, reappearance of cFn with the alternatively spliced EIIIA and EIIIB domains occurs 
after injury of different tissue types (ffrench-Constant et al., 1989; Jarnagin et al., 1994; Nickeleit 
et al., 1996; Ulrich et al., 1997). Injury-induced expression of cFn containing EIIIA is associated with 
increased cell proliferation, as demonstrated in a variety of cell types (Manabe et al., 1999; Stenzel 
et al., 2011; Olsen et al., 2012). EIIIA could theoretically facilitate proliferation of OPCs on cFn via 
binding to the integrins α9β1 (Olsen et al., 2012; Ou et al., 2013; Sun et al., 2013) and α4β1 (Liao 
et al., 2002), or by enhancing the binding affinity of other integrin receptors for Fn, most notably 
α5β1 and αvβ3 (Manabe et al., 1999; Xia and Culp, 1995; Manabe et al., 1997). However, integrins 
α4β1 and α9β1 are not expressed by OPCs or oligodendrocytes (Milner and ffrench-Constant, 
1994) and the EIIIA domain was not important for adhesion of OPCs to cFn, implying that EIIIA 
mediates proliferation of OPCs through an alternative mechanism. This mechanism may involve 
other domains of Fn, since alternative splicing of Fn can change the conformation of Fn, affecting 
the presentation of binding sequences and exposing cryptic binding sites (Pickford and Campbell, 
2004; Ventura et al., 2010). In addition to EIIIA, expression of the EIIIB domain was also upregulated 
after demyelination. Whereas EIIIB appears not to have a role in proliferation and migration of OPCs, 
its functional involvement in processes other than proliferation and migration cannot be excluded 
and merits further investigation. 
The apparent redundancy of pFn for recruitment of OPCs observed in our in vivo studies was 
unexpected, given that stimulation of cell proliferation and migration by pFn is well documented 
for several cell types (To and Midwood, 2011; von Au et al., 2013), including OPCs (Milner et al., 
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1996; Baron et al., 2002; Hu et al., 2009). Our in vitro proliferation studies also suggested that pFn 
and cFn are equally capable of promoting OPC proliferation. After pFncKO, a compensatory increase 
in cFn may have occurred, mediated by astrocytes, microglia/macrophages and endothelial cells 
(Stoffels et al., 2013a). From these cell types, astrocytes are thought to represent the major source 
of Fn after toxin-induced demyelination (Hibbits et al., 2012; Stoffels et al., 2013a), which is further 
supported in this study, given the pronounced reduction in Fn levels after aFncKO. Therefore, a 
compensatory increase in cFn could explain the absence of a clear phenotype after pFncKO, in 
agreement with studies of other tissues (Sakai et al., 2001). However, the observation that a+pFncKO 
does not substantially amplify the reduction in OPC numbers during demyelination may support 
an alternative explanation, namely that excessive leakage of pFn to the demyelinated area does not 
occur on lysolecithin-induced demyelination, despite breakdown of the blood-brain barrier (Ford 
et al., 1990). Hence, in contrast to previous studies, in which pFn was considered a predominant 
source of the Fn matrix in tissue (Moretti et al., 2007), our findings indicate that cFn rather than pFn 
is the major component of the Fn matrix expressed after toxin-induced CNS demyelination. In MS 
lesions, where immune-mediated blood-brain barrier disruption is more diffuse, pFn may be a more 
prominent source of Fn.
Although the transient expression of cFn from astrocytes promotes recruitment of OPCs after 
remyelination, cFn is not required for remyelination. Relative redundancy of astrocyte-derived cFn, 
in spite of decreased OPC proliferation after aFncKO, is consistent with the concept that OPCs are 
normally recruited in excess relative to the numbers required for remyelination following small, focal, 
toxin-induced lesions (Franklin and ffrench-Constant, 2008; Stidworthy et al., 2004). In addition, 
functional compensation may result from the increased expression of several other ECM proteins 
in demyelinated lesions (Zhao et al., 2009). In support of this, osteopontin, another ECM molecule 
expressed after demyelination, is also redundant for remyelination (Zhao et al., 2008). In contrast 
to stimulation of OPC proliferation by astrocyte-derived cFn, which promotes recovery, persistent 
expression of Fn variants in pathology mediates failure of tissue regeneration (Stoffels et al., 2013b). 
In particular the EIIIA domain is involved in adverse remodelling after tissue injury (Muro et al., 
2008; Kohan et al., 2010; Arslan et al., 2011; Hirshoren et al., 2013). In MS lesions, Fn assembles into 
aggregates, which is likely mediated by inflammatory factors. Astrocytes are an important source of 
Fn aggregates, and these Fn aggregates contribute to remyelination failure (Stoffels et al., 2013a). 
Since our findings indicate that astrocyte-derived cFn is a non-essential element for remyelination, 
developing therapeutic approaches that remove aggregates of Fn, inhibitory to remyelination, from 
MS lesions, represent a legitimate translational objective. 
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Promoting endogenous remyelination in multiple sclerosis (MS) benefits from insights into inhibitory 
molecules that mediate remyelination failure. Fibronectin assembles into aggregates in MS, which 
impair oligodendrocyte differentiation and remyelination. Microglia and macrophages are required 
for complete remyelination, and normally switch from an M1 pro-inflammatory phenotype on 
demyelination to a supportive, M2 phenotype during remyelination. Here, we investigated effects 
of fibronectin aggregates on microglia and macrophage phenotypes. 
Bone marrow macrophages and microglia from newborn rats were exposed to a) plasma 
fibronectin coatings, b) coatings of deoxycholate-insoluble fibronectin aggregates, c) interferon-γ 
(IFN-γ) treatment, as an inducer of the M1 phenotype, d) interleukin-4 (IL-4) treatment, to promote 
the M2 phenotype, or e) were left unstimulated on uncoated plastic. In line with an M2 phenotype, 
exposure of microglia to fibronectin aggregates enhanced microglia proliferation, as was also 
observed on IL-4 treatment. However, in resemblance to IFN-γ treatment, exposure to fibronectin 
aggregates induced an amoeboid morphology of microglia and macrophages, and stimulated 
phagocytosis by macrophages. Culturing microglia and macrophages on fibronectin aggregates did 
not affect mRNA expression of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin-
1β and interleukin-12, but neither was there any effect on the expression of the anti-inflammatory 
cytokines arginase-1, CCL-2 and CCL-7. However, coatings of fibronectin aggregates, but not plasma 
fibronectin, promoted nitric oxide expression by microglia and macrophages.
In summary, macrophages and microglia grown on aggregated fibronectin showed a distinct 
phenotype with several pro-inflammatory features, including enhanced levels of nitric oxide. 
Therefore, persistent expression of fibronectin aggregates in MS lesions may maintain features of 
the M1 phenotype in microglia and macrophages, thereby possibly impairing remyelination.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic central nervous system (CNS) disease, of which inflammation, 
demyelination and neurodegeneration are major pathological features (Trapp et al. 1998, Barnett, 
Prineas 2004, Lassmann, Bruck & Lucchinetti 2007). Myelin regeneration (remyelination) by 
oligodendrocyte progenitor cells (OPCs) (Zawadzka et al. 2010) is apparent in early stages of MS 
(Patrikios et al. 2006). However, remyelination fails in chronic demyelinated lesions despite a relative 
excess of OPCs in the majority of MS lesions (Wolswijk 1998, Wolswijk 2002, Kuhlmann et al. 2008). 
Chronic demyelination correlates to neurological disability in MS (Trapp, Ransohoff & Rudick 1999). 
Hence, promoting endogenous remyelination is an attractive therapeutic strategy for structural 
recovery of MS lesions that will benefit from insights into mechanisms of remyelination failure.
Innate immune activity is an important feature of MS, as signified by activation of resident 
microglia and invasion of macrophages from the circulation through the disrupted blood-brain 
barrier (Bruck et al. 1995, Carson 2002). Effector functions of microglia and invaded macrophages 
depend on their phenotype, of which two major categories can be discerned. First, the pro-
inflammatory phenotype M1 is characterized by secretion of reactive oxygen species and pro-
inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-12. The 
M1 phenotype is induced in vitro by stimulation with interferon-γ (IFN-γ) or lipopolysaccharide (LPS). 
Conversely, the alternatively activated M2 phenotype involves predominantly anti-inflammatory 
properties, including expression of arginase-1, CC chemokine ligand (CCL)-2, CCL-7, the mannose 
receptor, and growth factors such as insulin-like growth factor-1 (IGF-1) and platelet-derived growth 
factor (PDGF) (M2a, M2c) (Gordon 2003, Martinez, Helming & Gordon 2009). The M2 phenotype 
results from stimulation with interleukin-4 (IL-4) or IL-13. Although the M1/M2 concept was originally 
defined for macrophages, microglia are capable of adopting similar phenotypes (Durafourt et al. 
2012). After demyelination, microglia and macrophages acquire a predominantly pro-inflammatory 
M1 phenotype, which leads to an increase of phagocytosis as well as expression of, among others, 
TNF-α, IL-1β and inducible nitric oxide synthetase (iNOS). During later stages of remyelination, 
however, oligodendrocyte differentiation benefits from a switch to the M2 phenotype, characterized 
by expression of arginase-1 and the mannose receptor (Olah et al. 2012, Voss et al. 2012, Miron et 
al. 2013). Signals from the micro-environment largely determine the phenotype of microglia and 
macrophages (Zhang, Mosser 2008).
Demyelination alters the expression of extracellular matrix (ECM) molecules (van Horssen, 
Dijkstra & de Vries 2007, Zhao et al. 2009), such as the glycoprotein fibronectin (Fn). Fn is transiently 
expressed as a dimer in demyelinated lesions (Zhao et al. 2009, Stoffels et al. 2013), resulting from 
plasma leakage across the blood brain barrier (Sobel, Mitchell 1989, van Horssen et al. 2005), and 
synthesis by local cells, including astrocytes (Stoffels et al. 2013, Hibbits et al. 2012). However, 
in MS lesions, Fn assembles into stable aggregates (aFn), which is likely mediated by ongoing 
inflammation, and aFn impairs oligodendrocyte differentiation and remyelination (Stoffels et 
al. 2013). Current evidence suggests that soluble dimeric plasma Fn (pFn) promotes several pro-
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inflammatory functions of microglia (Milner, Campbell 2003, Milner et al. 2007, Goos et al. 2007, 
Ribes et al. 2010, Summers, Kielty & Pinteaux 2009). Given that remyelination likely benefits from a 
switch between a pro-inflammatory, M1 phenotype of microglia/macrophages on demyelination, 
to a M2 phenotype at later stages of remyelination (Miron et al. 2013), we investigated here how 
aFn affects microglia and macrophage phenotypes. Our data reveal that deposited fibronectin 
aggregates induce a distinct phenotype of microglia and bone marrow macrophages, supporting 
several pro-inflammatory features such as an amoeboid morphology and NO production. In this 
way, by sustaining distinct pro-inflammatory features of microglia and macrophages, aFn may 
further contribute to remyelination failure in MS.
MATERIAL AND METHODS
Cell culture
Microglia. Mixed glial cultures were derived from the cerebrum of newborn Wistar rats (P0-P2, 
Harlan, NL) and cultured in T75 flasks (Nunc, Naperville, IL) in Dulbecco’s modified Eagle medium 
(DMEM; Gibco, Paisley, UK) containing 10% fetal-calf serum (FCS, Bodinco, Alkmaar, NL) and 
antibiotics (Life Technologies, Paisly, UK) for 10-12 days as described (McCarthy, de Vellis 1980, Bsibsi 
et al. 2012). To obtain shake-off microglia, flasks were mechanically shaken on an orbital shaker for 
1 h at 150 rpm, after which the supernatant was centrifuged for 10 min at 1000 rpm. Cell pellets 
were resuspended in microglia medium (DMEM (Gibco) containing 10% Fn-free FCS (see below), 
antibiotics (Life Technologies) and rat recombinant macrophage colony-stimulating factor (M-CSF; 
0.01 μg/ml, Peprotech, Rocky Hill, NJ) to ensure maturation of the immature neonatal microglia 
(Santambrogio et al. 2001). Shake-off microglia were cultured for 4 days at 37°C on 10 cm dishes 
(1,5-2.0 x 106 cells/dish, Corning, Lowell, MA). Subsequently, mixed glial culture flasks were shaken 
overnight at 240 rpm, 37°C and floating OPCs were purified by differential adhesion on 10 cm dishes 
(Greiner Bio One, Alphen aan den Rijn, NL), with the cells adhering to the bottom of the dish being 
in vast majority microglia. These differential adhesion microglia were cultured in microglia medium 
for 3 days at 37°C. Both microglia cultures, obtained from shake-off and differential adhesion, were 
pooled at the start of the experiments. At this stage, microglia cultures were typically > 95% pure, 
with approximately 4% astrocytes and >1% oligodendrocyte lineage cells as assessed by cell specific 
immunocytochemistry (see below) for ionized calcium-binding adaptor molecule-1 (Iba1; Abcam, 
Cambridge, UK), aldehyde dehydrogenase 1, member L1 (Aldh1L1; Neuromab, Davis, CA) and Olig2 
(Millipore, Billerica, MA) respectively. 
Astrocytes. To acquire purified astrocyte cultures, the remaining astrocyte monolayer of the 
mixed glial culture flasks was trypsinized and passaged once before experimental use (Bsibsi et 
al. 2012). Regular immunocytochemistry for glial fibrillary acidic protein (GFAP; Millipore) was 
performed as described below to assure sufficient purity of the astrocyte cultures (>97%). 
Macrophages. To obtain bone marrow macrophages, hind legs of newborn Wistar rats (P0-P2, 
Harlan) were dissected and the bone marrow cavity of femur and tibia flushed with macrophage 
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medium, containing Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco), 10% Fn-free FCS 
(see below), 1% sodium pyruvate (Gibco), 0.05 M beta-mercaptoethanol (Sigma-Aldrich, St. Louis, 
MO) and antibiotics (Life Technologies). After centrifuging suspensions for 10 min at 1000 rpm, 
pellets were resuspended in BMM medium containing M-CSF (0.01μg/ml; Peprotech) to differentiate 
myeloid progenitor cells towards macrophages (Martinez et al. 2006). Macrophages were incubated 
for 7-8 days at 37°C on 10 cm dishes (2.0 x 106 cells/dish) (Boltz-Nitulescu et al. 1987, Davis 2013). 
Typical BMM cultures contained > 95% macrophages, as assessed by immunocytochemistry (see 
below) for isolectin-B4 (IB4; Invitrogen, Breda, NL).
Stimulations. At the start of experiments, microglia or macrophages were gently scraped in 
appropriate medium without M-CSF, and plated for experiments on 24-well plates (Nunc; 50.000/
well in 500 µL of appropriate medium for 24 h), 8-well Permanox chamber-slides (Nunc; 30.000/well 
in 400 µL of appropriate medium for 24 h, except NO assays: 100.000/well in 300 µL of appropriate 
medium for 24 h), or 6-well plates (Corning, 1.0 106/well in 2000 µL for 6 h). Wells were pre-coated 
with pFn or aFn (see below), and after 1 h at 37°C, cells in uncoated wells were stimulated with 
either rat recombinant IFN-γ (5 U/μl, Peprotech), rat recombinant IL-4 (10 μg/ml, Peprotech) or left 
unstimulated.
Deoxycholate-insoluble fibronectin aggregates 
Deoxycholate (DOC)-insoluble aFn was prepared from primary rat astrocytes (Stoffels et al. 
2013). Astrocytes were cultured on 10 cm dishes (1.0 x106 cells/dish; Corning) in DMEM (Gibco) 
containing 10% heat-inactivated FCS (Bodinco) and antibiotics (Life Technologies), stimulated 
with polyinosinic:polycytidylic acid (pI:pC, 50 µg/mL, GE Healthcare, Freiburg, Germany) for 2 
days at 37ºC to induce aggregation. After removal of astrocytes by water-lysis for 2 h at 37ºC, the 
remaining deposited astroglial matrices were scraped in ice-cold 2% DOC buffer (2% deoxycholate 
and Complete Mini protease inhibitor cocktail (Roche, Mannheim, Germany) in 20 mM Tris-HCl, pH 
8.0) and further solubilized for 30 min on ice. To separate DOC-insoluble aFn from the suspension, 
centrifugion was performed for 30 min at 13300 rpm. Pellets were washed three times in phosphate 
buffer saline (PBS) followed by resuspension in PBS using a syringe and 25 gauge needle. As a 
result, a solution of DOC-insoluble proteins was obtained from the astroglial matrix, containing 
predominantly aFn, and lacking other extracellular matrix glycoproteins, such as laminin, because 
these are not DOC-insoluble (Stoffels et al. 2013). The protein concentration was determined by 
Bradford’s protein assay (BioRad, Hercules, CA) using bovine serum albumin (BSA) as a standard. 
To confirm the presence of aggregated Fn and the absence of dimeric Fn, Western Blot analysis on 
aFn preparations was routinely performed as described (Stoffels et al. 2013) To coat wells, either 
bovine pFn (Sigma-Aldrich) or DOC-insoluble aFn were applied for 3 h at 37°C, using 5 µg on 8-well 




To eliminate Fn from FCS (Bodinco), a Gelatin Sepharose 4B column (GE Healthcare) was used 
according to the manufacturer’s instructions. Resulting Fn-free serum was filter-sterilized for cell 
culture using 0.2 μM Whatman filters (GE Healthcare) and stored at -20°C until use. The virtual 
absence of Fn from the filtered serum and presence of Fn in the eluate was confirmed using Western 
blot analysis (data not shown).
BrdU incorporation assay
Microglia or macrophages were allowed to incorporate 5-bromo-2-deoxyuridine (BrdU) (10 µM, 
Roche) for 24 h. Cells were fixed in 4% paraformaldehyde (PFA) for 20 min, and additionally fixed 
in 5% acetic acid in ethanol for 20 min. BrdU was detected using reagents from the BrdU Labelling 
and Detection Kit I (Roche) according to the manufacturer’s instructions with the addition of 
Iba1 (Abcam; 1:500) and Alexa Fluor© 546-conjugated anti-rabbit antibody (Invitrogen; 1:500) for 
microglia or Alexa Fluor© 546-conjugated IB4 (Invitrogen; 1:500) for macrophages, and visualization 
of nuclei with DAPI (Sigma, 1 µg/mL). The numbers of BrdU-positive nuclei were blindly counted 
relative to the Iba1- or IB4+-positive cells (at least 150 cells per condition) from images captured 
with a Leica TCS SP8 Confocal Laser Scanning Microscope.
Immunocytochemistry
Microglia or macrophages were fixed with 4% PFA for 20 min. After 30 min of blocking with 4% BSA 
in PBS containing 0.1% Triton (Sigma-Aldrich), cells were incubated for 1 h with primary antibodies 
in 4% BSA. Primary antibodies used were against Iba1 (Abcam; 1:500), Olig2 (Millipore; 1:1000), 
Aldh1L1 (NeuroMab; 1:50), GFAP (Millipore; 1:500) or Alexa Fluor© 546-conjugated IB4 (Invitrogen; 
1:500). Cells were washed three times with PBS and incubated for 25 min with appropriate Alexa 
Fluor©-conjugated secondary antibodies (Invitrogen; 1:500). Nuclei were stained with DAPI (1 mg/
ml), and fluorescence mounting medium (Dako, Heverlee, Belgium) was added to prevent image 
fading. Images were analyzed using an Olympus Provis AX70 fluorescent microscope (Olympus, 
New Hyde Park, NY) or a Leica TCS SP8 Confocal Laser Scanning Microscope. For morphology 
analysis, the morphology of each cell was scored as being ‘ramified’, ‘amoeboid’ or ‘other’. Microglia 
or macrophages were considered ‘ramified’ if the shape was elongated with processes, ‘amoeboid’ 
if swollen with few processes, and ‘other’ if the shape could not be classified as either ‘ramified’ or 
‘amoeboid’.  
Real-time, quantitative polymerase chain reaction (real-time qPCR)
Microglia or macrophages were cultured for 6 h, after which total RNA was extracted using the 
RNeasy Micro Kit (Qiagen, Hamburg, Germany) according to the manufacturer’s instructions. 500 
ng of RNA was reversely transcribed using oligo (dT)12-18 (500 μg/ml), 10 mM dNTP Mix, 0.1 M 
dithiothreitol (DTT), 5x first strand buffer and Moloney Murine Leukemia Virus Reverse Transcriptase 
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(M-MLV RT) (all from Invitrogen). 
Real-time qPCR was performed using the Applied Biosystems 7900HT Real-Time PCR System. 
Each reaction contained 5 ng cDNA, 10 pM primers (listed in table 1) and ABsolute SYBR Green 
Rox mix (Thermo Scientific, Landsmeer, NL). No-template controls were performed to ensure that 
amplification was not a result of contamination with genomic DNA. Gene expression levels were 
analyzed using the 2-ΔΔct method (Livak, Schmittgen 2001), with normalization against HMBS or 
GAPDH. Similar results were obtained for both housekeeping genes; graphs shown means from 
normalization against HMBS. 
Phagocytosis assay
Microglia or macrophages were cultured for 24 h, after which fluorescein isothiocyanate (FITC) 
labeled latex beads (1μm, Polyscience, Eppelheim, Germany) were added at a dilution of 10:1 
beads:cells. Phagocytosis of the beads was allowed to proceed for 1 h, after which cells were fixed in 
4% PFA. Cells were incubated with DAPI (1 µg/ml) and Alexa Fluor 568-conjugated IB4 (Invitrogen; 
1:500) in 4% BSA for 2 h, washed in PBS and mounted using FluorSave (Calbiochem Millipore, 
Amsterdam, NL). In a blinded manner, the numbers of phagocytosed beads per cell were counted 
for 100 cells per condition, taking also into account their morphology, using an Olympus Provis 
AX70 fluorescent microscope (Olympus, New Hyde Park, NY).











Microglia or macrophages were cultured for 24 h, after which the medium was collected. The 
medium was briefly centrifuged for 5 min at 1200 rpm to eliminate cells from the medium. Then, 
medium was added to a reagent of 0.01% N-(1-Naphthyl)-ethylenediamine dihydrochloride (Fluka 
Analytical, Sigma-Aldrich) and 0.001% sulfanilamide (Sigma-Aldrich) in 2M HCl. The absorbance 
was measured at 550 nm and the NO concentration determined using a standard curve of sodium 




Lactate dehydrogenase and MTT assay
To determine the cytotoxicity of DOC-insoluble fibronectin aggregates, microglia or macrophages 
were cultured in 24-wells plates (Corning) on different concentrations of aFn (2 µg, 5 µg or 10 µg), 
while cells cultured on uncoated plastic were used as control, and wells kept with only culture 
medium were used for background subtraction  All conditions were prepared in triplicate. After 
24 h, the medium (lactate dehydrogenase (LDH) assay) and cells [3- (4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; MTT assay] were analyzed as described (Stoffels et al. 2013). Briefly, the 
release of LDH into the medium was measured using a commercial LDH assay kit (Roche) according 
to manufacturer’s instructions. The effect on cell viability was determined with an MTT assay, for 
which cells were incubated with MTT diluted in culture medium (0.5 mg/ml, Sigma-Aldrich) for 4 h. 
MTT-formazan crystals were collected in dimethyl sulphoxide and absorption was measured at 560 
nm. 
Statistical analysis
Data were analyzed using SPSS and GraphPad Prism (GraphPad Inc, California, CA) and are reported 
as mean ± standard error of the mean (S.E.M.) of 2-5 experiments. Results of the proliferation, 
morphology, real-time qPCR, LDH and MTT analyses are presented as a relative to the unstimulated 
cells (US, set to 100% in each independent experiment). For categorical variables (BrdU proliferation 
assay, morphology), logistic regression was performed to compare proportions between the 
different conditions. Other data with continuous variables were tested for normality using the 
Kolmogorov-Smirnov normality tests. Since distributions of these data sets were incompatible with 
a normal distribution, the Kruskal-Wallis test was performed to compare means of all conditions in 
these experiments (real-time qPCR, phagocytosis assay, NO expression, LDH and MTT assays). For all 
analyses, p-values below 0.05 were considered statistically significant.
RESULTS
Fibronectin aggregates and plasma fibronectin promote proliferation of microglia, but not of 
bone marrow macrophages
During CNS demyelination, microglia and infiltrating macrophages increase their numbers by 
proliferation (Remington et al. 2007), thereby presumably maximizing their effector functions. In 
addition, ECM proteins, such as pFn and vitronectin, are upregulated in demyelinated lesions (Zhao 
et al. 2009, Stoffels et al. 2013, Sobel, Mitchell 1989, van Horssen et al. 2005, Hibbits et al. 2012, Satoh, 
Tabunoki & Yamamura 2009), and provide signals to enhance proliferation of microglia via integrin 
β1 (Nasu-Tada, Koizumi & Inoue 2005). To assess whether aFn, which is typically present in MS 
lesions (Stoffels et al. 2013), also contributes to such an expansion, we analyzed the effect of coated 
aFn and pFn substrates on proliferation of microglia and macrophages, using a BrdU incorporation 
assay. To this end, microglia or bone marrow macrophages, both derived from neonatal rats, were 
cultured on either uncoated wells, pFn or aFn. This approach revealed that of Iba1-positive microglia 
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left unstimulated, on average 10 ± 1% incorporated BrdU. However, as shown in Fig. 1A, proliferation 
of microglia increased by approximately 2-fold when cultured on both pFn and aFn coatings. 
Importantly, to eliminate a potential contribution of pFn normally present in serum, microglia and 
bone marrow macrophages were cultured in Fn-depleted serum at all conditions. Furthermore, to 
represent the M1 and M2 phenotypes, cells were also stimulated with IFN-γ or IL-4, respectively 
(Gordon 2003). For microglia, IL-4 induced a significant increase in proliferation (approximately 2.5-
fold), in line with previous observations (Suzumura et al. 1994), whereas IFN-γ hardly, if at all altered 
proliferation (Fig. 1A). 
Proliferation of IB4-positive macrophages was prominent and 20% ± 4% of the unstimulated cells 
incorporated BrdU (US, Fig. 1B). When the cells were grown on pFn or aFn coatings, proliferation of 
the macrophages was not markedly altered relative to unstimulated cells (Fig. 1B), in contrast to the 
substantial increase in proliferation of microglia (Fig. 1A). In addition, IL-4 did not alter proliferation 
of macrophages compared to US, whereas IFN-γ significantly reduced their proliferation (Fig. 
























































Figure 1. Fibronectin aggregates and plasma fibronectin promote proliferation of microglia, but not 
bone marrow macrophages.
A,B. Microglia (A) or bone marrow macrophages (B) were left unstimulated (US), cultured on plasma fibronectin 
(pFn) or fibronectin aggregates (aFn), or treated with interferon-γ (IFN-γ; 5 U/μl) or interleukin-4 (IL-4; 10 μg/ml). 
Subsequently, proliferation was determined by allowing the cells to incorporate BrdU for 24 h. BrdU-positive 
cells that also expressed Iba1 (microglia) or isolectin-B4 (macrophages) were counted. Compared to US microglia 
(10 ± 1% S.E.M.), proliferation was enhanced by culturing microglia on pFn and aFn substrates, resembling 
observation on IL-4 treatment. Conversely, compared to US macrophages (20 ± 4%, S.E.M, proliferation of 
macrophages on pFn and aFn coatings was not significantly affected.  Bars represent mean percentages of cells 
incorporating BrdU, relative to US (set at 100%) from 3 independent experiments. Error bars show standard 
errors of the mean. Statistical analyses were performed using logistic regression for each experiment separately, 
representative statistical outcomes are summarized in the graph (* p < 0.05).
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(Kreutzberg 1996, Vereyken et al. 2011), we next analyzed whether aFn similarly aff ects microglia 
and macrophage morphology. 
Fibronectin aggregates and plasma fi bronectin shift microglia and bone marrow macrophage 
morphologies towards amoeboid
M1 activated microglia and macrophages are characterized by a fl at and rounded amoeboid 
morphology (Fig. 2A), whereas M2 polarized cells are predominantly ramifi ed with elongated 
extensions (Fig. 2B) (Milner, Campbell 2003, Vereyken et al. 2011). To investigate whether aFn 
induces a morphology consistent with either phenotype, we performed immunocytochemistry 






















































































































































Figure 2. Fibronectin aggregates and plasma fi bronectin shift microglia and bone marrow macrophage 
morphologies towards amoeboid. 
A-F. Microglia (A,B,C,D) or bone marrow macrophages (E,F) were left unstimulated (US), cultured on plasma 
fi bronectin (pFn) or fi bronectin aggregates (aFn), or treated with interferon-γ (IFN-γ; 5 U/μl) or interleukin-4 (IL-
4; 10 μg/ml). After 24 h, microglia (A,B,C,E) or macrophages (D,E) were immunostained with isolectin-B4, and 
morphologies of 100 cells per condition were scored as ‘amoeboid’ (A), ‘ramifi ed’(B) or ‘other’, with examples 
of US microglia shown in A and B. Dashed lines represent values of US cells set at 100% for each independent 
experiment. Note that the proportion of microglia and macrophages with an amoeboid morphology was 
promoted by IFN-γ treatment, pFn or aFn coatings relative to US cells (C-F). Bars represent mean values of each 
condition relative to US cells from 4 independent experiments. Error bars show the standard error of the mean. 
Statistical analyses were performed using logistic regression for each experiment separately, and representative 
statistical outcomes are summarized in the graph (* p < 0.05). Scale bar is 10 µm.
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‘amoeboid’ (Fig. 2A), ‘ramified’ (Fig. 2B), or ‘other’. The data revealed that both unstimulated microglia 
and macrophages predominantly displayed an amoeboid morphology. Hence, in unstimulated 
microglia, the relative contributions to the various morphological features were 55 ± 10% amoeboid, 
30 ± 9% ramified and 15 ± 5% ‘other’. In unstimulated macrophages, relative contributions were 
51 ± 8% amoeboid, 31 ± 6% ramified and 18 ± 4% ‘other’. These findings are in line with previous 
observations, which also revealed that culture conditions, and specifically culture serum, slightly 
activate microglia and macrophages towards the M1 phenotype (Adams et al. 2007, Ransohoff, 
Perry 2009). Following culture of the cells on pFn and aFn coatings, a significant increase, relative 
to unstimulated cells, was observed in the fraction of both microglia and macrophages displaying 
an amoeboid morphology, an effect similar to IFN-γ treatment (Fig. 2C-F). Simultaneously, the 
proportion of ramified microglia and macrophages decreased on pFn or aFn substrates, as well 
as following IFN-γ treatment (Fig. 2C-F). In contrast, and rather unexpectly (Wirjatijasa et al. 2002), 
exposure to IL-4 did not significantly change the morphology of microglia and macrophages relative 
to unstimulated cells (Fig. 2C-F). Importantly, the relative fractions of microglia and macrophages 
classified as being of ‘other’ morphology did not differ between all of the conditions examined 
(data not shown). Therefore, pFn and aFn shift the morphology of microglia and macrophages 
towards amoeboid, in line with the M1 phenotype. To further define the phenotype of microglia 
and macrophages, triggered on exposure to aFn, we next analyzed cytokine and chemokine mRNA 
levels, indicative of either M1 or M2. 
Fibronectin aggregates and plasma fibronectin do not alter cytokine and chemokine gene 
expression representative for M1 or M2 by microglia and bone marrow macrophages 
A typical feature of the M1 phenotype is the expression of pro-inflammatory cytokines, whereas 
M2 polarization generally induces the expression of anti-inflammatory factors (Gordon 2003). Here, 
we examined gene expression of TNF-α, IL-1β and IL-12 as representatives of the M1 phenotype. To 
mark anti-inflammatory M2 polarization, we analyzed mRNA levels of arginase-1, CCL-2 and CCL-7 
(Gordon 2003, Martinez, Helming & Gordon 2009). Culturing microglia on either pFn or aFn did not 
change the expression of pro-inflammatory cytokines compared to unstimulated microglia (Fig. 3A). 
Surprisingly, pro-inflammatory cytokine gene expression was also not induced after IFN-γ exposure 
(Fig. 3A), in spite of the amoeboid morphology that was promoted at these same conditions (Fig. 
2C,E). Anti-inflammatory gene expression was not enhanced by culturing microglia on pFn, whereas 
on aFn, CCL-7 expression was slightly increased (Fig. 3B). Further, IL-4 treatment markedly enhanced 
anti-inflammatory gene expression, most notably for arginase-1 and CCL-7 (Fig. 3B). In resemblance 
to the observations of microglia, culturing macrophages on pFn and aFn did also not induce a clear 
expression of either M1 or M2 cytokine gene signature (Fig. 3C,D). Rather, exposure to IFN-γ slightly 
upregulated the pro-inflammatory cytokine genes TNF-α and IL-12 (Fig. 3C), whereas IL-4 enhanced 
expression of arginase-1 and CCL-7 genes (Fig. 3D). Thus far, our descriptive analyses of morphology 
and mRNA signatures suggest a pro-inflammatory phenotype of either cell type on pFn and 
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aFn, albeit without potent cytokine expression corresponding to M1. We therefore subsequently 
investigated functional properties of microglia and macrophages, grown on aFn coatings. 
Fibronectin aggregates and plasma fibronectin selectively affect phagocytosis in microglia 
versus bone marrow macrophages 
Phagocytosis by microglia and macrophages can be triggered by αvβ1 integrin-mediated signaling 
(Dupuy, Caron 2008, Ballana et al. 2011, Welser-Alves et al. 2011), with the integrin being a receptor 
for Fn. Here, we analyzed phagocytosis by measuring the numbers of fluorescently-labeled latex 
beads of 1 µm in diameter that were ingested over a period of 1 h by cells of either cell type (Chow, 































































































































































































































Figure 3. Fibronectin aggregates and plasma fibronectin do not alter cytokine and chemokine gene 
expression, representative of M1 or M2 phenotypes, in microglia and bone marrow macrophages.
A-D. Microglia (A,B) or bone marrow macrophages (C,D) were left unstimulated (US), cultured on plasma 
fibronectin (pFn) or fibronectin aggregates (aFn), or treated with interferon-γ (IFN-γ; 5 U/μl) or interleukin-4 
(IL-4; 10 μg/ml) for 6 h, after which total RNA was extracted. Cytokine and chemokine gene expression levels 
were analyzed using quantitative real-time PCR against pro-inflammatory markers for the M1 phenotype (tumor 
necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-12 (IL-12)) (A, C) and anti-inflammatory markers 
for the M2 phenotype (arginase-1 (Arg-1), CCL-2 and CCL-7) (B, D) against HMBS (shown) and GAPDH (not 
shown, but yielding comparable findings). Bars represent mean expression levels versus US (set at 1 for each 
independent experiment) from 3 independent experiments, error bars show the standard error of the mean. 
Statistical analyses were performed using the Kruskal-Wallis test, followed by Dunn’s Multiple Comparison Test, 
and did not reveal significant differences.
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microglia amounted to 12 ± 1 beads/h. Culturing microglia on pFn or aFn did not markedly alter 
their phagocytotic activity (Fig. 4A). However, exposure of the microglia to IFN-γ or IL-4 reduced 
phagocytic activity of the cells by approximately 2-fold, showing a remaining ingestion activity of 5 
± 1 beads/h in both conditions (Fig. 4A). 
Preliminary experiments further revealed that macrophages similarly displayed phagocytic 
activity, but these cells were less active in performing phagocytosis than microglia. Unstimulated 
macrophages ingested 4 beads/h (Fig. 4B), as compared to 10 beads/h by microglia (Fig. 4A). 
However, in contrast to microglia, phagocytotic activity of macrophages increased when the cells 
were cultured on pFn and aFn, or exposed to IFN-γ treatment. Similar to observations of microglia, 
exposure to IL-4 significantly reduced phagocytosis by macrophages (Fig. 4B). 
Phagocytosis is considered a feature of M1-polarized microglia/ macrophages (Mosley, Cuzner 
1996). Therefore, an enhanced uptake of beads may reflect the predominance of an amoeboid 
morphology. Indeed, on morphologically classifying each phagocytosing cell, a predominant 



















































US IFN-γ IL-4 pFn aFn
*
***
Figure 4. Fibronectin aggregates and plasma fibronectin promote phagocytosis by bone marrow 
macrophages, but not by microglia. 
A,B. Microglia (A) or bone marrow macrophages (B) were left unstimulated (US), cultured on plasma fibronectin 
(pFn) or fibronectin aggregates (aFn), or treated with interferon-γ (IFN-γ; 5 U/μl) or interleukin-4 (IL-4; 10 μg/
ml). Then, microglia and macrophages were allowed to phagocytose fluorescently-labeled latex beads for 1 
h. The numbers of ingested beads were counted in isolectin-B4-positive cells. Bars represent mean numbers 
of phagocytosed beads. Error bars show the standard error of the mean. Representative graphs of duplicate 
experiments are shown. Statistical analyses were performed using the Kruskal-Wallis test, followed by Dunn’s 
Multiple Comparison Test (* p < 0.05; ** < 0.01; *** < 0.001).
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and macrophages, respectively. However, the numbers of beads phagocytosed per cell by amoeboid 
microglia did not significantly differ from the numbers of beads phagocytosed per cell by microglia 
of ramified or intermediate morphologies (Kruskal-Wallis test). In contrast, ramified macrophages 
phagocytosed significantly less beads on average than macrophages of amoeboid or intermediate 
morphologies (p < 0,01; Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test). Between 
the different conditions, however, the numbers of beads phagocytosed by ramified macrophages 
were similar to the numbers indicated above for each condition (Fig. 4B), when morphology was 
not taken into account. Therefore, differences in numbers of beads phagocytosed by microglia or 
macrophages do not merely signify dynamic changes that are reflected by their morphology. These 
results indicate that, in contrast to treatment with IFN-γ and IL-4, culturing microglia on aFn or pFn 
substrates does not markedly reduce phagocytosis. In addition, our preliminary data indicate that 
phagocytosis by bone marrow macrophages is promoted when the cells are grown on pFn and aFn 
coatings, in accordance with findings on IFN-γ treatment. 
Fibronectin aggregates, but not plasma fibronectin, promote nitric oxide release by microglia 
and bone marrow macrophages
Because synthesis of reactive oxygen species is another important pro-inflammatory characteristic 
of microglia and macrophages (Gordon 2003) with relevance for MS (Smith, Lassmann 2002), 
we next examined NO release in the culture medium at 24 h after the different treatments. This 
approach revealed that whereas unstimulated microglia released little NO, culturing microglia on 
aFn tends to enhance NO levels in the medium (Fig. 5A). Similarly, IFN-γ treatment reproducibly 
increased NO release by microglia, and this enhancement was more prominent than when the cells 
were cultured on aFn coatings (Fig. 5A). Remarkably, culturing microglia on pFn did not enhance NO 
release as compared to unstimulated microglia (Fig. 5A). 
For macrophages, NO levels in the culture medium displayed a very similar trend in response 
to the various conditions as those observed for microglia. A reproducible increase in NO release 
was triggered in macrophages grown on aFn, but not pFn coatings, while an approximate 4.5-fold 
increase in NO release was measured on exposure to IFN-γ (Fig. 5B). It should be noted that although 
unstimulated microglia and macrophages secreted fairly similar amounts of NO, in an absolute 
sense macrophages displayed an approximately 2.5-fold higher NO production on aFn coatings and 
after IFN-γ treatment (Fig. 5A,B). 
To exclude the possibility that NO release by microglia and macrophages on aFn coatings 
may be a consequence of a cytotoxic effect induced by aFn, we performed LDH and MTT assays 
at different concentrations of aFn for both cell types. As shown in supplementary Fig. 1A and 1C, 
we found that LDH release by unstimulated microglia (0.50 mU/mL ± 0.05) and macrophages (1.1 
mU/mL ± 0.25) did not differ from LDH release by cells of either type grown on aFn coatings. Also, 
microglia viability, as measured by MTT reduction, was comparable to the viability of unstimulated 
cells (supplementary Fig. 1B). Although viability of macrophages was slightly affected on aFn 
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(supplementary Fig. 1D), this reduction was not significant. Hence, aFn coatings do not induce 
significant cytotoxicity of microglia and macrophages, consistent with previous findings for OPCs 
(Stoffels et al. 2013). Therefore, these results indicate that aFn coatings promote a physiological 
relevant release of NO by microglia and macrophages. 
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Figure 5. Fibronectin aggregates, but not plasma fibronectin, promote nitric oxide release by microglia 
and bone marrow macrophages.
A,B. Microglia (A) or bone marrow macrophages (B) were left unstimulated (US), cultured on plasma fibronectin 
(pFn) or fibronectin aggregates (aFn), or treated with interferon-γ (IFN-γ) or interleukin-4 (IL-4). Then, nitric oxide 
(NO) levels in the culture medium were analyzed as described in ‘Materals and Methods’. Note that IL-4 reduced 
NO expression of microglia (A) and macrophages (B) relative to US cells, whereas IFN-γ and aFn enhanced NO 
synthesis. Bars represent mean NO concentrations for microglia (A) and macrophages (B) from 3 independent 
experiments, error bars show the standard error of the mean. Statistical analyses were performed using the 
Kruskal-Wallis test, followed by Dunn’s Multiple Comparison Test (* p < 0.05).
DISCUSSION
In this study, we characterized microglia and macrophage phenotypes on coatings of Fn, an ECM 
protein that aggregates in MS lesions, thereby inhibiting remyelination (Stoffels et al. 2013). Our data 
revealed that pFn and aFn coatings enhanced proliferation of microglia, but did not significantly 
affect proliferation of bone marrow macrophages. Furthermore, both microglia and macrophages 
displayed a predominantly amoeboid morphology on pFn and aFn coatings. However, relative to 
unstimulated cells, these conditions did not lead to an induced expression of pro-inflammatory 
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or anti-inflammatory chemokine and cytokine genes. Rather, a slight but significant increase in 
phagocytosis by macrophages was observed when grown on pFn and aFn coatings. Moreover, 
in both microglia and macrophages, NO levels were enhanced on aFn, but not pFn substrates. 
Therefore, our data indicate that aFn promotes a distinct phenotype of microglia and macrophages 
with pro-inflammatory features. 
Several microglia and macrophage inflammatory features were induced to a similar extent by 
both pFn and aFn, including a predominantly amoeboid morphology of macrophages, increased 
proliferation of microglia and enhanced phagocytosis by macrophages. Therefore, aggregation of 
Fn, which results from strong, non-covalent protein-protein interactions and is defined by DOC-
insolubility (Ohashi, Erickson 2009), may represent  a continuous state of pFn signaling, thereby 
activating several properties of microglia and macrophages. However, the aFn matrix also induced an 
additional effect compared to pFn, in that aFn enhanced NO release by microglia and macrophages. 
Possibly, this effect may be related to the potential presence of cellular Fn in aFn, which contains 
the alternatively spliced EIIIA and EIIIB domains that are absent from plasma derived pFn (Paul et al. 
1986). The EIIIA domain is a ligand for the α9β1 receptor, and activation of this receptor promotes NO 
production in a human colon adenocarcinoma cell line (Gupta, Vlahakis 2009), indicating a possible 
mechanism for the aFn-mediated increase in NO levels. In previous studies, it has been reported 
that soluble pFn may also promote NO synthesis (Goos et al. 2007) as well as synthesis of pro-
inflammatory cytokines, such as TNF-α (Goos et al. 2007, Ribes et al. 2010). Our seemingly opposing 
findings, which revealed that pFn coatings do not promote NO release and that both pFn and aFn 
coatings do not induce mRNA expression of pro-inflammatory cytokines, can likely be attributed 
to the different signaling properties of Fn coatings as opposed to those of soluble Fn. Immobilized 
Fn coatings, which probably better mimic the deposited Fn matrix in MS lesions than soluble Fn, 
enforce clustering of  integrin receptors, and may also bind to different receptors, both integrins and 
others (Geiger et al. 2001). Indeed, the upregulation of, among others, TNF-α by soluble pFn is likely 
mediated via Toll-like receptor 4 (TLR-4) (Goos et al. 2007, Ribes et al. 2010), whereas coatings of pFn 
and aFn do not activate TLR-4 (our unpublished observations). This may also explain why Fn did not 
markedly enhance phagocytosis by microglia in our studies, which is considered to be mediated 
via TLR-4 (Ribes et al. 2010). Furthermore it should be noted that we investigated relatively naïve 
microglia and macrophages, whereas priming of microglia and macrophages may enhance their 
responsiveness to Fn. For instance, LPS-primed microglia respond to soluble pFn by additionally 
increasing IL-1β production (Summers, Kielty & Pinteaux 2009). 
Microglia and bone marrow macrophages are distinct cell types (Graeber 2010), but their effector 
functions in MS are typically considered to be similar, as further enforced by the absence of a marker 
to distinguish both cell types (Rawji, Yong 2013). To clarify whether both cell types respond similarly 
to aFn, we directly compared activation profiles from microglia and bone marrow macrophages 
obtained in parallel from the same pool of neonatal rats. Although microglia and macrophages 
responded similarly with respect to morphology, NO synthesis and cytokine gene expression, 
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several differences were also apparent. First, microglia displayed more prominent phagocytotic 
activity than macrophages, with unstimulated microglia phagocytosing approximately 2.5-fold 
more beads than unstimulated macrophages. Potent phagocytosis by microglia is in line with 
previous reports (Durafourt et al. 2012, Mosley, Cuzner 1996) and likely sustains the notion that 
phagocytosis by microglia occurs without priming in CNS physiology (Schafer et al. 2012, Sierra et 
al. 2013). In addition, macrophages enhanced pro-inflammatory cytokine gene expression more 
readily on IFN-γ treatment than microglia, whereas microglia responded to IL-4 with a much greater 
increase of anti-inflammatory gene expression. Together with a more pronounced NO release by 
macrophages on IFN-γ and aFn, these findings support the concept that macrophages are immune 
mediators per se, whereas microglia display more plasticity with diverse, non-immunological roles 
in the healthy brain (Graeber 2010). 
The overall effects of microglia and macrophage activation by aFn on remyelination remain to 
be established. Phagocytosis of myelin debris by macrophages is thought to promote remyelination 
(Kotter et al. 2006, Takahashi et al. 2007), but phagocytosis of neuronal debris can also enhance 
myelin and axonal destruction by the adaptive immune system (Huizinga et al. 2012). Similarly, NO 
has favorable effects on immune activation in MS, but also mediates oligodendrocyte and myelin 
injury (Smith, Lassmann 2002). In general, however, the early phase of remyelination benefits 
from M1 polarized microglia/ macrophage activity, whereas oligodendrocyte differentiation and 
myelin production are promoted by a switch to the M2 phenotype during later stages (Miron et 
al. 2013). Hence, transient Fn expression on demyelination (Zhao et al. 2009, Stoffels et al. 2013) 
likely contributes to the temporal M1 phenotype of microglia and macrophages, whereas the 
persistent presence of aFn in MS may prevent the necessary switch to an M2 phenotype. Indeed, 
in active MS lesions, macrophages are predominantly M1 polarized, although a major subset is also 
of an intermediate activation status (Vogel et al. 2013). In this way, aFn, among other factors, may 
promote unfavorable microglia and macrophage polarization. In addition to directly inhibiting OPC 
differentiation (Stoffels et al. 2013), this may represent an indirect mechanism for how aFn impairs 
remyelination. 
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Supplementary figure 1. Fibronectin aggregates do not induce cell cytotoxicity as determined by lactate 
dehydrogenase release and an MTT assay.
A-D. Microglia (A) or bone marrow macrophages (B) were left unstimulated (US) or cultured on fibronectin 
aggregates (aFn; 2 µg, 5 µg or 10 µg respectively) for 24 h, followed by measurements of lactate dehydrogenase 
(LDH) release in the culture medium (A,C) and of MTT reduction (B,D). Bars represent means, error bars show the 
standard error of the mean. Statistical analyses were performed using the Kruskal-Wallis test, followed by Dunn’s 
Multiple Comparison Test, and did not reveal significant differences. 
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Tissue injury initiates extracellular matrix molecule expression, including fibronectin production by 
local cells and fibronectin leakage from plasma. To benefit tissue regeneration, fibronectin promotes 
opsonization of tissue débris, migration, proliferation and contraction of cells involved in the 
healing process, as well as angiogenesis. When regeneration proceeds, the fibronectin matrix is fully 
degraded. However, in a diseased environment, fibronectin clearance is often disturbed, allowing 
structural variants to persist and contribute to disease progression and failure of regeneration. Here, 
we discuss first how fibronectin helps tissue regeneration, with a focus on normal cutaneous wound 
healing as an example of complete tissue recovery. Then, we continue to argue that, although the 
fibronectin matrix generated following cartilage and central nervous system white matter (myelin) 
injury initially benefits regeneration, fibronectin clearance is incomplete in chronic wounds (skin), 
osteoarthritis (cartilage) and multiple sclerosis (myelin). Fibronectin fragments or aggregates persist, 
which impair tissue regeneration. The similarities in fibronectin-mediated mechanisms of frustrated 
regeneration indicate that complete fibronectin clearance is a prerequisite for recovery in any tissue. 
Also, they provide common targets for developing therapeutic strategies in regenerative medicine.
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Fibronectin – elements of the scaffold
Fibronectin (Fn) is a high molecular weight glycoprotein, that consists of three types of repeating 
amino acid units, named type I, type II and type III repeats (Fig. 1). The structure of Fn depends 
on whether it is secreted in plasma or synthesized by resident cells. Plasma Fn (pFn) is produced 
by hepatocytes, and present in human blood at a concentration of 300 μg/mL (Nishinarita et al. 
1990, Goos et al. 2007). Cellular Fn (cFn) contains the alternatively spliced extra domain A (EDA) 
Figure 1. Structure of fibronectin and major fibronectin fragments that are generated in osteoarthritis. 
The yellow circles represent type I, the blue elipses type II and the red circles type III repeats. The alternative 
splice variants are referred to as ‘A’ for the EDA/EIIIA domain, ‘B’ for the EDB/EIIIB domain, and V for the V-region. 
Protein interaction sites are depicted above the linear structure, integrin binding sites below. PSHRN and 
RGD refer to these specific fibronectin domains. Four main fibronectin fragments with catabolic potential in 
osteoarthritis (OA) are shown under the double headed arrows. The arrows correspond to the cleaving sites of 
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and/or extra domain B (EDB) (nomenclature for humans; for rodents: EIIIA and EIIIB). In addition, a 
third alternatively spliced domain, the IIICS domain (for rodents: the V-region), can be included, but 
regulations for its inclusion haven’t been fully discovered yet. pFn and cFn are secreted as a dimer, in 
which both subunits do not have to contain the same alternatively spliced variants. Physiological Fn 
monomers and dimers will hereafter be referred to as ‘native Fn’. The main Fn receptors comprise a 
variety of integrin receptors (Fig. 1) (Plow et al. 2000). In addition, Fn binds other extracellular matrix 
(ECM) molecules, including heparin, collagen and fibrin, and together these protein networks form 
the ECM (Pankov, Yamada 2002). 
The main function of Fn is to serve as a scaffold for cell adhesion and migration, thereby 
also regulating cell proliferation and differentiation (Pankov, Yamada 2002, Mosher 1988). 
These functions are supported by a variety of small proteins, such as growth factors, when they 
accumulate in the Fn network, increasing their concentration locally. Hence, these small molecules 
can be regarded as ‘the builders’ on a scaffold of ECM including Fn, although Fn itself also stimulates 
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tissue regeneration. The Fn matrix is essential for normal embryonic development (George et al. 
1993). In healthy adult tissue, Fn is expressed at low levels. Transient Fn (re)-expression by plasma 
leakage and synthesis from resident cells is a common ‘default’ response of tissue injury, ranging 
from skin wounds to joint inflammation (Scanzello, Plaas & Crow 2008) and myelin degradation 
(demyelination). Here, we discuss first how this temporary Fn matrix facilitates tissue regeneration, 
with a focus on normal cutaneous wound healing as an example of complete tissue regeneration. 
Next, we review how in osteoarthritis (OA) and multiple sclerosis (MS), clearance of the Fn matrix is 
disturbed, and contributes to failure of tissue regeneration via distinct mechanisms. 
The fibronectin scaffold helps to rebuild tissue: focus on cutaneous wound healing
Wounds are defined as disruption of the normal anatomical structure and function of tissue. The 
wound healing process is the physiological response to wounding in any tissue. Therefore, when we 
discuss how Fn benefits cutaneous wound healing, these functions equally apply to other tissues, 
although detailed features vary between tissue types (Velnar, Bailey & Smrkolj 2009). In cutaneous 
wounds, regeneration involves a) haemostasis and inflammation to provide temporary closure 
of the defect, b) migration and proliferation of epithelial cells to replace the temporary seal, and 
c) maturation and remodelling of the new epithelium and angiogenesis (reviewed, among many 
others, in (Velnar, Bailey & Smrkolj 2009, Tonnesen, Feng & Clark 2000, Baum, Arpey 2005)). Fn is 
involved in each of these steps to a greater or lesser extent (extensively reviewed in: (Clark 1988, 
Colvin 1989, Midwood et al. 2006)). 
On skin injury, a temporary Fn matrix (‘the Fn scaffold’) originates from plasma leakage and 
cellular expression. First, whole blood containing pFn leaks from the disrupted vessels and pFn is a 
major component of the subsequently formed haemostatic clot, although pFn is not essential for 
normal haemostasis (Sakai et al. 2001). Haemostatic thrombi are, however, more stable with pFn than 
without (Ni et al. 2003). The haemostatic clot provides the basis of a provisional matrix, which also 
contains fibrin and other plasma proteins. The provisional matrix secures additional haemostasis, 
and assists migration and proliferation of epithelial cells. The presence of pFn in this matrix is not 
essential for normal wound healing (Sakai et al. 2001), which is explained by compensatory actions 
of cFn. For as soon as a few hours (Sakai et al. 2001) after wounding, cells start to deposit Fn in the 
provisional matrix. Initially, mainly platelets secrete cFn (Sakai et al. 2001), followed by macrophages, 
then fibroblasts (Brown et al. 1993), and possibly endothelial cells (Takamiya et al. 2006). In addition, 
neutrophils express Fn mRNA at 24 hours (Takamiya et al. 2006), but are negative again at 2 days after 
skin wounding (Brown et al. 1993). Therefore, neutrophils also contribute to initial cFn expression 
early after wounding. Analogous to cutaneous wounds, a temporary Fn matrix is generated on 
cartilage damage (Miller et al. 1984) and myelin damage (demyelination) in the central nervous 
system (CNS) (Sobel, Mitchell 1989, van Horssen et al. 2005, Satoh, Tabunoki & Yamamura 2009, 
Hibbits et al. 2012, Stoffels et al. 2013). In these injuries, Fn leaks from plasma (Sobel, Mitchell 1989, 
van Horssen et al. 2005) and is secreted by resident chondrocytes in cartilage (Chevalier et al. 1996, 
137
Fibronectin in tissue regeneration
5
Chevalier, Groult & Hornebeck 1996), and resident astrocytes, microglia and endothelial cells in the 
CNS (Stoffels et al. 2013). Therefore, the generation of a temporary Fn scaffold with pFn and cFn is a 
common response to tissue injury. 
Functions attributed to the transient Fn matrix include stimulation of: a) coating and 
ingestion (opsonization) from tissue débris by inflammatory cells, b) migration and proliferation 
of regenerating cells via chemo- and/or haptotaxis, and c) angiogenesis [for cutaneous wounds 
reviewed in: (Tonnesen, Feng & Clark 2000, Clark 1988, Midwood et al. 2006, Clark 2001)]. Fn functions 
are similar among different tissue injuries, but mechanisms are best described in cutaneous wound 
healing. Fibroblast migration in wound healing requires functional RGD, heparin II and cFn IIICS 
domains (Clark et al. 2003) (Fig. 1), and is promoted by EIIIA from cFn via β-catenin (Bielefeld et al. 
2011) and integrin α9β1 for keratinocytes (Singh et al. 2004). Further, myofibroblast differentiation 
is stimulated by EIIIA (Serini et al. 1998) via integrin α4β7 (Kohan et al. 2010). In fact, EIIIA is essential 
for normal wound contraction in mice as shown via EIIIA knockout (Muro et al. 2003), although in 
mice from a different genetic background, EIIIA knockout did not impair wound healing (Tan et al. 
2004). Without EIIIB, mouse rib fractures heal normally, but more specific experiments are required 
to confirm its redundancy in cutaneous wound healing, especially since fibroblast proliferation and 
Fn matrix assembly in vitro are slightly reduced on EIIIB knockout (Fukuda et al. 2002).
Before tissue regeneration is completed, the Fn matrix is cleared. However, if Fn persists, this 
correlates to chronic failure of regeneration. In cutaneous wounds, analysis of wound fluid from 
human chronic venous ulcers showed persistence of Fn degradation products, possibly as a result of 
increased matrix metalloproteinase 9 (MMP-9) activity (Grinnell, Ho & Wysocki 1992, Moor, Vachon & 
Gould 2009). Certainly, failure of tissue regeneration is mediated by many factors, including changes 
in expression of growth factors, cytokines and matrix proteins as well as receptor expression patterns, 
and tissue oxygen levels (Falanga 2004, Widgerow 2012). Therefore, a structurally altered Fn matrix 
will only contribute to failure of regeneration in a complex interplay with changes in other factors, 
but nonetheless mediates tissue damage. Fn degradation products in chronic venous ulcers, for 
example, likely stimulate neutrophil degranulation (Wachtfogel et al. 1988), and EIIIA activates Toll-
like receptor 4 (TLR4) on inflammatory cells. This TLR4 stimulation may help opsonization of tissue 
débris at first, but eventually results in chronic inflammation (Okamura et al. 2001, Gondokaryono 
et al. 2007). Interestingly, Fn fragments have also been implicated in OA disease progression, which 
will be discussed next. 
Osteoarthritis: fibronectin fragments contribute to cartilage damage
OA is characterized by articular cartilage damage, resulting in joint destruction. The pathophysiology 
of OA is not fully understood. The current pathogenesis concept is based on increased cytokine 
and chemokine activation as a result of many factors, including ageing and chronic wear and tear 
on cartilage. In this concept, cytokines and chemokines contribute to protease production by 
chondrocytes, and inhibition of cartilage synthesis. This damages articular cartilage, and eventually 
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also joint synovium, ligaments, tendons and muscles (Loeser 2008, Edmonds 2009), causing pain 
and impairment of motility. The Fn matrix that is generated on the initial cartilage injury, is not 
completely degraded in OA. As a result, Fn fragments contribute to a) persistent local inflammation 
via innate immune system activation, and b) direct cartilage damage. 
Local joint inflammation results from Fn persistence in several ways. First, after Fn is degraded into 
multiple fragments by proteases (Fig. 1), Fn binds the C1q component of the complement system 
(Bing et al. 1982, Carsons et al. 1988), likely resulting in chronic stimulation of leukocytes. Secondly, 
the fragment containing EIIIA stimulates TLR4, as discussed above in the context of complicated 
wound healing (Okamura et al. 2001, Lasarte et al. 2007). However, although the roles of EIIIA-TLR4 
interactions in chronic wounds remain hypotheses based on in vitro studies, there is more evidence 
for the significance of this binding for joint damage. Injecting EIIIA-containing fragments into joints 
of mice results in joint swelling through the release of pro-inflammatory cytokines from mast cells 
(Gondokaryono et al. 2007). Therefore, although innate immune system activation by Fn initially 
facilitates tissue débris clearance on cartilage damage, non-degraded Fn fragments contribute to 
chronic synovial inflammation in OA.
Cartilage damage in OA (and in rheumatoid arthritis) is also mediated by Fn fragments via 
suppression of sulfated proteoglycans, and via stimulation of chondrocytes and synovial fibroblasts 
to secrete catabolic cytokines and MMPs. The four major characterized Fn fragments include a 29-
kDa heparin-binding fragment, a gelatin-binding fragment, a cell-binding fragment and 40-kDa 
heparin-binding fragment (Yasuda 2006, Sofat 2009) (Fig. 1). These Fn fragments are present at 
high levels in synovial fluid from OA patients (Xie, Meyers & Homandberg 1992), and in human 
osteoarthritic cartilage (Zack et al. 2006). Fn fragments result from degradation of the Fn matrix, 
mediated by MMP-1, -3, -8 and -13 and by the aggrecanases ADAMTS-4 and -5 (Sofat 2009, Gendron 
et al. 2007, Zack et al. 2009). Native Fn has no adverse effects on cartilage, and low concentrations of 
Fn fragments show anabolic effects (Homandberg, Hui 1994). However, at higher concentrations Fn 
fragments stimulate cartilage chondrolysis in vitro (Homandberg, Meyers & Xie 1992, Yasuda, Poole 
2002) via different effector molecules and different pathways. 
First, Fn fragments contribute to release of pro-inflammatory cytokines. These include IL-1, TNFα 
and IL-6 in cultured human cartilage for the 29-kDa heparin-binding fragment (Homandberg et al. 
1997), and IL-6, IL-8 (Pulai et al. 2005) and IL-7 (Long et al. 2008) in human articular chondrocytes 
for the cell-binding fragment. These cytokines subsequently stimulate MMP expression from 
chondrocytes, including MMP-1, -2, -3, -9 and -13 (Werb et al. 1989, Xie et al. 1994, Yasuda et al. 2003, 
Stanton, Ung & Fosang 2002), which enhance cartilage degradation. For example, chondrocytes 
release MMP-3 on stimulation with the 29-kDa heparin-binding fragment, but blocking antibodies 
to TNF-α, IL-1 and IL-6 suppress this release (Homandberg et al. 1997). Activation of some of these 
cytokines and MMPs is mediated by the nuclear factor-κβ (NF- κβ) transcription pathway (Pulai et 
al. 2005), whereas activation of others involves mitogen-acitvated protein kinase (MAPK) pathway 
activation (reviewed in: (Yasuda 2006)). 
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Secondly, Fn fragments induce MMP expression directly via cell surface receptors. For example, 
the 40-kDa heparin-binding fragment stimulates MMP release from chondrocytes via upregulation 
of NF-κβ through the phosphoinotiside-3-OH kinase (PI3K)/Akt pathway and the CD44 hyaluronan 
receptor (Yasuda et al. 2003, Yasuda 2011). Interestingly, the same heparin-binding fragment also 
binds TLR4 to initiate aggrecanase release from chondrocytes (Sofat, Robertson & Wait 2012). The 
cell-binding Fn fragment binds integrin α5β1 on chondrocytes and fibroblasts, which induces the 
secretion of MMP-13 and degradation of cartilage (Werb et al. 1989, Forsyth, Pulai & Loeser 2002, 
Homandberg, Costa & Wen 2002). This interaction requires reactive oxygen species as second 
messengers (Del Carlo et al. 2007). Although native Fn also binds to integrin receptors, native Fn 
stimulation does not cause a catabolic response from chondrocytes. This contrast can be explained 
by the hypothesis of ‘Fn-integrin imbalance’. According to this hypothesis, Fn fragments alter 
normal Fn signals in chondrocytes by binding to distinct integrin receptors, but at the same time 
not binding to others. Therefore, chondrocytes perceive signals from altered clusters of integrins, 
and this initiates a catabolic response in OA (Werb et al. 1989, Huhtala et al. 1995, Peters, Loredo & 
Benton 2002). Further, Fn fragments expose cryptic binding sites, which also explains the altered 
signaling compared to native Fn.
Thirdly, besides stimulation of cytokine and subsequent proteinase (MMP) production, Fn 
fragments, such as the 29-kDa heparin-binding fragment, damage cartilage via suppression of 
cartilage matrix synthesis, including sulfated proteoglycans (Homandberg, Hui 1994, Homandberg, 
Meyers & Williams 1993). Also, the heparin-binding Fn fragment spanning the COOH-terminal 
induces an enhanced release of the free radical nitric oxide (NO) (Yasuda et al. 2004). Although 
most of the data discussed are generated in vitro, additional in vivo studies show that injection of Fn 
fragments into rabbit knee joints results in cartilage destruction and joint swelling, resembling OA 
in humans (Homandberg, Meyers & Williams 1993, Williams et al. 2003). 
In order to reverse Fn fragment-mediated cartilage destruction in OA, and perhaps also 
rheumatoid arthritis, the following designs may be considered: a) prevention of Fn fragmentation, 
b) clearance of Fn fragments, and c) by-pass of harmful Fn fragment signals. Attempts at by-
passing Fn fragment signals is, to our knowledge, the only approach to have been tested so far. 
Anti-oxidants, including N-acetylcysteine, glutathione and allopurinol, increase proteoglycan levels 
on Fn fragments as a result of a reduction of the catabolic cytokines TNF-α, IL-1 and IL-6 in vitro 
(Homandberg, Hui & Wen 1996a, Homandberg, Hui & Wen 1996b). Glucosamine and chondroitin 
sulfate mixtures also increase proteoglycan levels after Fn fragment administration to cultured 
cartilage (Homandberg et al. 2006). Despite these modest, favorable effects on the damage caused 
by Fn fragments, none of these agents are currently used in clinical treatments of OA. Another 
agent, hyaluronan, is in clinical use for OA, mainly because patients’ pain and joint function can 
improve on this drug (Edmonds 2009). One of the underlying mechanisms for its benefit could 
comprise preventing the catabolic effects of Fn fragments, because on Fn fragment injection 
into rabbit joints, hyaluronan upregulates proteoglycan levels and improves histological disease 
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characteristics (Williams et al. 2003). In addition, after treatment with Fn fragments, hyaluronan 
promotes proteoglycan levels, and decreases NO levels in cultured human articular cartilage from 
OA patients (Kang et al. 1999, Yasuda 2010). Whether hyaluronan contributes to structural cartilage 
improvement in OA needs yet to be established in human patients.  
Multiple sclerosis: fibronectin aggregates inhibit regeneration of myelin
MS is a chronic disease of the CNS. Although the pathogenesis is unknown, many factors are 
recognized to play a role in MS onset, including genetics and environmental factors, such as cigarette 
smoking, Epstein Barr virus infection and vitamin D levels (Ascherio, Munger & Lunemann 2012). 
Pathological hallmarks are CNS inflammation, myelin degeneration (demyelination) and axonal 
loss, which clinically reflect as neurological disability. Progression of MS occurs in distinct patterns, 
ranging from rapid accumulation of disability in primary and secondary progressive MS to episodes 
of fulminant inflammation and recovery in relapsing-remitting MS. On demyelination, regeneration 
of myelin (remyelination) is attempted by oligodendrocyte progenitor cells (OPCs), which can 
differentiate into myelin-forming oligodendrocytes. However, remyelination ultimately fails in MS, 
despite the presence of OPCs (Wolswijk 1998, Wolswijk 2002), leaving axons unprotected by myelin 
sheaths, and therefore vulnerable to further degeneration (Trapp, Nave 2008, Franklin, ffrench-
Constant 2008, Franklin et al. 2012). Temporary, dimeric Fn expression occurs on demyelination, but 
Fn aggregates in MS lesions (Stoffels et al. 2013). Persistence of Fn, likely in the form of Fn aggregates, 
is involved in the pathology of chronic MS via a) (chronic) stimulation of inflammation, and b) direct 
inhibition of OPC maturation to oligodendrocytes (Fig. 2).
Inflammation in MS involves, among others, the entry of immune cells to the brain, and the 
pathological activation of CNS resident microglia. Leukocyte invasion to the brain in relapsing-
remitting MS requires migration across the blood-brain barrier. The blood-brain barrier contains 
endothelial cells and astrocytes (Ballabh, Braun & Nedergaard 2004), expressing Fn (van Horssen et 
al. 2005, Man et al. 2009). In order to cross the blood-brain barrier, leukocytes express integrin α4β1, 
which mainly binds to vascular cell adhesion molecule 1 (VCAM1) (Rudick et al. 2012), but also to the 
CS1-peptide, which is a domain of Fn (a site within the V-region) (Fig. 1) on endothelial cells, or can 
be expressed independently of Fn on astrocytes (van der Laan et al. 1997, van der Laan et al. 2002). 
The α4β1-Fn CS1 interaction is blocked by natalizumab, an approved drug for relapsing-remitting 
MS (Man et al. 2009). Also, interferon β-1b, another drug for relapsing-remitting MS, inhibits the 
ability of T-lymphocytes to migrate via Fn on endothelial cells (Stuve et al. 1996). Therefore, Fn on 
endothelial cells contributes to leukocyte invasion in relapsing-remitting MS. Although cell migration 
and proliferation on Fn usually benefit tissue regeneration, these examples demonstrate that such 
physiological functions contribute to pathology under inappropriate circumstances. As an aside, 
stimulation of cell proliferation by Fn also becomes pathological in cancer metastases, when cancer 
cells invade new tissue and proliferate there (Kaplan et al. 2005, Malik et al. 2010, Reticker-Flynn et 
al. 2012). Further, Fn contributes to MS inflammation by instructing the CNS resident microglia and, 
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possibly, invaded macrophages. Fn interacts with integrin α5β1 on microglia to enhance MMP-9 
secretion (Milner et al. 2007). Also, Fn may bind to TLR4 on microglia, as has been suggested for 
wound healing and OA before. Expression of TLR3 and -4 is upregulated in human MS lesions (Bsibsi 
et al. 2002), with TLR4 primarily localized to microglia (Bsibsi et al. 2002, Lehnardt et al. 2002). In 
vitro, pFn activates microglial cells to secrete pro-inflammatory cytokines, including IL-1β (Summers, 
Kielty & Pinteaux 2009), TNF-α, CXCL1, CCL3 and CCL5, and enhances phagocytosis by microglia 
(Ribes et al. 2010). Because these effects depend on the presence of MyD88, they likely result from 
TLR4 stimulation. Interestingly, in these studies, pFn was examined, suggesting that pFn contributes 
to TLR4-stimulation as well as EIIIA-containing Fn fragments (Okamura et al. 2001). Immune 
activated microglia likely facilitate remyelination in MS. For example, phagocytosis of myelin débris 
is necessary for complete remyelination (Kotter et al. 2006) and moderate inflammatory activity 
enhances remyelination (Li et al. 2005, Setzu et al. 2006). Also, macrophage/microglia activation 

































































































Figure 2. On central nervous system injury in multiple sclerosis, improper fibronectin degradation is 
related to failure of remyelination and disease progression. Myelin injury initiates fibronectin (Fn) expression 
from plasma leakage, and secretion by astrocytes, macrophages/ microglia and endothelial cells (depicted from 
top to bottom respectively). This Fn matrix promotes myelin regeneration via different mechanisms, including 
stimulation of oligodendrocyte progenitor cell (OPC) migration and proliferation. 
Complete removal of the Fn matrix corresponds to remyelination, whereas Fn aggregates mediate failure of 




stimulation by LPS induces indirect loss of OPCs and oligodendrocytes, and neurodegeneration 
in vivo (Lehnardt et al. 2002, Lehnardt et al. 2003). Therefore, the overall effects of Fn-microglia 
interactions in MS remain to be established, as well as the effects of Fn aggregates. 
Fn also directly affects OPCs. OPCs express a variety of integrin receptors during the (re)
myelination process, including the Fn receptors αvβ1, αvβ3, αvβ5 and αvβ8 (Milner, ffrench-
Constant 1994, Blaschuk, Frost & ffrench-Constant 2000, Zhao et al. 2009a). In vitro, coatings of pFn 
stimulate integrin αvβ1 to enhance OPC migration (Frost et al. 1996, Milner et al. 1996). In addition, 
αvβ3 integrin stimulation by physiological levels of platelet-derived growth factor A (PDGF-A) 
and Fn enhances OPC proliferation (Baron, Shattil & ffrench-Constant 2002). Further, integrin 
αvβ5 signalling is important for OPC differentiation (Blaschuk, Frost & ffrench-Constant 2000). 
These studies indicate that Fn promotes recruitment and subsequent proliferation of OPCs in the 
demyelinated area via αvβ1, αvβ3 and αvβ5 integrins, benefiting remyelination. However, in vitro 
myelin-formation of OPCs is impaired on pFn, mediated by β1-integrin signaling and mislocalized 
MMP-9 activity (Buttery, ffrench-Constant 1999, Siskova et al. 2006, Siskova et al. 2009). This 
impairment of OPC maturation initially plays a useful role in remyelination, because it allows for 
precise timing of the remyelination process (Franklin, ffrench-Constant 2008). However, as soon as 
OPC recruitment has been completed, αv integrin expression decreases (Zhao et al. 2009b) and the 
Fn matrix should be degraded, allowing OPCs to proceed to form myelin. Indeed, downregulation of 
Fn precedes remyelination on toxin-induced demyelination (Hibbits et al. 2012, Stoffels et al. 2013, 
Zhao et al. 2009a). In contrast, in chronic relapsing experimental autoimmune encephalomyelitis (cr-
EAE), an animal model for relapsing-remitting MS, Fn aggregates in the lesion areas. Fn aggregates 
also persist in chronic demyelinated MS lesions, and inhibit CNS remyelination on toxin-induced 
demyelination in vivo (Stoffels et al. 2013). The mechanism for remyelination impairment needs 
yet to be established, but could comprise the perturbation of oligodendrocyte process outgrowth, 
myelin-membrane directed vesicular transport and membrane microdomain formation, as has 
been shown for pFn (Siskova et al. 2006, Siskova et al. 2009, Baron et al. 2003, Maier et al. 2005).
How Fn aggregates are formed in MS warrants further investigation. Organization of Fn into 
fibrils (fibrillogenesis) and, ultimately, assembly into a three-dimensional matrix is a well-balanced 
process during tissue development and regeneration [extensively reviewed in (Singh, Carraher 
& Schwarzbauer 2010, To, Midwood 2011b)]. Fn aggregation, as defined by deoxycholate (DOC)-
insolubility, is likely the result of strong, noncovalent protein-protein interactions (Chen, Mosher 
1996, Ohashi, Erickson 2009) (our unpublished observations), and participation of other extracellular 
proteins in this matrix (Ohashi, Erickson 2009). Fn aggregation may be appropriate during initial 
stages of tissue regeneration (Singh, Carraher & Schwarzbauer 2010, To, Midwood 2011b, McKeown-
Longo, Mosher 1983). However, excessive Fn deposition and inappropriate remodeling contribute 
to scarring and fibrosis, and frustrate complete tissue regeneration (To, Midwood 2011b, Midwood, 
Williams & Schwarzbauer 2004). Under physiological circumstances, maintenance of the Fn matrix 
requires continuous Fn synthesis by cells (Sottile, Hocking 2002), but in MS, Fn mRNA levels were 
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undetectable in chronic demyelinated lesions, where Fn aggregates nonetheless persisted (Stoffels 
et al. 2013). This suggests that inappropriate remodeling, rather than continuous Fn deposition, is 
crucial for Fn aggregation in MS lesions. Fn remodeling into aggregates is likely mediated by self-
assembly, interaction with binding sites on other proteins as well as with cellular receptors (mainly 
integrin receptors), and local enzyme activity (Singh, Carraher & Schwarzbauer 2010, To, Midwood 
2011a, Ohashi, Erickson 2011). Because transglutaminase activity is proposed to be required for Fn 
aggregation (Geiger et al. 2001, Nelea, Nakano & Kaartinen 2008), and transglutaminase interactions 
with Fn are active in MS (van Strien et al. 2011), this enzyme is one of the factors that may contribute 
to Fn aggregation in MS, but this requires further investigation. 
Concluding remarks: timely removal of the fibronectin scaffold is necessary to complete the 
build
In the development of therapeutic strategies for the promotion of tissue regeneration, there is 
much focus on the initiating mechanisms of specific diseases, for example via the identification 
of gene expression patterns relevant to disease onset. The rationale behind this approach is that 
to unravel the disease pathogenesis will likely provide targets for stopping tissue degeneration 
by its cause. Alternatively, a more pragmatic strategy is to tackle persistent factors in the injury 
environment that hamper regeneration. Fn is such a factor. This review illustrates similarities among 
the responses to injury in different tissues in the creation of a Fn matrix. Fn initially facilitates 
regeneration of skin, cartilage and myelin, mainly via stimulating the recruitment of inflammatory 
and regenerative cells. However, whereas Fn is totally removed before complete regeneration takes 
place, persistent structural variants contribute to failing regeneration in OA and MS. Mechanisms by 
which persistent Fn mediates regeneration failure differ between specific tissue types, but showed 
similarities, especially in their interaction with the immune system. Therefore, adequate clearance 
of the Fn matrix benefits regeneration, and incomplete degradation contributes to failure of tissue 
regeneration (Fig. 2).
The contribution of a residual Fn matrix in regeneration failure is not limited to the tissues 
that have been discussed in this review. For example, in myocardial infarction, the Fn matrix is 
necessary for myofibroblast recruitment and differentiation (Dobaczewski, Gonzalez-Quesada & 
Frangogiannis 2010), but on incomplete clearance of the matrix, the EIIIA-containing Fn mediates 
adverse cardiac remodeling (Arslan et al. 2011). Also, accumulation of Fn fragments occurs during 
intervertebral disc degeneration (Oegema et al. 2000), and further enhances disc degradation via 
stimulation of MMP expression (Greg Anderson et al. 2003, Xia, Zhu 2011). These examples further 
emphasize the benefit of complete degradation from the Fn matrix for tissue regeneration. This 
also underlines the importance of tightly-regulated dynamic ECM expression in general (Lu et al. 
2011), especially because collagen fragments and persistence of tenascin-C also contribute to OA 
pathology (Chowdhury et al. 2010, Goh et al. 2010). Similarly, the high-molecular weight variant of 
hyaluronan, present in MS lesions, inhibits remyelination (Back et al. 2005).
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In designing therapies to improve tissue regeneration, both the good and the bad sides of Fn 
can be taken into account. Taking advantage of the pro-regenerative properties of Fn, it can be 
attempted to speed up regeneration by exogenous administration of Fn. In designing such therapies, 
it is essential to consider the concept of ‘dynamic reciprocity’, which refers to the importance of 
well-balanced receptor and ligand signaling in time. In this concept, Fn administration can only 
add to healing if its (integrin) receptors are still upregulated (Widgerow 2012). Despite a potential 
mismatch between Fn and its receptors in chronic wounds, a modest additional benefit has been 
demonstrated for Fn-based therapies here. For example, after wounding the skin from obese 
diabetic mice (Livant et al. 2000), and also on rat peritoneal injury (Miyamoto et al. 2010), the PHSRN 
fragment from the 9th type III domain accelerates wound healing. This acceleration benefits from 
the physiological properties of Fn, including an increased fibroblast and keratinocyte adhesion and 
migration, wound contraction (Livant et al. 2000) and angiogenesis via integrin α5β1 on epidermal 
and endothelial cells (Feng, Mrksich 2004, Zeng et al. 2009). Similarly, pFn slightly accelerates 
wound healing in rats when topically applied onto skin wounds (Lariviere et al. 2003, Qiu, Kwon & 
Kamiyama 2007), and when injected after incisional wounding in a dose-dependent manner (Kwon, 
Qiu & Hiraon 2007). In patients with persistent corneal epithelial defects, topical application of pFn 
shows modest beneficial effects on healing (McCulley et al. 1993). Wound dressings, including Fn-
based therapies, benefit healing in carefully selected wounds, and only in a subset of wounded 
patients (Boateng et al. 2008). Therefore, the therapeutic potential of exogenous Fn application 
could further be enhanced by selecting specific patient groups, such as wounded patients with 
diabetes mellitus (Qiu, Kwon & Kamiyama 2007). In addition, these therapies may be more effective 
when Fn domains are coupled to a) other supportive proteins, such as hylauronan (Ghosh et al. 
2006), b) growth factors, such as PDGF (Lariviere et al. 2003) and hepatocyte growth factor (Okiyama 
et al. 2011), or c) glycoprotein hormones, such as erythropoietin (Kohan et al. 2010, Hamed et al. 
2011). Finally, in another elegant approach, a fibrin/Fn matrix was designed, that could bind the 
growth factors PDGF, vascular endothelial growth factor (VEGF) and bone morphogenetic protein 
(BMP) to enhance healing of skin wounds from diabetic mice (Martino et al. 2011). 
To overcome the detrimental properties of persistent Fn, multiple strategies are possible: a) 
ensuring proper Fn clearance, b) eliminating Fn structural variants once they emerge, and c) by-pass 
of harmful Fn signals. We briefly discussed therapeutic strategies in OA and MS that, among their 
other actions, by-pass Fn signals. By-passing strategies included hyaluronic acid (OA), natalizumab 
and interferon β-1b (MS), although these effects occur secondary to how the drugs were designed. 
These and the other approaches warrant further investigation. To accelerate our understanding, a 
multidisciplinary approach will be helpful, comparing good and bad sides of Fn and Fn therapies 
between tissues. This will expand our insight into how improper Fn clearance is mediated, and 
could be overcome. These insights will likely benefit therapeutic strategies that promote tissue 
regeneration. 
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Multiple sclerosis (MS) is a chronic central nervous system (CNS) disease. The pathology of MS 
is characterized by inflammation, neurodegeneration and degradation of myelin (demyelination), 
the insulating membrane layer that enwraps axons and is produced by oligodendrocytes (Trapp 
et al. 1998, Barnett, Prineas 2004, Lassmann, Bruck & Lucchinetti 2007). Because myelin facilitates 
rapid nerve impulse conduction and protects axonal integrity, demyelination largely contributes to 
typical symptoms of MS, such as loss of motor and sensory functions. Indeed, chronic demyelination 
correlates to neurological disability in MS (Trapp, Ransohoff & Rudick 1999). Whereas regeneration 
of myelin (remyelination) by oligodendrocyte progenitor cells (OPCs) (Zawadzka et al. 2010) 
is apparent in early stages of MS (Patrikios et al. 2006), remyelination fails in chronic MS lesions. 
Therefore, structural therapeutic benefit is expected from promoting endogenous remyelination 
in MS. In order to effectively enhance endogenous remyelination, insights into mechanisms of 
remyelination failure in MS are pivotal. Endogenous remyelination likely fails in MS due to a) 
defective recruitment of OPCs to a subset of MS lesions (Williams et al. 2007, Boyd, Zhang & Williams 
2013), and b) a failure of OPCs to differentiate into oligodendrocytes, which likely accounts for 
remyelination in the majority of MS lesions (Wolswijk 1998, Wolswijk 2002, Kuhlmann et al. 2008, 
Franklin, Ffrench-Constant 2008).
A major impediment for oligodendrocyte differentiation is the continuous expression of 
inhibitory signals, many of which originate from the altered microenvironment of OPCs in MS 
lesions (chapter 1). Specifically, the extracellular matrix (ECM) is extensively remodeled in MS 
lesions (Sobel, Mitchell 1989, Gutowski, Newcombe & Cuzner 1999, van Horssen et al. 2005, van 
Horssen et al. 2006, Satoh, Tabunoki & Yamamura 2009), and aberrant signaling by several ECM 
proteins inhibits oligodendrocyte differentiation (Back et al. 2005, Lau et al. 2012). In this thesis, 
the role of the ECM glycoprotein fibronectin in remyelination was further investigated. Fibronectin 
is a dimeric protein, of which two major variants are discerned. Plasma fibronectin is continuously 
produced by hepatocytes and circulates in the plasma. Additionally, resident cells synthesize cellular 
fibronectin after tissue injury. Cellular fibronectin contains one or two alternatively spliced domains, 
EIIIA (nomenclature for rodents; EDA in humans) and EIIIB (EDB in humans), and may also contain 
the V-region (IIICS for humans). In demyelinated lesions, fibronectin is expressed (Sobel, Mitchell 
1989, van Horssen et al. 2005, van Horssen et al. 2006, Satoh, Tabunoki & Yamamura 2009, Zhao et 
al. 2009, Hibbits et al. 2012), and in vitro, fibronectin inhibits oligodendrocyte maturation (Buttery, 
ffrench-Constant 1999, Maier et al. 2005, Siskova et al. 2006, Siskova et al. 2009).
In chapter 2, the expression patterns of fibronectin were examined in experimental models 
of demyelination and in MS lesions. This study revealed that an upregulation of fibronectin 
expression occurred after experimentally-induced demyelination and in demyelinated MS lesions. 
Whereas fibronectin likely leaked through the disrupted blood-brain barrier into demyelinated 
lesions, local cells also synthesized fibronectin. Major cellular sources of fibronectin were identified, 




clearance correlated to complete remyelination, which is normally observed after toxin-induced 
demyelination. However, persistent expression of fibronectin corresponded to remyelination failure 
in chronic MS lesions. Moreover, in these inflammatory lesions, fibronectin was expressed in the form 
of deoxycholate-insoluble aggregates, rather than the dimers that were transiently expressed after 
toxin-induced demyelination. In vitro, these fibronectin aggregates were obtained from astrocytes 
by stimulating the cells with lipopolysaccharide (LPS), an immune mediator of the innate immune 
response. Indeed, fibronectin aggregates were only detected in demyelinated lesions on prolonged 
activation of the immune system, i.e. in active MS lesions and the chronic experimental autoimmune 
encephalomyelitis (cr-EAE) model. To analyze the functional consequences of fibronectin aggregates 
for oligodendrocyte differentiation, astrocyte-derived fibronectin aggregates were injected into 
toxin-induced demyelinated lesions, using saline injected lesions as controls. This demonstrated that 
fibronectin aggregates inhibit oligodendrocyte differentiation and impair remyelination. In further 
support of these findings, fibronectin aggregates were expressed at low level in remyelinated MS 
lesions (‘shadow plaques’).
Not only did astrocytes produce fibronectin aggregates, astrocytes also synthesized the transient, 
dimeric fibronectin matrix that preceded complete remyelination. Therefore, in chapter 3, the 
functional significance of transient fibronectin expression by astrocytes for complete remyelination 
was investigated, together with the significance of plasma fibronectin. Hereto, conditional knockout 
of fibronectin was induced from astrocytes, from plasma or from both astrocytes and plasma. Then, 
focal demyelination was created by injection of lysolecithin into the spinal cord ventral funiculus, and 
the course of remyelination studied versus littermate control animals injected with corn oil. These 
experiments revealed that astrocyte-derived fibronectin was important for OPC recruitment after 
demyelination, whereas plasma fibronectin was redundant. Additional in vitro studies showed that 
specifically the EIIIA domain from astrocyte-derived fibronectin stimulated proliferation of OPCs, 
but not their migration. The EIIIA domain was previously reported to increase cellular adhesion to 
fibronectin, thereby enhancing proliferation (Manabe, Oh-e & Sekiguchi 1999), but a role of EIIIA 
in adhesion of OPCs to fibronectin was not detected in our studies. Despite the contribution of 
astrocyte-derived fibronectin to proliferation of OPCs, remyelination completed normally in the 
absence of fibronectin from astrocytes. Therefore, the EIIIA domain of fibronectin from astrocytes 
promotes recruitment of OPCs, but is not essential for remyelination.
In addition to preventing differentiation of OPCs, fibronectin aggregates may also signal to 
other cells present in MS lesions. Indeed, soluble plasma fibronectin has been shown to promote 
several pro-inflammatory properties of microglia (Milner, Campbell 2003, Milner et al. 2007, 
Ribes et al. 2010). Innate immune activity from microglia and infiltrating macrophages benefits 
remyelination (Li et al. 2005, Kotter et al. 2005). In particular pro-inflammatory activity, characteristic 
for the M1 phenotype of microglia and macrophages, contributes to remyelination shortly after 
demyelination (Olah et al. 2012, Voss et al. 2012, Miron et al. 2013). However, at later stages, a switch 
in the microglia/ macrophage phenotype towards the anti-inflammatory, M2 phenotype stimulates 
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oligodendrocyte differentiation (Miron et al. 2013). Therefore, in chapter 4, it was investigated 
whether fibronectin aggregates induce a microglia/ macrophage phenotype, which may impair 
remyelination indirectly. In this study, coatings of fibronectin aggregates as well as plasma 
fibronectin were found to enhance proliferation of microglia, similar to the M2 phenotype provoked 
by interleukin-4 treatment. However, fibronectin aggregates and plasma fibronectin coatings also 
stimulated microglia and bone marrow macrophages to adopt an amoeboid morphology, similar 
to the M1 phenotype induced by interferon-γ. Although coatings of fibronectin aggregates did not 
promote expression of mRNA suggestive of the M1 or M2 phenotype, fibronectin aggregates, but 
not plasma fibronectin, did tend to promote nitric oxide expression by microglia and bone marrow 
macrophages, a feature also induced by interferon-γ treatment. This study suggests that fibronectin 
aggregates promote distinct pro-inflammatory features in microglia and macrophages. Functional 
consequences of this microglia and macrophage phenotype, induced by fibronectin aggregates, for 
remyelination remain to be established. 
In studying the biology of remyelination, it has been proposed helpful to consider remyelination 
as the default response to myelin injury, bearing many similarities to regenerative processes 
occurring in other tissues of the body (Franklin, ffrench-Constant 2008). Along this line of thought, 
in chapter 5, the generation of a fibronectin matrix was reviewed as a common local response 
to tissue injury, resulting from injury to the skin (wounds), cartilage (osteoarthritis) and myelin 
(demyelination). This revealed common benefits of the fibronectin matrix for tissue regeneration, 
with important functions being the opsonization of tissue debris, as well as stimulation of 
migration, proliferation and contraction of cells involved in the healing process. However, in several 
diseases, clearance of fibronectin from the injured tissue environment is disturbed, allowing for 
the persistence of fibronectin structural variants. Fibronectin fragments persist in chronic wounds 
and osteoarthritis, whereas fibronectin aggregates remain present in MS lesions. Adverse functions 
of fibronectin structural variants for tissue regeneration were discussed, illustrating differences 
between tissue types, but also similarities. For instance, fibronectin structural variants tend to 
interact with the innate immune system, likely ensuring release of pro-inflammatory cytokines 
and nitric oxide in osteoarthritis and multiple sclerosis. The similarities in fibronectin-mediated 
mechanisms of frustrated regeneration indicate that complete degradation of not only fibronectin 
aggregates in MS, but also fibronectin structural variants in other diseases will contribute to tissue 
recovery. Also, identifying similar mechanisms of failed regeneration will likely provide common 





This thesis identifies a dual role for fibronectin in remyelination of MS lesions, both helpful and 
adverse. To support remyelination, fibronectin promotes proliferation of OPCs and may contribute 
to transient pro-inflammatory polarization of microglia and bone marrow macrophages (chapter 
5, Fig. 2). Future studies may identify additional beneficial functions of dimeric fibronectin. For 
example, fibronectin may coat myelin debris and thereby favor its phagocytosis (Clark 1988), which 
likely facilitates remyelination (Kotter et al. 2006). Also, fibronectin could favorably interact with 
other stimulatory factors in the demyelinated environment, most notably with growth factors such 
as transforming growth factor-β (TGF-β) (Fontana et al. 2005) and platelet-derived growth factor-AA 
(PDGF-AA) (Baron, Colognato & ffrench-Constant 2005), to increase their local availability. Although 
such beneficial functions of fibronectin are essential for embryonic development (George et al. 
1993), results presented in this thesis imply that benefits of fibronectin are redundant for complete 
remyelination. Conclusive evidence on the redundancy of fibronectin for remyelination may be 
obtained in studies of remyelination after complete, conditional knockout of fibronectin, preventing 
fibronectin expression from any cellular source. Nevertheless, because a failure in recruitment of 
OPCs is apparent in a minority of MS lesions (Williams et al. 2007, Boyd, Zhang & Williams 2013), the 
theoretical possibility of therapeutically exploiting the beneficial functions of dimeric fibronectin 
in such lesions may be considered, paralleling strategies that promote wound healing (reviewed in 
chapter 5). However, in addition to major practical obstacles that would have to be overcome, such 
as identifying these lesions in patients and delivering fibronectin to inside these lesions, there is 
also the obvious risk of fibronectin aggregation. Hence, in attempts to take therapeutic advantage 
of beneficial functions of fibronectin in MS, it may be more feasible to target upstream regulators of 
fibronectin expression, which likely comprise, among other factors, TGF-β, retinoic acid and vitamin 
D (Borsi et al. 1990, Magnuson et al. 1991), in combination with strategies to prevent aggregation 
(further discussed below).
This thesis also demonstrates that aggregation of fibronectin in MS lesions impairs 
oligodendrocyte differentiation and remyelination (chapter 5, Fig. 2). Next to defective recruitment 
of OPCs (Williams et al. 2007, Boyd, Zhang & Williams 2013), the majority of MS lesions likely fail 
to remyelinate due to an impairment of oligodendrocyte differentiation (Wolswijk 1998, Wolswijk 
2002, Kuhlmann et al. 2008, Franklin, ffrench-Constant 2008). In line with this hypothesis, several 
factors that promote oligodendrocyte differentiation have been identified, which may be relatively 
deficient in MS, such as agonists of the retinoic acid receptor-γ (Huang et al. 2011). Furthermore, 
a list of inhibitors of oligodendrocyte differentiation in MS lesions are now known (reviewed in 
chapter 1), to which fibronectin aggregates were added in this thesis. Although such inhibitors 
each have the ability to impair oligodendrocyte differentiation as such, potential interactions of 
their simultaneous presence in MS are unknown. Therefore, in future studies aimed at promoting 
endogenous remyelination, several hypotheses may be taken into account. Whereas it may be 
sufficient to overcome negative signals from a key inhibitor of oligodendrocyte differentiation in 
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the MS environment, it cannot be excluded that other hampering signals may then still prevail and 
frustrate remyelination. Additionally, after inhibitory signals have been overcome, the absence of 
stimulatory factors may constitute another obstacle before endogenous remyelination resumes. 
Nevertheless, it is predicted from this thesis that interference with the adverse effects of fibronectin 
aggregates will in any case (further) contribute to endogenous remyelination in MS, either 
independently or in combination with other therapies.
Theoretically, negative signals delivered by fibronectin aggregates could be counteracted 
by a) preventing fibronectin aggregation, b) clearing fibronectin aggregates from MS lesions, or 
c) masking cells for harmful fibronectin aggregate signals. Development of strategies to prevent 
fibronectin aggregation will benefit from a thorough understanding of how fibronectin aggregates 
are formed. Assembly of fibronectin in fibrils (fibrillogenesis) and, ultimately, a three-dimensional 
matrix is a complex, well-balanced process during tissue development and regeneration, during 
which fibronectin temporarily becomes DOC-insoluble (McKeown-Longo, Mosher 1983, Singh, 
Carraher & Schwarzbauer 2010, To, Midwood 2011). Conversion of dimeric fibronectin to fibronectin 
aggregates likely involves i) ongoing fibronectin synthesis by local cells, and ii) remodeling of the 
fibronectin matrix, which requires self-assembly, interactions with binding sites on other ECM 
proteins and with cellular receptors (such as integrin receptors), as well as local activity of several 
enzymes (Singh, Carraher & Schwarzbauer 2010, To, Midwood 2011, Sottile, Hocking 2002, Ohashi, 
Erickson 2011). In chronic MS lesions, fibronectin mRNA levels are downregulated, whereas 
fibronectin aggregates persist (chapter 2), suggesting that inappropriate remodeling mediates 
fibronectin aggregation in MS more dominantly than continuous fibronectin synthesis. To elucidate 
how fibronectin is remodeled, each of the required steps described above may be studied. In 
particular the enzyme transglutaminase may be of interest, because transglutaminase activity is 
likely required for fibronectin aggregation (Geiger et al. 2001, Nelea, Nakano & Kaartinen 2008) and 
this enzyme interacts with fibronectin in MS lesions (van Strien et al. 2010). Studies of aggregate 
formation by interactions between fibronectin and cellular receptors, which may be therapeutically 
blocked, also warrant investigation. In studying mechanisms of fibronectin aggregation in this way, 
it may be useful to take into account that not only fibronectin, but also other ECM components are 
extensively remodeled in the inflammatory MS environment. Many ECM proteins are permanently 
upregulated (Fawcett, Asher 1999, van Horssen, Dijkstra & de Vries 2007) and some are known to be 
structurally altered, for instance hyaluronan (Back et al. 2005). Together with cellular components, 
in particular reactive astrocytes, the remodeled ECM eventually forms a glial scar in MS lesions. The 
glial scar has long been recognized as an end-result of frustrated regeneration in a chronic lesion 
environment (Fawcett, Asher 1999), but surprisingly little is known about how the ECM is remodeled 
to form the glial scar. However, the interplay between ECM proteins is worthwhile addressing, 
among others because conformational changes in other ECM proteins may further facilitate 
fibronectin aggregation. For example, different conformations of tenascin-C exert distinct effects 




from careful examination of adverse remodeling in other parts of the body with similar key players, 
such as pulmonary fibrosis, in which fibronectin is strongly involved (Muro et al. 2008). Also, master 
regulators of remodeling will likely be similar among tissue types, with an obvious candidate being 
TGF-β (To, Midwood 2011, Leask, Abraham 2004). In short, a better understanding of fibronectin 
and ECM remodeling may provide targets for interfering with fibronectin aggregation and also with 
glial scarring, thereby promoting regeneration. Appropriate timing of an intervention to prevent 
aberrant scarring will likely be pivotal.
In a second approach, therapeutic benefit may be achieved by clearing fibronectin aggregates 
from the MS environment. Fibronectin clearance is normally mediated by endocytosis, requiring 
β1 integrin and caveolin-1 (Shi, Sottile 2008), and is facilitated by local protease activity. Important 
proteases that mediate degradation of fibronectin are matrix metalloproteinases (MMPs), including 
MMP-3, -7, -9, -10 and -13, and members of the protease family ‘a disintegrin and metalloproteinase 
with thrombospondin motifs’ (ADAMTS), such as ADAMTS-5 (Lu et al. 2011). Expression of MMPs and 
ADAMTS, in turn, is regulated by other enzymes, including tissue inhibitors of metalloproteinases 
(TIMPs), and by the ECM. Indeed, several MMPs and TIMPs are upregulated after experimental 
demyelination (Skuljec et al. 2011). The importance of adequate proteolysis has become evident 
from, for example, MMP-9 null mice, in which experimental remyelination is impaired (Larsen et 
al. 2003), which could also reflect hampered clearance of fibronectin. In MS lesions, MMP activity 
is disturbed with a distinct upregulation of many MMP members (Agrawal, Lau & Yong 2008). 
Restoring a balance in MMP activity may favor fibronectin aggregate clearance. This would require 
a thorough understanding of the normal balance between proteases involved in degradation of 
fibronectin and the ECM, which is currently lacking (To, Midwood 2011).
Finally, inhibitory effects of fibronectin aggregates on remyelination could be overcome 
by blocking signals from fibronectin aggregates to cellular receptors on OPCs, microglia and 
macrophages. In this approach, fibronectin aggregate signals may be blocked at several levels, 
for example by interfering with receptor–fibronectin interactions, or by inhibiting adhesion 
molecules that mediate signals from fibronectin, such as glycosphingolipids associated with lipid 
rafts (Simons, Toomre 2000). A candidate approach could identify possible targets to overcome 
signals from fibronectin aggregates in this way. Possibly in contrast to preventing aggregation or 
clearing fibronectin aggregates, masking cells for the adverse signals of fibronectin aggregates 
may involve relatively few molecular players. As an additional advantage, blocking signaling by 
fibronectin aggregates may enhance endogenous remyelination regardless of the time at which 
blocking agents are administered, whereas the time window for successfully preventing fibronectin 
aggregation may be narrow. Hence, the most feasible option to overcome the impairment of 
remyelination by fibronectin aggregates may be to block their signals to OPCs and other cell types, 
such as microglia and infiltrated macrophages. Based on the studies presented in this thesis, it is 
predicted that such strategies to overcome adverse effects of fibronectin aggregates will contribute 
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Als een salamander zijn staart verliest, groeit de staart vanzelf weer terug. Een sterk staaltje weefsel 
regeneratie, dat is voorbehouden aan reptielen en waar mensen alleen van kunnen dromen. Of... 
is dat zo? Misschien is het menselijk lichaam niet zo veerkrachtig als dat van een salamander, maar 
toch groeien ook onze weefsels tot op zekere hoogte terug na beschadiging. Overweeg dit eens, 
bijvoorbeeld: wanneer u, een gezond mens, zich in uw vingers snijdt, dan geneest de huid zichzelf, 
soms zelfs zonder litteken. Ook als een weefsel of orgaan beschadigt raakt door een ziekte, dan 
ziet men bij weefselonderzoek vaak vergelijkbare tekenen van een genezingsproces zoals zich dat 
afspeelt in een wond van de huid. Maar de genezing van een weefsel is doorgaans onvolledig indien 
de beschadiging onderdeel is van een ziekte. Misschien kunnen we proberen te begrijpen waarom 
de genezing van het weefsel in dergelijke gevallen niet slaagt, zodat we met gebruik van dergelijke 
kennis het lichaam een handje kunnen helpen en weefsel terug kunnen laten groeien. Een beetje 
zoals de staart van de salamander. 
Vanuit deze invalshoek werd in dit proefschrift het genezingsproces van myeline, de vette 
isolatie rondom zenuwen (zie onder), bestudeerd in de ziekte multiple sclerose (MS), een ziekte 
van het centrale zenuwstelsel. Het centrale zenuwstelsel laat zich inderdaad vergelijken met een 
centrale; een drukke communicatiecentrale van de zenuwen van de hersenen en het ruggenmerg, 
die informatie uitwisselen met de rest van het lichaam. Gevoelens van warmte of knellende 
schoenen, het zien van letters, woorden en zinnen, het omslaan van een bladzijde; dergelijke 
informatie ontstaat in het centrale zenuwstelsel of wordt daarin voor een belangrijk deel verwerkt. 
Een patiënt met MS heeft plaatselijke beschadigingen (‘laesies’) aan het centrale zenuwstelsel, 
waardoor de warmte van een hete ovenschaal op de hand niet meer goed gevoeld wordt of een 
deel van een bladzijde niet gezien kan worden, bijvoorbeeld. In het begin van de ziekte zijn deze 
beperkingen vaak tijdelijk van aard en de laesies genezen gedeeltelijk, maar uiteindelijk krijgen 
veel MS patiënten steeds meer handicaps, die niet meer herstellen. Beschikbare therapieën kunnen 
het aantal aanvallen van MS dat optreedt iets verminderen, maar de voortgang van de ziekte niet 
geheel remmen. Ook kan ontstane schade niet geheel worden hersteld. 
Om te begrijpen waarom in het zenuwstelsel van MS patiënten dergelijke beschadigingen 
niet genezen, is het zinvol te bestuderen uit welke cellen het zenuwstelsel is opgebouwd en hoe 
deze worden aangetast door de ziekte, zoals werd gedaan in hoofdstuk 1. De ene helft van het 
centrale zenuwstelsel bestaat uit zenuwcellen (neuronen; Figuur 1), de lange signaalcellen die 
vaak vergeleken worden met elektriciteitskabels, en die elektrische zenuwsignalen (zoals: ‘uw 
hand is warm’ of ‘dit lees ik nu’) communiceren tussen de hersenen en de rest van het lichaam. 
De andere helft bestaat uit glia cellen; een verzamelnaam voor vele verschillende celtypen. ‘Glia’ is 
afgeleid van het Griekse woord voor ‘lijm’ en inderdaad werd lang aangenomen dat glia cellen als 
belangrijkste functie hadden steun te bieden aan de neuronen. Maar de laatste tijd ontdekken we 
dat glia cellen ook functies vervullen naast het ondersteunen van neuronen. Voor dit proefschrift 
zijn de belangrijkste soorten glia cellen die werden bestudeerd: a) astrocyten; stervormige cellen 
(Figuur 1), waarvan de precieze functies nog onopgehelderd zijn, b) microglia (Figuur. 1); cellen die 
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zusjes zijn van de veelzijdige afweercellen ‘macrofagen’ buiten het zenuwstelsel, maar daarnaast 
waarschijnlijk ook een rol spelen in het aanpassen van neuronale netwerken, en c) oligodendrocyten 
en hun voorlopercellen, oligodendrocyt precursor cellen (OPCs) (Figuur 2). OPCs zijn kleine, ronde 
cellen met korte uitlopers. Tijdens de ontwikkeling van het zenuwstelsel groeien de uitlopers van de 
OPCs uit tot lange, brede membranen (vliezen), die zich tenslotte heel strak om de uitlopers van de 
neuronen (‘axonen’) heen wikkelen. Deze omhulsels rondom axonen noemen we ‘myeline scheden’ 
(Figuur 2). OPCs groeien uit tot oligodendrocyten onder invloed van een intern regelsysteem; 
een soort ‘interne klok’, die wordt aangestuurd door externe signalen van buiten de cel. Het 
myeline van de volwassen oligodendrocyt zorgt op deze manier voor elektrische isolatie van een 
groot gedeelte van het axon, zodat de zenuwcellen boodschappen (zoals ‘til deze bladzijde op’) 
sneller doorgegeven. Daarnaast beschermt myeline het axon en bespaart het axon mogelijk ook 
voedingsstoffen. 
Een belangrijk onderdeel van de ziekte MS is dat myeline plaatselijk beschadigt (‘demyelinisering’), 
hoewel nog niet duidelijk is hoe dat precies gebeurt. OPCs blijven verspreid door het volwassen 
zenuwstelsel en zouden daarom theoretisch nieuwe oligodendrocyten en nieuw myeline kunnen 
maken om de myeline schade in MS te herstellen. Dit proces heet ‘remyelinisering’. In diermodellen 
is al aangetoond dat remyelinisering kan leiden tot functioneel herstel; het zenuwstelsel gaat weer 
beter werken en bijvoorbeeld de hete ovenschaal zou weer kunnen worden gevoeld. Inderdaad zien 
we ook in sommige MS laesies een nieuw, dun laagje myeline. Maar in de meeste MS laesies blijven 
we een groot aantal OPCs aantreffen, die niet uitgroeien tot volwassen oligodendrocyten en die 
geen nieuw myeline maken. Remyelinisering faalt dus in MS. Waarom slagen OPCs er meestal niet in 
nieuw myeline te maken? Het antwoord is niet geheel opgehelderd, maar het is waarschijnlijk dat zich 




Figuur 1. Enkele belangrijke cellen uit het centrale zenuwstelsel: een neuron, waarvan de lange uitloper ‘axon’ 
wordt genoemd; een astrocyt en een microglia cel.
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a) negatieve signalen, die groei belemmeren en b) te weinig positieve signalen voor uitgroei van 
OPCs. Het is belangrijk te achterhalen uit welke signaalmoleculen deze obstakels bestaan, zodat 
we kunnen proberen therapieën te ontwikkelen die extra positieve signalen ontwikkelen en/
of de negatieve signalen blokkeren. En op die manier genezing van myeline bevorderen. Enkele 
negatieve signaalmoleculen voor OPC uitgroei zijn al geïdentificeerd in MS. In dit proefschrift werd 
de rol van het eiwit fibronectine onderzocht.
Fibronectine is een belangrijk eiwit van de extracellulaire matrix; een netwerk van signaaleiwitten 
rondom cellen. In hoofdstuk 2 laten wij zien dat fibronectine nauwelijks wordt gemaakt in het 
gezonde zenuwstelsel, maar dat het zich ophoopt na beschadiging van myeline (demyelinisering, 
dus) in MS. Ook in diermodellen, waarin demyelinisering experimenteel wordt toegebracht, vinden 
we plaatselijk nieuw fibronectine. Belangrijke celtypen die fibronectine uitscheiden zijn astrocyten, 
microglia/macrofagen en bloedvatwand cellen (endotheel cellen) en daarnaast ‘lekt’ fibronectine 
waarschijnlijk uit het plasma van beschadigde bloedvaten. In sommige diermodellen geneest 
myeline spontaan en in dergelijke modellen zien we dat fibronectine wordt afgebroken tijdens 
het herstelproces. Echter, wanneer myeline niet geneest, zoals in een ander model en in MS, dan 
blijft ook fibronectine aanwezig. In dergelijke laesies met beperkt myeline herstel verandert ook 
de eiwitstructuur van fibronectine; dan klontert fibronectine samen tot aggregaten, waarschijnlijk 
onder invloed van weefselontsteking. Dus: de blijvende aanwezigheid van fibronectine aggregaten 
hangt samen met het falen van myeline genezing. Dat is een interessante correlatie, maar betekent 
het ook een causaal verband? Om dit te onderzoeken zetten we astrocyten in een kweekschaal aan 
tot het maken van fibronectine aggregaten. Vervolgens brachten we deze fibronectine aggregaten 
aan in experimentele, gedemyeliniseerde laesies, die normaal gesproken spontaan genezen. Echter, 
na toedienen van fibronectine aggregaten is het herstelproces beperkt. Daarom dragen fibronectine 
aggregaten in MS laesies bij aan het falen van myeline genezing. 







Figuur 2. De oligodendrocyt precursor cel (OPC) groeit in enkele stappen uit tot een volwassen oligodendrocyt. 
Dit gebeurt onder invloed van een ‘interne klok’, die tevens wordt aangestuurd door externe signalen uit het 
milieu van de OPC. De volwassen oligodendrocyt maakt contact met axonen. Dan wikkelt het vettige vlies 
(membraan) van de oligodendrocyt zich strak om het axon. Zo ontstaat de myeline schede, die er onder andere 
voor zorgt dat zenuwprikkels sneller door het zenuwstelsel kunnen reizen.
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Hoewel fibronectine aggregaten dus nadelig zijn voor myeline herstel, heeft de tijdelijke, niet-
geaggregeerde fibronectine matrix, die wordt gemaakt na myeline beschadiging, waarschijnlijk 
eerst een gunstige invloed op OPCs. Maar hoe belangrijk is fibronectine voor OPCs? Misschien 
kunnen OPCs ook wel zonder fibronectine. Als dat het geval is, kunnen we misschien al in een 
vroeg stadium fibronectine verwijderen om aggregatie te voorkomen. Om dit te onderzoeken 
maakten we in hoofdstuk 3 gebruik van de conditionele knockout techniek. Door genetische 
manipulatie verkregen we muizen die verschillende typen fibronectine niet meer maken, namelijk: 
a) geen fibronectine in het plasma (bloed; plasma fibronectine), b) geen fibronectine gemaakt 
door astrocyten, c) geen fibronectine in plasma én niet van astrocyten. Daarna beschadigden 
we plaatselijk het myeline in het ruggenmerg (we maakten een demyeliniserende laesie), die 
spontaan zou moeten genezen in ongeveer drie weken. Inderdaad genazen alle laesies ook 
zonder de verschillende typen fibronectine. Echter, zonder fibronectine van astrocyten (astrocyt 
fibronectine) waren er minder OPCs. OPCs vermenigvuldigden zich minder goed zonder astrocyt 
fibronectine, en misschien werden ze ook minder goed aangetrokken. Inderdaad is uit eerdere 
studies bekend dat fibronectine de vermenigvuldiging van OPCs in een kweekschaal (in vitro) 
bevordert. De eiwitstructuur van astrocyt fibronectine verschilt van die van plasma fibronectine, 
want astrocyt fibronectine kan enkele extra domeinen bevatten: EIIIA en EIIIB. Geven deze extra 
domeinen misschien de gunstige signalen af van astrocyt fibronectine? Dit onderzochten we in 
een kweekschaal, en zo vonden we dat met name EIIIA, en niet EIIIB, van astrocyt fibronectine 
belangrijk is voor de vermenigvuldiging van OPCs. Fibronectine, vooral als het is gemaakt door 
astrocyten, heeft dus een positieve invloed op de vermenigvuldiging van OPCs, maar waarschijnlijk 
is fibronectine geen noodzakelijk signaal voor myeline genezing. Dit is een belangrijk inzicht bij het 
ontwikkelen van therapieën die het schadelijke aggregeren van fibronectine tegengaan. 
Fibronectine kan niet alleen signalen geven aan OPCs, maar ook aan andere cellen die een 
rol spelen in MS en aanwezig zijn in de laesies. Een belangrijk voorbeeld hiervan wordt gevormd 
door microglia cellen, die binnen het zenuwstelsel een functie vervullen in ontstekingsreacties, 
en macrofagen, ontstekingscellen die uit het bloed infiltreren in het zenuwstelsel. Daarom 
onderzochten we in hoofdstuk 4 of fibronectine aggregaten de ontstekingseigenschappen 
van microglia en macrofagen beïnvloeden, hetgeen schadelijk zou kunnen zijn voor myeline 
genezing in MS. Uit deze studies bleek dat het uiterlijk van microglia en macrofagen verandert 
door fibronectine aggregaten; ze worden meer opgezwollen (‘amoeboid’), een uiterlijk dat past bij 
ontstekingsactivatie. Ook worden macrofagen door fibronectine aggregaten aangezet tot het ‘eten’ 
van materialen uit hun omgeving (‘fagocytose’). Zowel microglia als macrofagen kunnen specifieke 
ontstekingsprofielen aannemen, die passen bij bepaalde typen van weefselontsteking. In reactie 
op fibronectine aggregaten gebeurt dit echter waarschijnlijk niet. Interessant genoeg reageren 
microglia en macrofagen wel op fibronectine aggregaten door meer nitriet oxide uit te scheiden, 
een stofje dat betrokken is bij ontsteking in MS. Fibronectine aggregaten bevorderen dus bepaalde 
ontstekingseigenschappen van microglia en macrofagen. Hoe deze eigenschappen myeline 
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genezing beïnvloeden blijft vooralsnog onopgehelderd.
Eerder in deze samenvatting vergeleek ik verschillende typen van weefselgenezing met elkaar – 
de staart van de salamander, een wondje in uw vinger en myeline schade in MS. Inderdaad kennen 
deze processen gedeeltelijk overeenkomsten, ook al spelen ze zich af in verschillende weefsels. Bij het 
bestuderen van genezing in een bepaald weefsel, zoals van myeline in MS, kunnen we daarom leren 
van kennis die is opgedaan over genezing van ander weefsel, bijvoorbeeld een wond van de huid. 
Daarom werd in hoofdstuk 5, in een literatuur overzicht (review), vergeleken hoe fibronectine zich 
gedraagt na schade aan de huid (wonden), kraakbeen (artrose) en myeline (MS). Deze vergelijking 
maakte opnieuw duidelijk dat het ontstaan van fibronectine een gebruikelijke reactie is van het 
lichaam na weefselschade. Fibronectine heeft een positieve invloed op weefselgenezing, onder 
andere doordat het nieuwe cellen aantrekt en deze cellen helpt zich te vermenigvuldigen. Maar in 
een later stadium van weefselherstel, als er genoeg cellen zijn en deze overgaan tot het maken van 
nieuw weefsel, dan wordt fibronectine weer afgebroken. Afbraak van fibronectine correleert aan 
genezing van myeline, zoals onder andere aangetoond in hoofdstuk 2, maar ook aan genezing van 
de huid en kraakbeen. Echter, als de afbraak van fibronectine niet afdoende is, dan draagt dit ook in 
andere weefsels bij aan weefselschade. Fibronectine aggregaten verhinderen myeline genezing in 
MS (hoofdstuk 2), maar ook in chronische wonden en artrose verandert fibronectine van structuur; 
dan ontstaan fibronectine fragmenten. Met name in de context van artrose is veel onderzoek gedaan 
naar de schadelijke effecten van fibronectine fragmenten, die nieuwe kraakbeencellen remmen en 
daarnaast ook ongunstige ontstekingseigenschappen van lokale ontstekingscellen bevorderen. 
Fibronectine laat zich dus beschouwen als een steiger bij het aanmaken van nieuw weefsel: een 
handig eiwit, dat tijdelijk goed van pas komt, maar wel op tijd moet worden afgebroken om de 
wederopbouw van weefsel af te maken. 
Samenvattend beschrijft dit proefschrift meerdere rollen van fibronectine tijdens myeline 
genezing in MS. Terwijl fibronectine aanvankelijke gunstige effecten heeft, met name door 
vermenigvuldiging van OPCs te stimuleren, is de blijvende aanwezigheid van fibronectine aggregaten 
in MS laesies ongunstig voor myeline genezing. Therapeutische interventies om de schadelijke 
invloed van fibronectine aggregaten te overwinnen zullen daarom waarschijnlijk bijdragen aan 
herstel van myeline, en daarmee herstel van zenuwstelsel functies, in MS. Dergelijke therapeutische 
interventies moeten nog worden ontwikkeld. Met name het blokkeren van de signalen die worden 
afgegeven door fibronectine aggregaten lijkt theoretisch interessant (besproken in hoofdstuk 6). 
Door het gebruik van dergelijke strategieën groeit de hoop dat myeline van MS patiënten in de 




Rather than scientific communications, all pages of this book could alternatively convey stories 
about the process of scientific discovery that was undertaken in pursuit of this thesis. Such stories 
of endurance and good fortune – illustrating the benefits of a Sunday morning discussion in the 
lab, but also highlighting the utter frustration of yet another past-dinner-time attempt to persuade 
a shRNA experiment to work (it never did) – would perhaps not proof anything, but that does not 
mean they would not be worth telling. Such stories could uncover a particular reality – a reality 
described by Virginia Woolf in ‘A room of one’s own’ as: ‘something very erratic, very undependable 
– now to be found in a dusty road, now in a scrap of newspaper in the street, now a daffodil in the 
sun. It lights up a group in a room and stamps a casual saying. (…) But whatever it touches, it fixes 
and makes permanent.’ In my stories of scientific activity and PhD thesis writing – a journey at times 
‘very erratic, very undependable’ indeed –, I would always meet with enthusiastic and supportive 
colleagues and friends, whom I would like to ‘fix’ here and ‘make permanent’ in acknowledgement.
Before I identify the colleagues who have particularly supported me, let me stress that this 
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program of the University Medical Centre Groningen and I am grateful that I was allowed to follow 
this program. Michiel Hooiveld provided valuable advice before I subscribed. Additional sources of 
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much benefitted my understanding of the field. Also, I was given the opportunity to take several 
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(Groningen), 2010 (Alphen aan den Rijn) and 2012 (Nijmegen), for which I am grateful. Finally, this 
thesis could not have been completed without the approval of Professor H.E. de Vries, Professor 
H.W.G.M. Boddeke and Professor H.P.H. Kremer, whom I would like to thank for doing so. 
For the success and enormous pleasure of my research visits to the Franklin laboratory in 
Cambridge, I am indebted first of all to Clare Kew-Buckley; the friendliest and most helpful office 
neighbor a novice to both the lab and the UK, such as me, could have imagined. Other colleagues 
that always made the lab a place of much fun and learning for me include: Julia Ruckh-Rist, Jeff 
Huang, Jing-Wei Zhao, Magda Medeiros, Charlotte Bruce, David Coutts, Charlotte Humphries, 
Mike Peacock – and, during later research visits: Alerie Guzman, Alex Goncharevich, Nicholas 
Granger, Helen Blamires, Hilary Hu, Guy Bouvier, Glaucia Monteiro de Castro, Suzanne Mosley, Sybil 
Stacpoole, Adele Norman, Sam Sudar (who is also thanked for visiting, recently), Ginez Gonzalez, 
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the same reasons, I would like to thank Thora (Ragnhildur) Karadottir and colleagues from her lab: 
Iben Lundgaard, Aryna Waldron-Luzhynskaya, Hélène Gautier, Sonia Spitzer, Sergey Sitnikov, John 
Stockley and Sylvia Agathou. I further wish to thank Sarah Moyon for fun and support, both in the lab 
and as my roommate during the Euroglia conference of 2011 in Prague. Abbe Crawford and Muktha 
Natrajan were also very pleasant and helpful colleagues, and it was marvellous to have them visit me 
and Laura Meijer in Amsterdam in the spring of 2013. Of particular help was Dan Ma; a never failing 
source of friendliness and technical support. Professor Robin Franklin generously hosted my science 
visits, for which I am incredibly grateful, and whom I would further like to thank for enabling me to 
learn from his sharp mind and profound insights into the biology of remyelination and scientific 
status of the field. My special gratitude is extended to Chao Zhao for his dedicated mentorship and 
enthusiastic commitment to our projects. It’s been my enormous pleasure to learn and benefit from 
his vast technical expertise and extended knowledge, and I will miss the joy of our daily interactions.
The other half of the scientific work that led to this PhD thesis was performed in the Baron 
laboratory in Groningen. I am grateful to my colleagues at the Department of Cell Biology for 
pleasant collaboration, and thinking in particular of Sven IJzendoorn and his group: Herschel 
Dhekne, Chris Slim, Nai-Hua Hsao, Pieter Roelofs, Lucja Jarosz, Leon Klunder; further of Inge Zuhorn 
and her group: Julia Georgieva, Katica Stojanov, Zia ur Rehman, Bispo de Jesus, Cuifeng Wang 
and Edwin de Jong. Also, I wish to thank Nicoletta Kahya, Peter Meszaros, Jan Willem Kok and his 
technicians, Ina Hummel and Karin Klappe, who helped me find my way in ‘lab 2’. Many skilled 
colleagues collaborated with me in our ‘Multiple Sclerosis Research Group’, in particular: Marjolein 
Bijlard, Michel Vos, Charlotte de Jong and, briefly, Inge Werkman. Many experiments benefitted 
from the assistance of Jenny Dallinga-de Jonge and Anita Nomden. Erik Sikkema worked with me to 
unravel the effects of fibronectin aggregates on microglial cells and macrophages, and I would like 
to thank him for this. We were supported by a talented master student, Frederike Basedow, whom 
I would like to acknowledge here for her enthusiastic commitment and great ability to learn both 
technical and theoretical skills during the project. The office was an enjoyable place to work thanks 
to Bojana Mikus, Jing Qin and Hande Ozgen, who is further thanked for joining me on many fruitful 
coffee (or, later, tea) breaks and ‘stress relief’ evenings at the cinema. Mirjana Wojtal-Stancic gently 
helped me during early days in the lab and it was a pleasure to briefly share the office as well as a 
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scientific discussions about the manuscripts of the different chapters, from which I always learned 
much. To my co-promotor, Wia Baron, I am particularly indebted, among many other things for her 
immense and enthusiastic commitment to our project, which is exemplified by hundreds of e-mails, 
often in quick reply to e-mails of mine, and many meetings to discuss novel plans and protocols. Our 
in-depth discussions about discoveries in the field or the design of our experiments always revealed 
novel perspectives and helped me to shape my thoughts. I am grateful for opportunities to learn 
so much. 
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friends and family who never set foot in a laboratory. To all of these people so incredibly important 
to me: you know who you are, please feel my thanks. I would like to address a special word of thanks 
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ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs
AGG aggregate
Aldh1L1 aldehyde dehydrogenase 1 family member L1





BDNF brain derived neurotrophic factor
BMM bone-marrow macrophage
BMP bone morphogenetic protein
BrdU 5-bromo-2’-deoxyuridine
BSA bovine serum albumin
caMS chronic active multiple sclerosis
CCL chemokine ligand
cFn cellular fibronectin
ciMS chronic inactive multiple sclerosis
cKO conditional knockout
CNP 2’,3’-cyclic nucleotide 3’-phosphodiesterase
CNS central nervous system
cr-EAE chronic experimental autoimmune encephalomyelitis
CSF cerebrospinal fluid
CSPG chondroitin sulfate proteoglycan
CTRL control
CWM control white matter
CXCL cysteine-x-cysteine motif ligand
DAPI 4’,6-diamidino-2-phenylindole
DIG digoxigenin





DPL days post lesion
DTT dithiothreitol
EAE experimental autoimmune encephalomyelitis
ECM extracellular matrix
EDA extra domain A
EDB extra domain B
EGF epidermal growth factor
ER endoplasmatic reticulum
ErbB epidermal growth factor
FCS fetal calf serum
Fn fibronectin
FGF fibroblast growth factor
FITC fluorescein isothiocyanate
GalC galactosylceramide
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GFAP glial fibrillary acidic protein
GPR G-protein coupled receptor
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HDAC histone deacetylase
HLA human leukocyte antigen
HMBS synthase   
HMW high molecular weight
Iba ionized calcium-binding adapter molecule
IB4 isolectin-B4
Id Inhibitor of DNA-binding
IFA incomplete Freund’s adjuvant
IFN interferon
IGF insulin-like growth factor
IHC immunohistochemistry
IL interleukin
iPSC induced pluripotent stem cell
LDH lactate dehydrogenase
Ln laminin
LIF leukemia inhibitory factor
LPS lipopolysacharide
LXR liver X receptor
MAC macrophage
MAG myelin associated glycoprotein
MAL myelin and lymphocyte protein
MAPK mitogen-acitvated protein kinase
MBP myelin basic protein
M-CSF macrophage colony stimulating factor
MCT monocarboxylic acid transporter
MHC major histocompatibility class
MMP matrix metalloproteinase
MOG myelin oligodendrocyte glycoprotein
MRF myelin-gene regulatory factor
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MS multiple sclerose
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NADPH nicotinamide adenine dinucleotide phosphate
NDS normal donkey serum 
NF neurofascin
NG neuron-glia chondroitin sulphate proteoglycan
NGF nerve growth factor
NGS normal goat serum
NMDA N-methyl-D-aspartate
NO nitric oxide





OPC oligodendrocyte progenitor cell
PBS phosphate-buffered saline
PCR polymerase chain reaction
PDGF-AA platelet-derived growth factor-α
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PNS peripheral nervous system
PPAR peroxisome proliferator activator protein
PSA-NCAM polysialylated-neural cell adhesion molecule
qPCR quantitative polymerase chain reaction
rMS remyelinated multiple sclerosis
RNA ribonucleic acid
RT-PCR reverse transcription polymerase chain reaction
RXR retinoid X receptor
SD standard deviation
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis




SNARE soluble NSF attachment protein receptor
TBS tris-buffered saline
Tcf transcription factor
TGF transforming growth factor
TIMP tissue inhibitor of metalloproteinase
TLR toll-like receptor
TMEV Theiler’s murine encephalomyelitis virus
TNF tumor necrosis factor
TRITC tetramethylrhodamine
Trk tyrosine kinase receptor
TuJ1 neuron-specific class III beta-tubulin
US unstimulated
VAMPS vesicle-associated membrane proteins
VCAM vascular cell adhesion molecule
VEGF vascular endothelial growth factor
Wnt wingless-int
YY Yin Yang
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